Page last updated: 2024-10-27

gabapentin and Ache

gabapentin has been researched along with Ache in 418 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

ExcerptRelevanceReference
"The addition of gabapentin to moderate sedation during D&E did not result in lower maximum recalled procedural pain."9.69Gabapentin as an adjunct for pain management during dilation and evacuation: A double-blind randomized controlled trial. ( Brant, AR; Floyd, S; Lotke, PS; Reeves, MF; Scott, RK; Tefera, E; Ye, PP, 2023)
"The addition of venlafaxine to prophylactic gabapentin did not result in improvements in pain control and quality of life among patients with head and neck cancer."9.69Efficacy of Prophylactic High-Dose Gabapentin and Venlafaxine on Reducing Oral Mucositis Pain Among Patients Treated With Chemoradiation for Head and Neck Cancer: A Single-Institution, Phase 2, Randomized Clinical Trial. ( Attwood, K; Farrugia, M; Hermann, G; Iovoli, AJ; Ma, SJ; Neimanis, D; Singh, AK; Smith, KA; Wang, K, 2023)
"The purpose of this paper is to determine whether prophylactic gabapentin usage in patients undergoing definitive concurrent chemotherapy and radiation therapy (chemoRT) for oropharyngeal cancer (OPC) improves treatment-related oral mucositis pain, opioid use, and feeding tube (FT) placement."9.51Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma. ( Ali, H; Chang, S; Cook, A; Fakhoury, L; Ghanem, T; Han, X; Modh, A; Momin, S; Money, S; Movsas, B; Sheqwara, J; Siddiqui, F; Tam, S; Wu, V, 2022)
"Use of the gabapentinoids for pain continues to increase."9.41Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval. ( Al-Jammali, Z; Herink, MC; Williams, CD, 2023)
"This study aims to evaluate the efficacy of gabapentin treatment in dry eye disease (DED) and neuropathic ocular pain."9.41Is gabapentin effective in dry eye disease and neuropathic ocular pain? ( Ongun, GT; Ongun, N, 2021)
" At interim analysis, gabapentin use resulted in a decrease in pain (P = ."9.34Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation. ( Cmelak, A; Ghiam, M; Gibson, MK; Gilbert, J; Hawkins, D; Lou, D; Murphy, BA; Niermann, K; Smith, DK, 2020)
" Both gabapentin and duloxetine groups had significantly more reduction in pain VAS and WOMAC and its subscales compared to acetaminophen group, with no significant difference between groups."9.30Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis. ( Azami, A; Enteshari-Moghaddam, A; Habibzadeh, A; Isazadehfar, K; Jahanpanah, P; Mohebbi, H, 2019)
" Nonetheless, pain intensity reduction is achieved with 50% of the minimum required gabapentin dose alone (800 to 1600 mg/d) in classic NDD trials."9.22Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy. ( Aguilar Navarro, S; Mimenza Alvarado, A, 2016)
"HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)."9.22Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016)
"Pregabalin has been used for the treatment of pain."9.22A Validated Fluorometric Method for the Rapid Determination of Pregabalin in Human Plasma Applied to Patients With Pain. ( Kawakami, J; Naito, T; Yagi, T; Yoshikawa, N, 2016)
"Based on the obtained data, prophylactic lornoxicam controlled postendodontic treatment pain more effectively than did the placebo drugs, and gabapentin was more effective in controlling the pain than either lornoxicam or the placebo."9.19Analgesic efficacy of prophylactic gabapentin and lornoxicam in preventing postendodontic pain. ( Aktuna, S; Işik, B; Turan, A; Yaman, S, 2014)
"Gabapentin is increasingly being used for the treatment of postoperative pain and a variety of psychiatric diseases, including chronic anxiety disorders."9.17Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial. ( Clarke, H; Katz, J; Katznelson, R; Kirkham, KR; Ko, R; Ma, M; Mitsakakis, N; Orser, BA; Snyman, A, 2013)
"Gabapentin has demonstrated efficacy in clinical trials as a pre-emptive analgesic and in acute postoperative pain management."9.15Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. ( Marashi, SH; Nadjafi, A; Panah Khahi, M; Yaghooti, AA, 2011)
"To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)."9.14Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009)
"The clinical usefulness of gabapentin in combination with opioids for Japanese patients with neuropathic cancer pain was assessed in an open-label, single-center, prospective study."9.14A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010)
"Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally."9.14Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010)
"This study compared the efficacy and safety of tramadol/acetaminophen (T/A) and gabapentin in the management of painful diabetic neuropathy."9.14Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. ( Baik, SH; Cha, BY; Kim, CH; Kim, DS; Ko, KS; Ko, SH; Kwon, HS; Lee, JH; Mok, JO; Noh, JH; Park, IB; Park, TS; Son, HS; Yu, JM, 2010)
" The risk of phantom pain (gabapentin vs."9.12A randomized study of the effects of gabapentin on postamputation pain. ( Finnerup, NB; Jensen, TS; Keller, J; Kramp, S; Nikolajsen, L; Vimtrup, AS, 2006)
"Gabapentin, an oral non-opioid analgesic, has been used to decrease pain after a variety of surgical procedures."9.12Premedication with gabapentin: the effect on tourniquet pain and quality of intravenous regional anesthesia. ( Karamanlioglu, B; Pamukçu, Z; Turan, A; White, PF, 2007)
"To assess the efficacy and safety of gabapentin in patients with fibromyalgia."9.12Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007)
"To estimate the cost-effectiveness of branded pregabalin (PGB) versus generic gabapentin (GBP) in patients with neuropathic pain (NeP) due to painful diabetic polyneuropathy (DPN) or post-herpetic neuralgia (PHN) in Spain."9.12Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007)
"To test the hypotheses that both amitriptyline and gabapentin are more effective in relieving neuropathic pain than an active placebo, diphenhydramine."9.12Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. ( Courtade, D; Fiess, RN; Holmes, SA; Loubser, PG; Rintala, DH; Tastard, LV, 2007)
"To determine the analgesic effect of the addition of gabapentin to opioids in the management of neuropathic cancer pain."9.11Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. ( Arcuri, E; Barbieri, M; Bonezzi, C; Caraceni, A; De Conno, F; Gorni, G; Maltoni, M; Martini, C; Tirelli, W; Visentin, M; Yaya Tur, R; Zecca, E, 2004)
"Patients reported significant pain relief in favor of gabapentin in the first period."9.11Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. ( Kessels, AH; Stomp-van den Berg, SG; van de Vusse, AC; Weber, WE, 2004)
"We evaluated the effects of gabapentin and carbamazepine for pain relief in 36 Guillain-Barré syndrome patients."9.11The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. ( Kumar, A; Navkar, DV; Pandey, CK; Raza, M; Singh, UK; Tripathi, M, 2005)
"Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain."9.11Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005)
"A double-blind, randomised, placebo-controlled 8-week study was conducted to evaluate the efficacy and safety of gabapentin in the treatment of neuropathic pain, using doses up to 2400 mg/day."9.10Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. ( Serpell, MG, 2002)
"To assess the effects of gabapentin on sensory and motor symptoms in patients with restless legs syndrome (RLS)."9.10Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. ( de la Llave, Y; Garcia-Borreguero, D; Hernandez, G; Larrosa, O; Masramon, X; Verger, K, 2002)
"Gabapentin, an antiepileptic drug, has been used effectively for different types of pain management."9.10Gabapentin for the treatment of pain in guillain-barré syndrome: a double-blinded, placebo-controlled, crossover study. ( Agarwal, A; Baronia, A; Bose, N; Garg, G; Pandey, CK; Singh, N; Singh, PK; Singh, U, 2002)
"To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin."9.10Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003)
"The aim of our study was to explore a potential analgesic effect of gabapentin in patients with neuropathic pain caused by anticancer treatment."9.10Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. ( Bosnjak, S; Jelic, S; Luki, V; Susnjar, S, 2002)
"Reports of gabapentin use in diabetic peripheral neuropathy pain stimulate a need for controlled trials to determine its comparative efficacy to the therapeutic standard of amitriptyline hydrochloride."9.09Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999)
"The objective of this study was to compare the efficacy and tolerability of gabapentin and amitriptyline monotherapy in painful diabetic neuropathy."9.09Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. ( Buffa, C; Chiroli, S; Dallocchio, C; Mazzarello, P, 2000)
"Twenty-one patients referred with refractory genitourinary pain were treated with oral gabapentin."9.09Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. ( Chancellor, MB; Chuang, YC; Kim, JC; Lee, JY; Sasaki, K; Smith, CP, 2001)
"To evaluate the effects of gabapentin on pain scores and opiate use."9.08The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997)
"A large case series of patients with centrally mediated pain, peripherally mediated pain, migraine, and tremor were treated in an open-label study with gabapentin (maximum of 2,700 mg/day)."9.08Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998)
"To evaluate the effect of gabapentin monotherapy on pain associated with diabetic peripheral neuropathy."9.08Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. ( Backonja, M; Beydoun, A; Edwards, KR; Fonseca, V; Garofalo, E; Hes, M; LaMoreaux, L; Schwartz, SL, 1998)
"Gabapentinoids are frequently used in the management of cancer pain."8.98A critical appraisal of gabapentinoids for pain in cancer patients. ( Bennett, MI; Jordan, RI; Mulvey, MR, 2018)
"This article reviews the existing literature on the use of gabapentin (Neurontin®) as a co-analgesic in treating the neuropathic pain in OM."8.93Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016)
"Gabapentin (GBP), originally an antiepileptic drug, is more commonly used in the treatment of neuropathic pain."8.90Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain. ( Butler, PM; Kurowski, D; Perloff, MD; Yan, PZ, 2014)
"Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain."8.86Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010)
"Multiple, large, high-quality trials have demonstrated the safety and efficacy of gabapentin and pregabalin in neuropathic pain."8.84Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. ( Gilron, I, 2007)
"Gabapentin is a drug that has been widely used in the treatment of chronic pain states."8.83alpha2delta and the mechanism of action of gabapentin in the treatment of pain. ( Lee, K; Luo, ZD; Maneuf, YP, 2006)
" Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes."8.82Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain."8.82The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003)
"This paper reviews the pharmacology and clinical effectiveness of gabapentin in the treatment of neuropathic pain."8.82Gabapentin in the treatment of neuropathic pain. ( Bennett, MI; Simpson, KH, 2004)
"To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice."8.82Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005)
" The search terms included pregabalin, PD144723, CI-1008, gabapentin, and neuropathic pain."8.82Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005)
"Gabapentin, which has been approved for add-on therapy of focal seizures, is increasingly used for treatment of neuropathic pain."8.81[Gabapentin therapy for pain]. ( Block, F, 2001)
"Although its exact mode of action is not known, gabapentin appears to have a unique effect on voltage-dependent calcium ion channels at the postsynaptic dorsal horns and may, therefore, interrupt the series of events that possibly leads to the experience of a neuropathic pain sensation."8.81Gabapentin: pharmacology and its use in pain management. ( Kam, PC; Rose, MA, 2002)
"There have been many proposed uses for gabapentin, including midscapular pain secondary to radiation myelopathy, RSD, neuropathic pain, postherpetic neuralgia, and migraine prophylaxis."8.79Use of gabapentin in pain management. ( Connelly, JF; Wetzel, CH, 1997)
"To observe the therapeutic effect of metformin on pathological pain in mice with radiation dermatitis and explore the underlying mechanism."8.31[Metformin alleviates pathologic pain in mice with radiation dermatitis by inhibiting p38MAPK/NF-κB signaling pathway]. ( An, Q; Cao, J; Han, F; Liu, H, 2023)
"Gabapentin is often used to manage pain in children with dystonic cerebral palsy, however the evidence for its effectiveness in this population is limited."8.02A pilot feasibility study of gabapentin for managing pain in children with dystonic cerebral palsy. ( Antolovich, G; Baker, F; Chalkiadis, G; Copeland, L; Harvey, A; McKinnon, C; Orsini, F; Rice, J; Scheinberg, A; Stewart, K; Thorley, M; Waugh, MC, 2021)
"We aimed to report our institution's experience with gabapentin therapy to manage agitation and pain in the neonatal intensive care unit (NICU) setting."7.96Gabapentin for pain, movement disorders, and irritability in neonates and infants. ( Burnsed, JC; Heinan, K; Letzkus, L; Zanelli, S, 2020)
"We assessed the efficacy and safety of extended-release gabapentin in a 15-week, open-label, single-arm, single-center study in patients with fibromyalgia (FM)."7.83The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study. ( Hong, KS; North, JM; Rauck, RL, 2016)
"The study objective was to describe presenting pain behaviors, daily dose, and response to gabapentin for the management of frequent recurrent pain in this population."7.81Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015)
"We report two cases of infants with NI, identified to have significant improvement in apnea following empiric treatment with gabapentin for presumed central pain and/or visceral hyperalgesia."7.79Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013)
"The involvement of voltage-dependent calcium channels and reactive oxygen species in the pathophysiology of neuropathic pain might justify the preventative administration of antioxidant enzymes, at low doses, in combination with gabapentin (GaP) to maximize its analgesic effect in an experimental model of neuropathic pain in rats."7.79Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model. ( Arcos, M; Barrios, C; Montes, F; Palanca, JM, 2013)
"The frequency of PHN after untreated zoster varies widely."7.79Postherpetic neuralgia: role of gabapentin and other treatment modalities. ( Beydoun, A, 1999)
"To characterize and compare healthcare resource utilization and costs among patients with painful diabetic peripheral neuropathy (pDPN) newly prescribed pregabalin or gabapentin in a real-world clinical setting."7.78Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. ( Harnett, J; Mardekian, J; Udall, M, 2012)
"This retrospective study evaluates the efficacy of gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck tumors."7.76Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010)
"The aim of this study was to assess the role of adding gabapentin (Neurontin) to the prescription of patients with opiate resistant pain as a result of critical limb ischaemia (CLI)."7.76Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010)
"To determine the utility of substitution of pregabalin (PGB) for gabapentin (GBP) therapy in the relief of neuropathic pain (NeP) in patients with peripheral neuropathy (PN)."7.76Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. ( Toth, C, 2010)
"Gabapentin, an anticonvulsant, is widely accepted as an alternative therapeutic agent for neuropathic pain and has proved to produce analgesic effects in a mouse model of visceral pain."7.76Analgesic effects of gabapentin on mechanical hypersensitivity in a rat model of chronic pancreatitis. ( Chen, H; Liao, XZ; Mao, YF; Sun, JH; Xiong, YC; Xu, H; Zhou, MT, 2010)
"Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy."7.76Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010)
"This retrospective study evaluated the efficacy of gabapentin for the treatment of pain syndromes related to radiation-induced mucositis in patients with head and neck cancers treated with concurrent chemoradiation."7.76Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010)
"The GABA amides of the antidepressants nortriptyline and fluoxetine, 1 and 2, were compared to their respective parent compounds in rodent models of pain."7.75Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. ( Aharoni, A; Geffen, Y; Gil-Ad, I; Halbfinger, E; Nisemblat, Y; Nudelman, A; Rephaeli, A; Tarasenko, I; Tarasenko, N; Weizman, A, 2009)
" Using pharmacological and transgenic approaches in mice, we evaluated adrenergic receptor (AR) implication in the action of the tricyclic antidepressant desipramine, the noradrenaline and serotonin reuptake inhibitor venlafaxine, and the noradrenaline reuptake inhibitor reboxetine."7.75Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. ( Barrot, M; Doridot, S; Freund-Mercier, MJ; Hein, L; Petit-Demoulière, N; Tessier, LH; Yalcin, I, 2009)
"In order to detect an anti-nociceptive interaction between morphine and gabapentin, the anti-allodynic and anti-hyperalgesic effects of these drugs, administered either separately or in combination, were determined using the von Frey and acetone tests in a rat model of neuropathic pain (Bennett model)."7.75Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. ( Cortés-Arroyo, AR; De la O-Arciniega, M; Díaz-Reval, MI; Domínguez-Ramírez, AM; López-Muñoz, FJ, 2009)
"Gabapentin is a gamma-aminobutyric acid analog used for numerous neurologic conditions, including neuropathic pain and epilepsy."7.75Gabapentin therapy for pain and irritability in a neurologically impaired infant. ( Cox, TH; Garner, SS; Haney, AL, 2009)
"During treatment and post-treatment phases, patients receiving Gp had cumulative morphine consumption and a mean daily pain score significantly lower than controls."7.74Effects of gabapentin on morphine consumption and pain in severely burned patients. ( Cuignet, O; Pirson, J; Soudon, O; Zizi, M, 2007)
"The effects of treatment with the anti-convulsant agents, lamotrigine and riluzole were compared with gabapentin in a rat experimental model of neuropathic pain."7.74A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2007)
"Clinical studies investigating the use of pregabalin and duloxetine for the management of diabetic peripheral neuropathy and post-herpetic neuralgia are reviewed."7.74Pregabalin and duloxetine for the treatment of neuropathic pain disorders. ( Terneus, W, 2007)
"Although gabapentin may relieve neuropathic pain by actions at many sites, these results suggest that its actions in the brain to cause spinal cholinergic activation predominate after oral administration."7.74Oral gabapentin activates spinal cholinergic circuits to reduce hypersensitivity after peripheral nerve injury and interacts synergistically with oral donepezil. ( Eisenach, JC; Hayashida, K; Parker, R, 2007)
"These data demonstrated the comparable efficacy of gabapentin with morphine in visceral pain."7.74Gabapentin action and interaction on the antinociceptive effect of morphine on visceral pain in mice. ( Meymandi, MS; Sepehri, G, 2008)
"To use gabapentin to relieve discomfort in a painful, blind glaucomatous eye of a patient unwilling to undergo further invasive treatment."7.74Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008)
"A rat model of cancer-induced bone pain using the MRMT-1 cell line injected into the tibia was established to investigate the efficacy of acute (10, 30, 100 mg/kg) and chronic (30 mg/kg) systemic gabapentin on electrophysiological superficial dorsal horn neuronal responses to natural and noxious electrical stimuli, as well as on pain-related behavior."7.73Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. ( Dickenson, AH; Donovan-Rodriguez, T; Urch, CE, 2005)
"The anticonvulsant gabapentin (GBP) has been shown effective for the treatment of neuropathic pain, although its mechanism of action remains unclear."7.73Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. ( Aiyar, J; Anker, N; Belley, M; Bristow, L; Campbell, B; Cohen, C; Park, KT; Ren, K; Stearns, B; Urban, MO, 2005)
"Here, we have examined the effect of the novel antinociceptive agent CHF3381 on the development of nocifensive behaviour as well as secondary mechanical allodynia and hyperalgesia induced by intraplantar injection of capsaicin in rats."7.73CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats. ( Bassani, F; Bergamaschi, M; Tonino Bolzoni, P; Villetti, G, 2005)
"Not all neuropathic pain patients gain relief from current therapies that include the anticonvulsant, gabapentin, thought to modulate calcium channel function."7.73Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. ( Dickenson, AH; Hunt, SP; Rahman, W; Rygh, LJ; Suzuki, R; Webber, M, 2005)
"Hindpaw mechanical allodynia was dose-dependently reversed by gabapentin (50 and 100 mg/kg, s."7.73Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006)
" In this study the co-administration of gabapentin with morphine is evaluated in acute model of pain."7.73Gabapentin enhances the analgesic response to morphine in acute model of pain in male rats. ( Meymandi, MS; Mobasher, M; Sepehri, G, 2006)
" In order to avoid drug interactions as well as adverse effects of carbamazepine in myasthenia gravis, gabapentin was chosen for the treatment of neuropathic pain."7.72Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin. ( Beuche, W; Scheschonka, A, 2003)
" When evaluated in the model of neuropathic pain caused by partial ligation of sciatic nerve, the hexanic extract inhibited the mechanical allodynia (77 +/- 7%), with a similar efficacy to the gabapentin (71 +/- 10%)."7.72Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003)
"Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg."7.72[Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003)
"We report and discuss a case of severe neuropathic orbital pain refractory to standard analgesics that responded well to treatment with the anticonvulsant gabapentin."7.72Treatment of neuropathic orbital pain with gabapentin. ( Kancharla, A; Sloan, PA, 2003)
"The antiepileptic drug, gabapentin, and another structurally related compound, pregabalin, are increasingly employed in the pharmacotherapy of chronic pain states, although their primary mechanism of action remains a topic of active study."7.72Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. ( Chesler, EJ; Kokayeff, A; Lariviere, WR; Mogil, JS; Ritchie, J; Wilson, SG, 2003)
"Combined spinal administration of gabapentin and low doses of morphine significantly reduces pain-related behaviors in this acute rat pancreatitis model, whereas these agents were ineffective when used alone in this dose range."7.72Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model. ( Lu, Y; Smiley, MM; Vera-Portocarrero, LP; Westlund, KN; Zidan, A, 2004)
"We report a case of neutropenia occurring in a patient receiving gabapentin for neuropathic pain."7.72Neutropenia occurring after starting gabapentin for neuropathic pain. ( Derbyshire, E; Martin, D, 2004)
"Although gabapentin was originally developed for treating partial seizures, it has been used mainly to treat various peripheral neuropathic pain conditions; however, there is very limited experience with gabapentin for the treatment of pain conditions of the central nervous system like central post-stroke pain syndrome."7.71Central post-stroke pain syndrome: yet another use for gabapentin? ( Chen, B; DeLisa, JA; Foye, PM; Nadler, SF; Stitik, TP, 2002)
"The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain."7.71Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002)
"The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain."7.71Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection. ( Andoh, T; Kuraishi, Y; Nojima, H; Shiraki, K; Takasaki, I, 2001)
"The objective of this study was to assess the efficacy and safety of Gabapentin as the sole analgesic in patients with HIV-related painful neuropathy."7.71Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations. ( Bottura, P; La Spina, I; Maggiolo, F; Porazzi, D; Suter, F, 2001)
"A patient with mycosis fungoides illustrates the problem of pain management during wound care and suggests the utility of a novel treatment, gabapentin."7.71Gabapentin for pain control in cancer patients' wound dressing care. ( Devulder, J; Lambert, J; Naeyaert, JM, 2001)
"To present two years of experience in the use of gabapentin for the alleviation of neuropathic pain in spinal cord injury patients."7.71Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002)
") gabapentin, administered before and after the injection of formalin into the rat hindpaw, on pain behavior and hemodynamics."7.70The effect of intrathecal gabapentin on pain behavior and hemodynamics on the formalin test in the rat. ( Yaksh, TL; Yoon, MH, 1999)
"Neuropathic pain is a syndrome that affects around 1% of population."6.71Treatment of diabetic neuropathic pain with gabapentin alone or combined with vitamin B complex. preliminary results. ( Espinoza-Raya, J; Granados-Soto, V; Medina-Santillán, R; Morales-Franco, G; Reyes-García, G, 2004)
"Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy."6.68Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997)
"His pain was scored as a five on a six-point visual analog scale, and it persisted despite routine supportive therapy."6.50[A case of Guillain-Barré syndrome with severe pain successfully controlled with acetaminophen, gabapentin, and parenterally infused fentanyl]. ( Anzai, S; Hashimoto, Y; Nagasawa, K; Suzuki, T, 2014)
"Gabapentin has become popular as a first-line treatment for neuropathic pain because of its efficacy as an antineuropathic agent and relatively benign side-effect profile."6.43The mechanism of action of gabapentin in neuropathic pain. ( Baillie, JK; Power, I, 2006)
"Gabapentin is a novel anticonvulsant that may have a unique effect on voltage-dependent Ca2+ channel currents at postsynaptic dorsal horn neurons."6.41Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000)
" However, studies of real-world gabapentinoid dosing demonstrate that the recommended dose targets are frequently not met and do not consider renal insufficiency."5.91Characterization of Outpatient Gabapentinoid Prescribing for Pain. ( A Bowman, L; Banks, C; Merrey, J; Waldfogel, JM, 2023)
"The addition of gabapentin to moderate sedation during D&E did not result in lower maximum recalled procedural pain."5.69Gabapentin as an adjunct for pain management during dilation and evacuation: A double-blind randomized controlled trial. ( Brant, AR; Floyd, S; Lotke, PS; Reeves, MF; Scott, RK; Tefera, E; Ye, PP, 2023)
"The addition of venlafaxine to prophylactic gabapentin did not result in improvements in pain control and quality of life among patients with head and neck cancer."5.69Efficacy of Prophylactic High-Dose Gabapentin and Venlafaxine on Reducing Oral Mucositis Pain Among Patients Treated With Chemoradiation for Head and Neck Cancer: A Single-Institution, Phase 2, Randomized Clinical Trial. ( Attwood, K; Farrugia, M; Hermann, G; Iovoli, AJ; Ma, SJ; Neimanis, D; Singh, AK; Smith, KA; Wang, K, 2023)
"The purpose of this paper is to determine whether prophylactic gabapentin usage in patients undergoing definitive concurrent chemotherapy and radiation therapy (chemoRT) for oropharyngeal cancer (OPC) improves treatment-related oral mucositis pain, opioid use, and feeding tube (FT) placement."5.51Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma. ( Ali, H; Chang, S; Cook, A; Fakhoury, L; Ghanem, T; Han, X; Modh, A; Momin, S; Money, S; Movsas, B; Sheqwara, J; Siddiqui, F; Tam, S; Wu, V, 2022)
"Chronic pain is a multifactorial disease comprised of both inflammatory and neuropathic components that affect ∼20% of the world's population."5.46sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. ( Bialer, M; Brennan, KC; Devor, M; Kaufmann, D; Smith, MD; West, PJ; White, HS; Yagen, B, 2017)
"Use of the gabapentinoids for pain continues to increase."5.41Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval. ( Al-Jammali, Z; Herink, MC; Williams, CD, 2023)
"Prophylactic gabapentin appears to be a promising treatment option for preventing pain, reducing opioids, and reducing weight loss in patients undergoing head and neck cancer therapy."5.41Prophylactic gabapentin during head and neck cancer therapy: a systematic review and meta-analysis. ( Murphy, BA; Smith, DK; Smith, LE, 2023)
"This study aims to evaluate the efficacy of gabapentin treatment in dry eye disease (DED) and neuropathic ocular pain."5.41Is gabapentin effective in dry eye disease and neuropathic ocular pain? ( Ongun, GT; Ongun, N, 2021)
"Gabapentin was found to reversibly decrease, but not suppress the flinching frequency of the second response peak only."5.40Semi-mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain. ( Danhof, M; Della Pasqua, O; Taneja, A; Troconiz, IF, 2014)
"6 h, oral bioavailability of 37% and 90%) with anti-inflammatory activity (ED 50 = 37 micromol/kg, mouse) and efficacy in pain models (thermal hyperalgesia, ED 50 = 72 micromol/kg, rat)."5.35Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. ( Adair, RM; Altenbach, RJ; Bettencourt, BM; Brioni, JD; Cowart, MD; Drizin, I; Esbenshade, TA; Fix-Stenzel, SR; Honore, P; Hsieh, GC; Liu, H; Marsh, KC; McPherson, MJ; Milicic, I; Miller, TR; Sullivan, JP; Wetter, JM; Wishart, N; Witte, DG, 2008)
"Here, we tested the effect of FK1706 on painful diabetic neuropathy in rat model of diabetes induced by streptozotocin (STZ)."5.35FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy. ( Matsuoka, N; Murai, N; Mutoh, S; Price, RD; Yamaji, T; Yamamoto, H; Yamazaki, S, 2008)
"Pain is the result of an emotional and sensory experience and preclinical models of OA can thus be useful to better understand the underlying mechanisms of the disease and test new therapeutic options."5.35Differential analgesic effects of morphine and gabapentin on behavioural measures of pain and disability in a model of osteoarthritis pain in rats. ( Dickenson, AH; Ghandehari, J; Vonsy, JL, 2009)
"Primary erythermalgia (erythromelalgia) is a rare autosomal dominant condition characterized by intermittent attacks of erythema, increased skin temperature and severe burning pain in the extremities, in a bilateral symmetrical distribution."5.35Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel. ( Atherton, D; Elmslie, F; Mansour, S; Mortimer, P; Natkunarajah, J, 2009)
"Gabapentin has established efficacy in the reduction of burn-induced hyperalgesia and allodynia in animal and human experimental burn models."5.35Successful use of gabapentin in acute pain management following burn injury: a case series. ( Cramond, T; Gray, P; Williams, B, 2008)
" At interim analysis, gabapentin use resulted in a decrease in pain (P = ."5.34Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation. ( Cmelak, A; Ghiam, M; Gibson, MK; Gilbert, J; Hawkins, D; Lou, D; Murphy, BA; Niermann, K; Smith, DK, 2020)
"Chronic muscle pain is a problem with high prevalence in clinical practice and its pharmacological treatment is difficult."5.34Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. ( Beyreuther, BK; Geis, C; Sommer, C; Stöhr, T, 2007)
"Ambroxol's effects were compared with those of gabapentin."5.33Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. ( Arndt, K; Gaida, W; Klinder, K; Weiser, T, 2005)
" This dosage produced a substantial but non-significant decrease in the incidence of postherpetic pain-related responses."5.32Effects of the suppression of acute herpetic pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice. ( Kuraishi, Y; Nojima, H; Shiraki, K; Takahata, H; Takasaki, I, 2004)
"Gabapentin (GBP) is a new antiepileptic agent with an original spectrum of activity."5.32[Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004)
"Gabapentin treatment significantly and reversibly changed the responses, consistent with the attenuation of the abnormal sensory behavior, and the attenuated responses lasted for the duration of the drug effect (up to 6 h)."5.31Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. ( Hulsebosch, CE; McAdoo, DJ; Perez-Polo, JR; Taylor, CP; Westlund, KN; Xu, GY, 2000)
" Both gabapentin and duloxetine groups had significantly more reduction in pain VAS and WOMAC and its subscales compared to acetaminophen group, with no significant difference between groups."5.30Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis. ( Azami, A; Enteshari-Moghaddam, A; Habibzadeh, A; Isazadehfar, K; Jahanpanah, P; Mohebbi, H, 2019)
"A variety of treatments for the pain were ineffective."5.30Gabapentin for treatment of neuropathic pain in a 12-year-old girl. ( McGraw, T; Stacey, BR, 1998)
"In this cohort, extended-release gabapentin, as compared with a placebo, did not reduce tampon test pain."5.27Gabapentin for the Treatment of Vulvodynia: A Randomized Controlled Trial. ( Bachmann, GA; Brown, CS; Foster, DC; Wan, J, 2018)
" Nonetheless, pain intensity reduction is achieved with 50% of the minimum required gabapentin dose alone (800 to 1600 mg/d) in classic NDD trials."5.22Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy. ( Aguilar Navarro, S; Mimenza Alvarado, A, 2016)
"HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)."5.22Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016)
"Pregabalin has been used for the treatment of pain."5.22A Validated Fluorometric Method for the Rapid Determination of Pregabalin in Human Plasma Applied to Patients With Pain. ( Kawakami, J; Naito, T; Yagi, T; Yoshikawa, N, 2016)
"Based on the obtained data, prophylactic lornoxicam controlled postendodontic treatment pain more effectively than did the placebo drugs, and gabapentin was more effective in controlling the pain than either lornoxicam or the placebo."5.19Analgesic efficacy of prophylactic gabapentin and lornoxicam in preventing postendodontic pain. ( Aktuna, S; Işik, B; Turan, A; Yaman, S, 2014)
"Gabapentin is increasingly being used for the treatment of postoperative pain and a variety of psychiatric diseases, including chronic anxiety disorders."5.17Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial. ( Clarke, H; Katz, J; Katznelson, R; Kirkham, KR; Ko, R; Ma, M; Mitsakakis, N; Orser, BA; Snyman, A, 2013)
"Gabapentin has demonstrated efficacy in clinical trials as a pre-emptive analgesic and in acute postoperative pain management."5.15Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. ( Marashi, SH; Nadjafi, A; Panah Khahi, M; Yaghooti, AA, 2011)
"To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)."5.14Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009)
" Up to estimated 336 patients (interim analyses) with acute herpes zoster pain (VAS > 30 mm) will be randomised to one of three groups (a) semi-standardised acupuncture (168 patients); (b) gabapentine with individualised dosage between 900-3600 mg/d (84 patients); (c) sham laser acupuncture."5.14Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial. ( Fleckenstein, J; Hoffrogge, P; Irnich, D; Kramer, S; Lang, PM; Lehmeyer, L; Mansmann, U; Pfab, F; Ring, J; Schober, GM; Schotten, KJ; Thoma, S; Weisenseel, P, 2009)
"The clinical usefulness of gabapentin in combination with opioids for Japanese patients with neuropathic cancer pain was assessed in an open-label, single-center, prospective study."5.14A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010)
"Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally."5.14Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010)
"This study compared the efficacy and safety of tramadol/acetaminophen (T/A) and gabapentin in the management of painful diabetic neuropathy."5.14Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. ( Baik, SH; Cha, BY; Kim, CH; Kim, DS; Ko, KS; Ko, SH; Kwon, HS; Lee, JH; Mok, JO; Noh, JH; Park, IB; Park, TS; Son, HS; Yu, JM, 2010)
"Topical gabapentin seems to be well-tolerated and associated with significant pain relief in women with vulvodynia."5.13Topical gabapentin in the treatment of localized and generalized vulvodynia. ( Blais, LR; Boardman, LA; Cooper, AS; Raker, CA, 2008)
" The analgesic activity of CHF3381 was investigated in the heat-capsaicin human pain model and compared with those of gabapentin."5.12CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model. ( Dahl, JB; Fabbri, L; Hilsted, KL; Imbimbo, BP; Mathiesen, O, 2006)
" The risk of phantom pain (gabapentin vs."5.12A randomized study of the effects of gabapentin on postamputation pain. ( Finnerup, NB; Jensen, TS; Keller, J; Kramp, S; Nikolajsen, L; Vimtrup, AS, 2006)
"Gabapentin, an oral non-opioid analgesic, has been used to decrease pain after a variety of surgical procedures."5.12Premedication with gabapentin: the effect on tourniquet pain and quality of intravenous regional anesthesia. ( Karamanlioglu, B; Pamukçu, Z; Turan, A; White, PF, 2007)
"To assess the efficacy and safety of gabapentin in patients with fibromyalgia."5.12Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007)
"To estimate the cost-effectiveness of branded pregabalin (PGB) versus generic gabapentin (GBP) in patients with neuropathic pain (NeP) due to painful diabetic polyneuropathy (DPN) or post-herpetic neuralgia (PHN) in Spain."5.12Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007)
"To test the hypotheses that both amitriptyline and gabapentin are more effective in relieving neuropathic pain than an active placebo, diphenhydramine."5.12Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. ( Courtade, D; Fiess, RN; Holmes, SA; Loubser, PG; Rintala, DH; Tastard, LV, 2007)
"To determine the analgesic effect of the addition of gabapentin to opioids in the management of neuropathic cancer pain."5.11Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. ( Arcuri, E; Barbieri, M; Bonezzi, C; Caraceni, A; De Conno, F; Gorni, G; Maltoni, M; Martini, C; Tirelli, W; Visentin, M; Yaya Tur, R; Zecca, E, 2004)
"Patients reported significant pain relief in favor of gabapentin in the first period."5.11Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. ( Kessels, AH; Stomp-van den Berg, SG; van de Vusse, AC; Weber, WE, 2004)
"We evaluated the effects of gabapentin and carbamazepine for pain relief in 36 Guillain-Barré syndrome patients."5.11The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. ( Kumar, A; Navkar, DV; Pandey, CK; Raza, M; Singh, UK; Tripathi, M, 2005)
"Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain."5.11Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005)
"A double-blind, randomised, placebo-controlled 8-week study was conducted to evaluate the efficacy and safety of gabapentin in the treatment of neuropathic pain, using doses up to 2400 mg/day."5.10Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. ( Serpell, MG, 2002)
"To assess the effects of gabapentin on sensory and motor symptoms in patients with restless legs syndrome (RLS)."5.10Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. ( de la Llave, Y; Garcia-Borreguero, D; Hernandez, G; Larrosa, O; Masramon, X; Verger, K, 2002)
"Gabapentin, an antiepileptic drug, has been used effectively for different types of pain management."5.10Gabapentin for the treatment of pain in guillain-barré syndrome: a double-blinded, placebo-controlled, crossover study. ( Agarwal, A; Baronia, A; Bose, N; Garg, G; Pandey, CK; Singh, N; Singh, PK; Singh, U, 2002)
"To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin."5.10Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003)
"The aim of our study was to explore a potential analgesic effect of gabapentin in patients with neuropathic pain caused by anticancer treatment."5.10Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. ( Bosnjak, S; Jelic, S; Luki, V; Susnjar, S, 2002)
"Reports of gabapentin use in diabetic peripheral neuropathy pain stimulate a need for controlled trials to determine its comparative efficacy to the therapeutic standard of amitriptyline hydrochloride."5.09Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999)
"The objective of this study was to compare the efficacy and tolerability of gabapentin and amitriptyline monotherapy in painful diabetic neuropathy."5.09Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. ( Buffa, C; Chiroli, S; Dallocchio, C; Mazzarello, P, 2000)
"Twenty-one patients referred with refractory genitourinary pain were treated with oral gabapentin."5.09Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. ( Chancellor, MB; Chuang, YC; Kim, JC; Lee, JY; Sasaki, K; Smith, CP, 2001)
"To evaluate the effects of gabapentin on pain scores and opiate use."5.08The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997)
"A large case series of patients with centrally mediated pain, peripherally mediated pain, migraine, and tremor were treated in an open-label study with gabapentin (maximum of 2,700 mg/day)."5.08Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998)
"To evaluate the effect of gabapentin monotherapy on pain associated with diabetic peripheral neuropathy."5.08Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. ( Backonja, M; Beydoun, A; Edwards, KR; Fonseca, V; Garofalo, E; Hes, M; LaMoreaux, L; Schwartz, SL, 1998)
"The gabapentinoid drugs gabapentin and pregabalin were originally developed as antiseizure drugs but now are prescribed mainly for treatment of pain."5.01A Clinical Overview of Off-label Use of Gabapentinoid Drugs. ( Brett, AS; Goodman, CW, 2019)
"Gabapentinoids are frequently used in the management of cancer pain."4.98A critical appraisal of gabapentinoids for pain in cancer patients. ( Bennett, MI; Jordan, RI; Mulvey, MR, 2018)
" Overall, there was a low quality of evidence that gabapentin, pregabalin, amitriptyline, and venlafaxine were effective in reducing pain intensity in patients with cancer pain."4.95Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review. ( de Graeff, A; Dijkstra, D; Jongen, JL; Mostovaya, I; van den Beuken-van Everdingen, MH; Vissers, KC, 2017)
"This article reviews the existing literature on the use of gabapentin (Neurontin®) as a co-analgesic in treating the neuropathic pain in OM."4.93Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016)
"Gabapentin (GBP), originally an antiepileptic drug, is more commonly used in the treatment of neuropathic pain."4.90Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain. ( Butler, PM; Kurowski, D; Perloff, MD; Yan, PZ, 2014)
"Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain."4.86Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010)
"Depomed is developing an extended-release (ER) oral formulation of gabapentin, a GABA receptor agonist commonly used for the treatment of epilepsy and seizures, neuropathic pain and hot flushes."4.84Gabapentin Extended-Release - Depomed: Gabapentin ER, Gabapentin Gastric Retention, Gabapentin GR. ( , 2007)
"Multiple, large, high-quality trials have demonstrated the safety and efficacy of gabapentin and pregabalin in neuropathic pain."4.84Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. ( Gilron, I, 2007)
"Gabapentin, a gamma-aminobutyric acid (GABA) analogue anticonvulsant, is also an effective analgesic agent in neuropathic and inflammatory, but not acute, pain systemically and intrathecally."4.83Mechanisms of the antinociceptive action of gabapentin. ( Cheng, JK; Chiou, LC, 2006)
"Gabapentin is a drug that has been widely used in the treatment of chronic pain states."4.83alpha2delta and the mechanism of action of gabapentin in the treatment of pain. ( Lee, K; Luo, ZD; Maneuf, YP, 2006)
" Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes."4.82Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain."4.82The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003)
"This paper reviews the pharmacology and clinical effectiveness of gabapentin in the treatment of neuropathic pain."4.82Gabapentin in the treatment of neuropathic pain. ( Bennett, MI; Simpson, KH, 2004)
"To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice."4.82Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005)
" The search terms included pregabalin, PD144723, CI-1008, gabapentin, and neuropathic pain."4.82Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005)
"Gabapentin, which has been approved for add-on therapy of focal seizures, is increasingly used for treatment of neuropathic pain."4.81[Gabapentin therapy for pain]. ( Block, F, 2001)
"Although its exact mode of action is not known, gabapentin appears to have a unique effect on voltage-dependent calcium ion channels at the postsynaptic dorsal horns and may, therefore, interrupt the series of events that possibly leads to the experience of a neuropathic pain sensation."4.81Gabapentin: pharmacology and its use in pain management. ( Kam, PC; Rose, MA, 2002)
"Gabapentin has been approved for the treatment of neuropathic pain in six European countries, New Zealand and Australia, and numerous countries in Latin America."4.81Gabapentin. Pfizer. ( Wheeler, G, 2002)
"Gabapentin, an antiepileptic agent, is a safe and versatile medication also used in the adjunctive treatment of painful disorders."4.80Interstitial cystitis and the potential role of gabapentin. ( Hansen, HC, 2000)
"There have been many proposed uses for gabapentin, including midscapular pain secondary to radiation myelopathy, RSD, neuropathic pain, postherpetic neuralgia, and migraine prophylaxis."4.79Use of gabapentin in pain management. ( Connelly, JF; Wetzel, CH, 1997)
" Examining antiepileptic prescribing to residents with ADRD who had disruptive behaviors and/or reported pain suggests that two of the most common antiepileptics, valproic acid and gabapentin, are being used in clinically distinct ways."4.31Antiepileptic prescribing to persons living with dementia residing in nursing homes: A tale of two indications. ( Candon, M; Gerlach, LB; Maust, DT; Strominger, J, 2023)
"To observe the therapeutic effect of metformin on pathological pain in mice with radiation dermatitis and explore the underlying mechanism."4.31[Metformin alleviates pathologic pain in mice with radiation dermatitis by inhibiting p38MAPK/NF-κB signaling pathway]. ( An, Q; Cao, J; Han, F; Liu, H, 2023)
" Because there was no difference in pain, analgesic usage, or time to discharge between groups, investigation regarding gabapentin use for outpatient urogynecologic surgery is needed."4.12Effects of Preoperative Gabapentin on Clinical Outcomes After Outpatient Midurethral Sling Placement. ( Dengler, KL; DiCarlo-Meacham, AM; Olsen, C; Stone, GW; Von Pechmann, W; Welch, EK; Wheat, JE, 2022)
"In patients with diabetic neuropathy who were prescribed gabapentin and pregabalin, there is an increased risk for heart failure, myocardial infarction, peripheral vascular disease, stroke, deep venous thrombosis, and pulmonary embolism with long-term use."4.12Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy. ( Blankfield, RP; Davis, PB; Kaebler, DC; Pan, Y; Xu, R, 2022)
" Acute morphine or gabapentin treatment partly attenuated allodynia in males, but not females."4.12Persistent sensory changes and sex differences in transgenic mice conditionally expressing HIV-1 Tat regulatory protein. ( Bagdas, D; Bigbee, J; Caillaud, M; Damaj, MI; Hauser, KF; Knapp, PE; McKiver, B; Nass, SR; Ondo, O; Paris, JJ; Toma, W; Warncke, UO, 2022)
"Gabapentinoid drugs (gabapentin and pregabalin) are increasingly used for pain as both patients and physicians seek opioid-sparing or opioid-reducing strategies."4.12Gabapentinoid Dosing and Associated Toxicities in Patients With or Without Concomitant Opioids During Hospitalization. ( Atayee, R; Lee, K; Sadeghi, S; Tu, TG, 2022)
"Little is known about relationships between opioid- and gabapentinoid-use patterns and healthcare expenditures that may be affected by pain management and risk of adverse outcomes."4.02Association Between Dual Trajectories of Opioid and Gabapentinoid Use and Healthcare Expenditures Among US Medicare Beneficiaries. ( Bhattacharjee, S; Kwoh, CK; Lo-Ciganic, WH; Malone, DC; Reisfield, GM; Slack, M; Tighe, PJ; Wilson, DL; Zhou, L, 2021)
"To evaluate if gabapentin permeates feline skin in vitro and in vivo and to determine if pain scores improve after administration."4.02A pilot study of transdermal gabapentin in cats. ( Costa, AP; Slovak, JE, 2021)
"Gabapentin is often used to manage pain in children with dystonic cerebral palsy, however the evidence for its effectiveness in this population is limited."4.02A pilot feasibility study of gabapentin for managing pain in children with dystonic cerebral palsy. ( Antolovich, G; Baker, F; Chalkiadis, G; Copeland, L; Harvey, A; McKinnon, C; Orsini, F; Rice, J; Scheinberg, A; Stewart, K; Thorley, M; Waugh, MC, 2021)
"We aimed to report our institution's experience with gabapentin therapy to manage agitation and pain in the neonatal intensive care unit (NICU) setting."3.96Gabapentin for pain, movement disorders, and irritability in neonates and infants. ( Burnsed, JC; Heinan, K; Letzkus, L; Zanelli, S, 2020)
"Gabapentin, a prescription medication approved for the treatment of seizures and neuralgia, is often prescribed off-label for substance use treatment, mental health problems, and pain."3.91Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers. ( Buttram, ME; Cicero, TJ; Ellis, MS; Kurtz, SP, 2019)
"Multiple approaches are needed to mitigate gabapentin misuse, including limiting availability in institutional settings and informal channels as well as addressing the needs of drug users who experience physical pain and withdrawal symptoms."3.91An ethnographic decision model of the initiation of gabapentin misuse among prescription and/or illicit opioid (mis)user. ( Buttram, ME; Cicero, TJ; Havens, JR; Kurtz, SP, 2019)
" She was diagnosed with shingles, started on valacyclovir and gabapentin, and eventually went on to deliver a healthy infant."3.88Shingles in Pregnancy: An Elusive Case of Left Upper Quadrant Abdominal Pain. ( Chin, JM; Schlueter, RJ; Wong, JW, 2018)
"Prior work applied hierarchical clustering, coarsened exact matching (CEM), time series regressions with lagged variables as inputs, and microsimulation to data from three randomized clinical trials (RCTs) and a large German observational study (OS) to predict pregabalin pain reduction outcomes for patients with painful diabetic peripheral neuropathy."3.88Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy. ( Alexander, J; Bonfanti, G; Brodsky, M; Edwards, RA; Emir, B; Grugni, R; Manca, L; Parsons, B; Savoldelli, A; Watt, S; Whalen, E, 2018)
" Daily gabapentin treatment attenuated mechanical allodynia and reduced face-grooming episodes in dIoN-CCI rats."3.85An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve. ( Chen, L; Ding, W; Doheny, JT; Lim, G; Mao, J; Shen, S; Yang, J; You, Z; Zhu, S, 2017)
"Gabapentinoids are effective adjunct drugs for reducing postoperative pain."3.83Comparison of the effects of gabapentin and pregabalin on wound healing in rats. ( Korkmaz, M; Sarıtaş, TB; Sarıtaş, ZK; Sevimli, A, 2016)
"We assessed the efficacy and safety of extended-release gabapentin in a 15-week, open-label, single-arm, single-center study in patients with fibromyalgia (FM)."3.83The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study. ( Hong, KS; North, JM; Rauck, RL, 2016)
" Mechanical allodynia elicited by burn injury was partially reversed by meloxicam (5 mg/kg), gabapentin (100 mg/kg) and oxycodone (3 and 10 mg/kg), while thermal allodynia and gait abnormalities were only significantly improved by amitriptyline (3 mg/kg) and oxycodone (10 mg/kg)."3.83Transcriptomic and behavioural characterisation of a mouse model of burn pain identify the cholecystokinin 2 receptor as an analgesic target. ( Deuis, JR; Lewis, RJ; Vetter, I; Yin, K, 2016)
" In particular, 14 and 15 were found to be more potent than morphine for both acute and inflammatory pain models and 100-fold more potent than gabapentin in a diabetic neuropathic pain model."3.81Antinociceptive Grayanoids from the Roots of Rhododendron molle. ( Li, Y; Liu, Y; Liu, YB; Lv, HN; Ma, SG; Qu, J; Yu, SS; Zhang, JJ, 2015)
" Data pertaining to demographics, diagnosis, oral morphine dose equivalent of the opioid at the time of discharge, adjuvant analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and pain scores as reported by nurses and physicians were collected."3.81Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements? ( Davis, MP; Gordon, P; Gross, J; Sharma, P; Shinde, S, 2015)
" Sleep disruption-induced hypersensitivity was pharmacologically characterized with drugs relevant for pain treatment, including gabapentin (30 mg/kg and 50 mg/kg), Ica-6p (Kv7."3.81Development and pharmacological characterization of a model of sleep disruption-induced hypersensitivity in the rat. ( Gilmour, G; Kennedy, JD; Schuh-Hofer, S; Treede, RD; Wafford, KA; Wodarski, R; Yurek, DA, 2015)
"The study objective was to describe presenting pain behaviors, daily dose, and response to gabapentin for the management of frequent recurrent pain in this population."3.81Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015)
"Synthetic approaches to gabapentin bioconjugates that overcome the tendency of gabapentin to cyclize into its γ-lactam are studied."3.80Gabapentin hybrid peptides and bioconjugates. ( Alamry, KA; Goncalves, K; Ibrahim, MA; Katritzky, AR; Lebedyeva, IO; Neubert, J; Ostrov, DA; Patel, K; Sileno, SM; Steel, PJ, 2014)
"We report two cases of infants with NI, identified to have significant improvement in apnea following empiric treatment with gabapentin for presumed central pain and/or visceral hyperalgesia."3.79Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013)
"The involvement of voltage-dependent calcium channels and reactive oxygen species in the pathophysiology of neuropathic pain might justify the preventative administration of antioxidant enzymes, at low doses, in combination with gabapentin (GaP) to maximize its analgesic effect in an experimental model of neuropathic pain in rats."3.79Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model. ( Arcos, M; Barrios, C; Montes, F; Palanca, JM, 2013)
"The frequency of PHN after untreated zoster varies widely."3.79Postherpetic neuralgia: role of gabapentin and other treatment modalities. ( Beydoun, A, 1999)
"To characterize and compare healthcare resource utilization and costs among patients with painful diabetic peripheral neuropathy (pDPN) newly prescribed pregabalin or gabapentin in a real-world clinical setting."3.78Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. ( Harnett, J; Mardekian, J; Udall, M, 2012)
"Prescription opioids and anticonvulsants such as gabapentin are often used as combination therapeutics for chronic as well as acute post-operative pain conditions although the effectiveness of such combinations may be dependent on the intensity of the pain state."3.78Temperature-dependent enhancement of the antinociceptive effects of opioids in combination with gabapentin in mice. ( Neelakantan, H; Walker, EA, 2012)
" A recent study from our laboratory revealed that gabapentin, a recommended first-line treatment for multiple neuropathic conditions, could also efficiently antagonize thermal hyperalgesia evoked by complete Freund's adjuvant (CFA)-induced monoarthritis (MA)."3.78Gabapentin reduces CX3CL1 signaling and blocks spinal microglial activation in monoarthritic rats. ( Deng, XM; Li, SS; Xu, B; Xu, H; Yang, JL; Zhang, WS; Zhang, YQ, 2012)
"This retrospective study evaluates the efficacy of gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck tumors."3.76Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010)
"The aim of this study was to assess the role of adding gabapentin (Neurontin) to the prescription of patients with opiate resistant pain as a result of critical limb ischaemia (CLI)."3.76Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010)
"To determine the utility of substitution of pregabalin (PGB) for gabapentin (GBP) therapy in the relief of neuropathic pain (NeP) in patients with peripheral neuropathy (PN)."3.76Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. ( Toth, C, 2010)
"Gabapentin, an anticonvulsant, is widely accepted as an alternative therapeutic agent for neuropathic pain and has proved to produce analgesic effects in a mouse model of visceral pain."3.76Analgesic effects of gabapentin on mechanical hypersensitivity in a rat model of chronic pancreatitis. ( Chen, H; Liao, XZ; Mao, YF; Sun, JH; Xiong, YC; Xu, H; Zhou, MT, 2010)
"Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy."3.76Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010)
"This retrospective study evaluated the efficacy of gabapentin for the treatment of pain syndromes related to radiation-induced mucositis in patients with head and neck cancers treated with concurrent chemoradiation."3.76Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010)
"The GABA amides of the antidepressants nortriptyline and fluoxetine, 1 and 2, were compared to their respective parent compounds in rodent models of pain."3.75Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. ( Aharoni, A; Geffen, Y; Gil-Ad, I; Halbfinger, E; Nisemblat, Y; Nudelman, A; Rephaeli, A; Tarasenko, I; Tarasenko, N; Weizman, A, 2009)
"Gabapentin is widely used in the management of pain."3.75Gabapentin toxicity in renal failure: the importance of dose adjustment. ( Miller, A; Price, G, 2009)
"Gabapentin is used in analgesic treatment of neuropathic pain, and large interindividual variation has been observed in the pharmacokinetics (PK) of the drug."3.75A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling. ( Carlsson, KC; Eriksen, HO; Hoem, NO; Karlsson, MO; Moberg, ER; van de Schootbrugge, M, 2009)
" Using pharmacological and transgenic approaches in mice, we evaluated adrenergic receptor (AR) implication in the action of the tricyclic antidepressant desipramine, the noradrenaline and serotonin reuptake inhibitor venlafaxine, and the noradrenaline reuptake inhibitor reboxetine."3.75Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. ( Barrot, M; Doridot, S; Freund-Mercier, MJ; Hein, L; Petit-Demoulière, N; Tessier, LH; Yalcin, I, 2009)
"Our data suggest that activation of spinal or dorsal root ganglion HCN channels or both is not involved in formalin-induced pain, and intrathecal gabapentin does not act as an HCN channel activator to achieve its antinociceptive effect in the formalin test."3.75Intrathecal gabapentin does not act as a hyperpolarization-activated cyclic nucleotide-gated channel activator in the rat formalin test. ( Chen, CC; Cheng, JK; Huang, YJ; Lin, CF; Lin, CS; Tsaur, ML, 2009)
"We compared the inhibitory action of gabapentin, which is used to treat neuropathic pain, on mechanical allodynia induced by chemotherapeutic agents, paclitaxel, oxaliplatin, and vincristine, in mice."3.75Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit. ( Andoh, T; Fujita, M; Gauchan, P; Ikeda, K; Kato, A; Kuraishi, Y; Sasaki, A, 2009)
"In order to detect an anti-nociceptive interaction between morphine and gabapentin, the anti-allodynic and anti-hyperalgesic effects of these drugs, administered either separately or in combination, were determined using the von Frey and acetone tests in a rat model of neuropathic pain (Bennett model)."3.75Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. ( Cortés-Arroyo, AR; De la O-Arciniega, M; Díaz-Reval, MI; Domínguez-Ramírez, AM; López-Muñoz, FJ, 2009)
"Gabapentin is a gamma-aminobutyric acid analog used for numerous neurologic conditions, including neuropathic pain and epilepsy."3.75Gabapentin therapy for pain and irritability in a neurologically impaired infant. ( Cox, TH; Garner, SS; Haney, AL, 2009)
"We examined reporting practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidiary, Parke-Davis (hereafter referred to as Pfizer and Parke-Davis) for off-label indications (prophylaxis against migraine and treatment of bipolar disorders, neuropathic pain, and nociceptive pain), comparing internal company documents with published reports."3.75Outcome reporting in industry-sponsored trials of gabapentin for off-label use. ( Bero, L; Dickersin, K; Scherer, RW; Vedula, SS, 2009)
"During treatment and post-treatment phases, patients receiving Gp had cumulative morphine consumption and a mean daily pain score significantly lower than controls."3.74Effects of gabapentin on morphine consumption and pain in severely burned patients. ( Cuignet, O; Pirson, J; Soudon, O; Zizi, M, 2007)
" To further establish the neurochemical basis for its supraspinally mediated analgesic action, concentrations of spinal noradrenaline, 4-hydroxy-3-methoxyphenylglycol (MHPG), serotonin (5-HT), 5-hydroxyindoleacetic acid (5-HIAA) and dopamine were measured using high-performance liquid chromatography in a murine neuropathic pain model that was prepared by partial ligation of the sciatic nerve (the Seltzer model)."3.74Neurochemical evidence that supraspinally administered gabapentin activates the descending noradrenergic system after peripheral nerve injury. ( Honda, M; Ono, H; Takasu, K; Takeuchi, Y; Tanabe, M, 2007)
"The effects of treatment with the anti-convulsant agents, lamotrigine and riluzole were compared with gabapentin in a rat experimental model of neuropathic pain."3.74A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2007)
"Clinical studies investigating the use of pregabalin and duloxetine for the management of diabetic peripheral neuropathy and post-herpetic neuralgia are reviewed."3.74Pregabalin and duloxetine for the treatment of neuropathic pain disorders. ( Terneus, W, 2007)
"Although gabapentin may relieve neuropathic pain by actions at many sites, these results suggest that its actions in the brain to cause spinal cholinergic activation predominate after oral administration."3.74Oral gabapentin activates spinal cholinergic circuits to reduce hypersensitivity after peripheral nerve injury and interacts synergistically with oral donepezil. ( Eisenach, JC; Hayashida, K; Parker, R, 2007)
"Although this is a small study, it appears that gabapentin and nortriptyline are effective in the treatment of idiopathic chronic orchialgia but not post-vasectomy pain."3.74Chronic orchialgia: consider gabapentin or nortriptyline before considering surgery. ( Lee, LK; Miller, B; Sinclair, AM, 2007)
"These data demonstrated the comparable efficacy of gabapentin with morphine in visceral pain."3.74Gabapentin action and interaction on the antinociceptive effect of morphine on visceral pain in mice. ( Meymandi, MS; Sepehri, G, 2008)
" The three models were benchmarked using compounds known to be active in neuropathic pain patients and nerve injury animal models, including gabapentin, amitriptyline and clonidine."3.74Transient allodynia pain models in mice for early assessment of analgesic activity. ( Cheevers, CV; Donello, JE; Gil, DW, 2008)
"We have previously demonstrated that gabapentin supraspinally activates the descending noradrenergic system to ameliorate pain hypersensitivity in mice with partial nerve ligation."3.74Gabapentin produces PKA-dependent pre-synaptic inhibition of GABAergic synaptic transmission in LC neurons following partial nerve injury in mice. ( Ono, H; Takasu, K; Tanabe, M, 2008)
"Gabapentin (GBP; 1-(aminomethyl)cyclohexane acetic acid) is used clinically in the treatment of pain."3.74Gabapentin evoked changes in functional activity in nociceptive regions in the brain of the anaesthetized rat: an fMRI study. ( Chapman, V; Governo, RJ; Marsden, CA; Morris, PG, 2008)
"Data were obtained from a cohort of 603 patients with neuropathic pain undergoing analgesic treatment with gabapentin who completed four health scales: Medical Outcomes Study Sleep Scale, Sheehan Disability Scale, Covi Anxiety Scale, and Raskin Depression scale."3.74Standard error of measurement as a valid alternative to minimally important difference for evaluating the magnitude of changes in patient-reported outcomes measures. ( Pardo, A; Rejas, J; Ruiz, MA, 2008)
"To use gabapentin to relieve discomfort in a painful, blind glaucomatous eye of a patient unwilling to undergo further invasive treatment."3.74Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008)
"There is evidence supporting the antinociceptive effects of carbamazepine, oxcarbazepine, gabapentin, and topiramate in various models of neuropathic pain as well as inflammatory somatic pain."3.74The antinociceptive effects of anticonvulsants in a mouse visceral pain model. ( Boskovic, B; Milovanovic, S; Paranos, S; Prostran, MS; Stepanovic-Petrovic, RM; Tomic, MA; Ugresic, ND; Vuckovic, SM, 2008)
"Duloxetine, a selective but balanced serotonergic and noradrenergic reuptake inhibitor, was evaluated in the acute nociceptive pain models of tail flick and hot plate in mice and in the persistent and/or inflammatory pain models of acetic acid-induced writhing in mice, carrageenan-induced thermal hyperalgesia and mechanical allodynia in rats, and capsaicin-induced mechanical allodynia in rats."3.73Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. ( Jones, CK; Peters, SC; Shannon, HE, 2005)
"A rat model of cancer-induced bone pain using the MRMT-1 cell line injected into the tibia was established to investigate the efficacy of acute (10, 30, 100 mg/kg) and chronic (30 mg/kg) systemic gabapentin on electrophysiological superficial dorsal horn neuronal responses to natural and noxious electrical stimuli, as well as on pain-related behavior."3.73Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. ( Dickenson, AH; Donovan-Rodriguez, T; Urch, CE, 2005)
"The anticonvulsant gabapentin (GBP) has been shown effective for the treatment of neuropathic pain, although its mechanism of action remains unclear."3.73Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. ( Aiyar, J; Anker, N; Belley, M; Bristow, L; Campbell, B; Cohen, C; Park, KT; Ren, K; Stearns, B; Urban, MO, 2005)
" In the current study, we evaluated the behavioral effects of two standard drugs used clinically for neuropathic pain, the anticonvulsant gabapentin and antidepressant imipramine, in rats at different times after peripheral nerve injury."3.73The effect of antinociceptive drugs tested at different times after nerve injury in rats. ( Borsook, D; Hama, AT, 2005)
"Here, we have examined the effect of the novel antinociceptive agent CHF3381 on the development of nocifensive behaviour as well as secondary mechanical allodynia and hyperalgesia induced by intraplantar injection of capsaicin in rats."3.73CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats. ( Bassani, F; Bergamaschi, M; Tonino Bolzoni, P; Villetti, G, 2005)
"The 5-HT re-uptake inhibitor fluoxetine (3-30 mg/kg), the NA re-uptake inhibitor reboxetine (3-30 mg/kg), the dual 5-HT and NA re-uptake inhibitor venlafaxine (3-100 mg/kg) and the dual DA and NA re-uptake inhibitor bupropion (3-30 mg/kg) were tested after intraperitoneal administration in rat models of acute, persistent and neuropathic pain."3.73Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. ( Blackburn-Munro, G; Nielsen, AN; Pedersen, LH, 2005)
"Not all neuropathic pain patients gain relief from current therapies that include the anticonvulsant, gabapentin, thought to modulate calcium channel function."3.73Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. ( Dickenson, AH; Hunt, SP; Rahman, W; Rygh, LJ; Suzuki, R; Webber, M, 2005)
" The effects of diacerhein were compared with those of gabapentin, a drug used clinically for the management of neuropathic pain."3.73The effects of diacerhein on mechanical allodynia in inflammatory and neuropathic models of nociception in mice. ( Calixto, JB; Campos, MM; Medeiros, R; Quintão, NLM; Santos, ARS, 2005)
"Hindpaw mechanical allodynia was dose-dependently reversed by gabapentin (50 and 100 mg/kg, s."3.73Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006)
" In this study the co-administration of gabapentin with morphine is evaluated in acute model of pain."3.73Gabapentin enhances the analgesic response to morphine in acute model of pain in male rats. ( Meymandi, MS; Mobasher, M; Sepehri, G, 2006)
"A series of mutual prodrugs derived from gabapentin, pregabalin, memantine, venlafaxine were synthesized and their pharmacological properties to treat neuropathic pain were investigated in a rat model of chronic sciatic nerve constriction injury (CCI)."3.72Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury. ( Bo-Hua, Z; He, L; Hong-Ju, Y; Jun-Wei, W; Nan, Z; Wei-Guo, S; Wei-Xiu, Y; Zhe-Hui, G; Zheng-Hua, G; Zhi-Pu, L; Zhong-Wei, J, 2004)
"Gabapentin has recently been used clinically as an antihyperalgesic agent to treat certain neuropathic pain states."3.72Gabapentin markedly reduces acetic acid-induced visceral nociception. ( Cui, M; Feng, Y; Willis, WD, 2003)
"Case report on a patient with SUNCT-syndrome (short lasting, unilateral neuralgiform headache attacks with conjunctival injection, sweating, and rhinorrhoea) who was successfully treated with gabapentin."3.72[Case report on a patient with SUNCT-syndrome]. ( Brinkschmidt, T; Jensen, U; Neumeier, S, 2003)
" In order to avoid drug interactions as well as adverse effects of carbamazepine in myasthenia gravis, gabapentin was chosen for the treatment of neuropathic pain."3.72Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin. ( Beuche, W; Scheschonka, A, 2003)
"To test whether gabapentin, an anticonvulsant, is able to inhibit responses to peritoneal irritation-induced visceral pain and to examine the effect of gabapentin on spinal cord amino acid release."3.72[Effect of anticonvulsant gabapentin on visceral nociception and its relationship with amino acid neurotransmitters released from spinal cord]. ( Cui, M; Feng, Y; Willis, WD, 2003)
" When evaluated in the model of neuropathic pain caused by partial ligation of sciatic nerve, the hexanic extract inhibited the mechanical allodynia (77 +/- 7%), with a similar efficacy to the gabapentin (71 +/- 10%)."3.72Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003)
"Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg."3.72[Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003)
"Little is known about current practice in using the anticonvulsant gabapentin in the management of cancer-related neuropathic pain."3.72The pattern of gabapentin use in a tertiary palliative care unit. ( al-Shahri, MZ; Oneschuk, D, 2003)
"We report and discuss a case of severe neuropathic orbital pain refractory to standard analgesics that responded well to treatment with the anticonvulsant gabapentin."3.72Treatment of neuropathic orbital pain with gabapentin. ( Kancharla, A; Sloan, PA, 2003)
"The antiepileptic drug, gabapentin, and another structurally related compound, pregabalin, are increasingly employed in the pharmacotherapy of chronic pain states, although their primary mechanism of action remains a topic of active study."3.72Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. ( Chesler, EJ; Kokayeff, A; Lariviere, WR; Mogil, JS; Ritchie, J; Wilson, SG, 2003)
"A pharmacokinetic-pharmacodynamic (PK/PD) model relating pain relief to gabapentin plasma concentrations was derived from a phase 3 study."3.72The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain. ( Cook, JA; Ewy, WE; Lockwood, PA; Mandema, JW, 2003)
"Combined spinal administration of gabapentin and low doses of morphine significantly reduces pain-related behaviors in this acute rat pancreatitis model, whereas these agents were ineffective when used alone in this dose range."3.72Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model. ( Lu, Y; Smiley, MM; Vera-Portocarrero, LP; Westlund, KN; Zidan, A, 2004)
"We report a case of neutropenia occurring in a patient receiving gabapentin for neuropathic pain."3.72Neutropenia occurring after starting gabapentin for neuropathic pain. ( Derbyshire, E; Martin, D, 2004)
"To clarify molecular substrates involved in the development of radicular pain, and to investigate the responsiveness of radicular pain to gabapentin."3.71Changes in expression of voltage-dependent ion channel subunits in dorsal root ganglia of rats with radicular injury and pain. ( Abe, M; Han, W; Kurihara, T; Shinomiya, K; Tanabe, T, 2002)
"Although gabapentin was originally developed for treating partial seizures, it has been used mainly to treat various peripheral neuropathic pain conditions; however, there is very limited experience with gabapentin for the treatment of pain conditions of the central nervous system like central post-stroke pain syndrome."3.71Central post-stroke pain syndrome: yet another use for gabapentin? ( Chen, B; DeLisa, JA; Foye, PM; Nadler, SF; Stitik, TP, 2002)
"The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain."3.71Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002)
"The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain."3.71Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection. ( Andoh, T; Kuraishi, Y; Nojima, H; Shiraki, K; Takasaki, I, 2001)
"The objective of this study was to assess the efficacy and safety of Gabapentin as the sole analgesic in patients with HIV-related painful neuropathy."3.71Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations. ( Bottura, P; La Spina, I; Maggiolo, F; Porazzi, D; Suter, F, 2001)
"A patient with mycosis fungoides illustrates the problem of pain management during wound care and suggests the utility of a novel treatment, gabapentin."3.71Gabapentin for pain control in cancer patients' wound dressing care. ( Devulder, J; Lambert, J; Naeyaert, JM, 2001)
"By use of the rat formalin test, a model of persistent pain, we examined the effect of a combination of amitriptyline and gabapentin, which are used to treat chronic pain in humans."3.71The interaction between gabapentin and amitriptyline in the rat formalin test after systemic administration. ( Heughan, CE; Sawynok, J, 2002)
" To resolve this issue, we combined immunocytochemical and patch recording techniques to study the actions of GBP on NMDA receptors in dorsal horn cells isolated from rats with inflammation and to determine the gamma-aminobutyric acid (GABA) content in the recorded cells."3.71Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons. ( Gu, Y; Huang, LY, 2002)
"To present two years of experience in the use of gabapentin for the alleviation of neuropathic pain in spinal cord injury patients."3.71Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002)
"Gabapentin is an effective option for the treatment of neuropathic pain syndromes because of its efficacy and favorable side-effect profile."3.70Gabapentin induced polyneuropathy. ( Gould, HJ, 1998)
") gabapentin, administered before and after the injection of formalin into the rat hindpaw, on pain behavior and hemodynamics."3.70The effect of intrathecal gabapentin on pain behavior and hemodynamics on the formalin test in the rat. ( Yaksh, TL; Yoon, MH, 1999)
"The anticonvulsant gabapentin is effective against neuropathic pain, but the primary site(s) and mechanism(s) of action are unknown."3.70Antinociceptive effect of systemic gabapentin in mononeuropathic rats, depends on stimulus characteristics and level of test integration. ( Christensen, D; Kayser, V, 2000)
"Gabapentin is a novel anticonvulsant that may be of value for the relief of clinical pain."3.69Spinal gabapentin is antinociceptive in the rat formalin test. ( Davis, AM; Elliott, KJ; Inturrisi, CE; Shimoyama, M; Shimoyama, N, 1997)
"The novel anti-epileptic drugs lamotrigine, felbamate and gabapentin were compared in rat experimental models of acute (tail flick) and chronic pain: the chronic constriction injury and spinal nerve ligation models."3.69The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. ( Fontana, DJ; Gogas, KR; Hedley, LR; Hunter, JC; Jacobson, LO; Kassotakis, L; Thompson, J, 1997)
"Pain was not found to be different between the treatment arms."2.94A single-institution, randomized, pilot study evaluating the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer. ( Attwood, K; Bourgeois, DJ; Hermann, GM; Iovoli, AJ; Miller, A; Platek, AJ; Singh, AK; Wang, C, 2020)
"This severe pain is mostly refractory to palliative analgesic treatment, and the latter was only detected by specific and sensitive outcomes."2.87Pain characterization and response to palliative care in dogs with naturally-occurring appendicular osteosarcoma: An open label clinical trial. ( Beauchamp, G; Blair, J; de Lorimier, LP; Lussier, B; Monteiro, BP; Moreau, M; Pelletier, JP; Troncy, E, 2018)
"Patients with diabetic polyneuropathy were examined to study their biological age, rate of aging and pain syndrome."2.76[Biological age and the pain syndrome at diabetic polyneuropathy]. ( Emel'ianov, VV; Galkin, VV; Nesterova, MV, 2011)
"Gabapentin is an important adjuvant to the management of opiate dependence both in acute detoxification as well as stabilisation phase."2.71Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent. ( Jain, MK; Kumar, P, 2003)
"Gabapentin 2400 mg/day was given in case of treatment failure or if imipramine treatment was not possible."2.71Therapeutic outcome in neuropathic pain: relationship to evidence of nervous system lesion. ( Bach, FW; Jensen, TS; Rasmussen, PV; Sindrup, SH, 2004)
"Neuropathic pain is a syndrome that affects around 1% of population."2.71Treatment of diabetic neuropathic pain with gabapentin alone or combined with vitamin B complex. preliminary results. ( Espinoza-Raya, J; Granados-Soto, V; Medina-Santillán, R; Morales-Franco, G; Reyes-García, G, 2004)
"Oxcarbazepine appears to be a promising alternative monotherapeutic approach for patients affected by PHN."2.71Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. ( Auletta, C; Brogi, A; Brogi, F; Criscuolo, S; Lippi, S, 2005)
"Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain."2.71Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans. ( Buchanan, TJ; Huggins, JP; Iannetti, GD; Smart, TS; Tracey, I; Vennart, W; Wise, RG; Zambreanu, L, 2005)
"Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy."2.68Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997)
"Mechanistic approaches and multimodal analgesic techniques have been clearly demonstrated to be the most effective pain management strategy to improve outcomes."2.55Analgesia in the surgical intensive care unit. ( Brudney, CS; Ehieli, E; Pyati, S; Yalamuri, S, 2017)
" Rodent models of CIPN have been developed using a range of dosing regimens to reproduce pain-like behaviours akin to patient-reported symptoms."2.53Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics. ( Duggett, NA; Flatters, SJL; Hopkins, HL, 2016)
"Pain was rated on a scale from 0 (no pain) to 10 (maximum pain)."2.52Pharmacological treatment for pain in Guillain-Barré syndrome. ( Liu, J; McNicol, ED; Wang, LN, 2015)
"Gabapentin is a reasonable first-line choice, and opioid medications can be added for more severe pain but there are few clinical trials to inform specific recommendations."2.52Headache and Pain in Guillain-Barré Syndrome. ( Farmakidis, C; Herskovitz, S; Inan, S; Milstein, M, 2015)
"His pain was scored as a five on a six-point visual analog scale, and it persisted despite routine supportive therapy."2.50[A case of Guillain-Barré syndrome with severe pain successfully controlled with acetaminophen, gabapentin, and parenterally infused fentanyl]. ( Anzai, S; Hashimoto, Y; Nagasawa, K; Suzuki, T, 2014)
"Pain was rated on a scale from 0 (no pain) to 10 (maximum pain)."2.49Pharmacological treatment for pain in Guillain-Barré syndrome. ( Liu, J; McNicol, ED; Wang, LN, 2013)
"Once established, postherpetic neuralgia is particularly difficult to treat, and is often resistant to conventional analgesics."2.47[Development of animal models of herpetic pain and postherpetic neuralgia and elucidation of the mechanisms of the onset and inhibition of allodynia]. ( Takasaki, I, 2011)
"Chronic pain is now viewed as a biopsychosocial phenomenon, in which biological, psychological, and social factors are at work."2.44Practical management strategies for the chronic pain patient. ( Forde, G; Stanos, S, 2007)
"neuropathic pain) is not very satisfactorily managed."2.44[Central and peripheral mechanisms in antinociception: current and future perspectives]. ( Fürst, Z, 2008)
"Migraine and headache studies are excluded in this revision."2.43Anticonvulsant drugs for acute and chronic pain. ( Carroll, D; Collins, S; Jadad, A; McQuay, H; Moore, A; Wiffen, P, 2005)
"Gabapentin has become popular as a first-line treatment for neuropathic pain because of its efficacy as an antineuropathic agent and relatively benign side-effect profile."2.43The mechanism of action of gabapentin in neuropathic pain. ( Baillie, JK; Power, I, 2006)
"Gabapentin was originally designed as an anti-convulsant gamma-aminobutyric acid (GABA) mimetic capable of crossing the blood-brain barrier."2.42Cellular and molecular action of the putative GABA-mimetic, gabapentin. ( Chung, FZ; Gonzalez, MI; Lee, K; Maneuf, YP; Pinnock, RD; Sutton, KS, 2003)
"The most common risk factor for shingles and its potential sequela, PHN, is advanced age."2.42Post-herpetic neuralgia case study: optimizing pain control. ( Baron, R, 2004)
"Gabapentin has demonstrated efficacy, specifically in painful diabetic neuropathy and postherpetic neuralgia."2.41Use of anticonvulsants for treatment of neuropathic pain. ( Backonja, MM, 2002)
"Gabapentin is a novel anticonvulsant that may have a unique effect on voltage-dependent Ca2+ channel currents at postsynaptic dorsal horn neurons."2.41Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000)
"Among the more common symptoms is spasticity."2.41Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001)
"Gabapentin is an amino acid, with a mechanism that differs from those of other anticonvulsant drugs such as phenytoin, carbamazepine or valproate."2.40A summary of mechanistic hypotheses of gabapentin pharmacology. ( Boden, P; Brown, JP; Dooley, DJ; Gee, NS; Kocsis, JD; Singh, L; Su, TZ; Taylor, CP; Welty, DF, 1998)
"Gabapentin exposure in treatment-seeking persons with OUD appears to be quite common, and use, both medically and nonmedically, frequently occurs alongside OAMs."1.91Understanding motivations and use typologies of gabapentin with opioid agonist medications. ( Buttram, ME; Ellis, MS; Qureshi, R, 2023)
" However, studies of real-world gabapentinoid dosing demonstrate that the recommended dose targets are frequently not met and do not consider renal insufficiency."1.91Characterization of Outpatient Gabapentinoid Prescribing for Pain. ( A Bowman, L; Banks, C; Merrey, J; Waldfogel, JM, 2023)
"Comorbid diagnosis of headache predicted use of topiramate and VPA, bipolar disease predicted use of LMT and VPA, pain predicted gabapentin, and schizophrenia was associated with VPAs use."1.91Prescribing Trends of Antiseizure Drugs in Women Veterans With Epilepsy. ( Amuan, ME; Henion, A; Lopez, MR; Panahi, S; Pugh, MJ; VanCott, AC, 2023)
"Epicrania fugax (EF) is a primary headache consisting of brief paroxysms of pain, lasting 1-10 s, that move through different nerve territories of one hemicranium with a linear or zigzag trajectory, although there are some clinical variants."1.91Drug-resistant epicrania fugax: Responding to onabotulinumtoxinA. ( Alberola-Amores, FJ; Moral-Rubio, J, 2023)
" Pharmacokinetic parameters were estimated using noncompartmental analysis."1.72Pharmacokinetics and pharmacodynamics of repeat dosing of gabapentin in adult horses. ( Cox, S; Gold, JR; Grubb, TL; Malavasi, L; Villarino, NL, 2022)
"Gabapentin treatment was initiated after baseline evaluation, and the RDD and visual analog scale (VAS) score were both evaluated regularly during the 2-week study period."1.72Rate-Dependent Depression: A Predictor of the Therapeutic Efficacy in Treating Painful Diabetic Peripheral Neuropathy. ( Calcutt, NA; Guan, Y; Lin, Z; Wang, Z; Xie, C; Zhou, X; Zhu, D; Zhu, Y, 2022)
"Gabapentin has emerged as a common therapy for a diverse group of pain syndromes and neurologic conditions in adults."1.62Gabapentin in Infants: Critical Evaluation of a Novel Sedative/Analgesic Medication. ( McPherson, C, 2021)
"Pain is a hallmark of this condition and can be extremely difficult to control."1.56Pain management in patients with end-stage renal disease and calciphylaxis- a survey of clinical practices among physicians. ( Chinnadurai, R; Lowney, AC; Miller, M; Sinha, S, 2020)
"Gabapentin was a prominent drug of abuse in two cohorts of the primarily opioid-using individuals."1.48A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky. ( Boland, EM; Havens, JR; Lofwall, MR; Quiroz, A; Staton, M; Vickers Smith, R; Young, AM, 2018)
" In the dose-response analysis, moderate-dose (OR 2."1.46Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. ( Antoniou, T; Gomes, T; Juurlink, DN; Mamdani, MM; Paterson, JM; van den Brink, W, 2017)
"Chronic pain is a multifactorial disease comprised of both inflammatory and neuropathic components that affect ∼20% of the world's population."1.46sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. ( Bialer, M; Brennan, KC; Devor, M; Kaufmann, D; Smith, MD; West, PJ; White, HS; Yagen, B, 2017)
"Diclofenac treatment produced dose-related reversal of CRANE at 0."1.42Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats. ( Bannon, AW; Joshi, SK; Zhu, CZ, 2015)
"Gabapentin was found to reversibly decrease, but not suppress the flinching frequency of the second response peak only."1.40Semi-mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain. ( Danhof, M; Della Pasqua, O; Taneja, A; Troconiz, IF, 2014)
"Gabapentin, commonly used to treat neuropathic pain, produced increased NAc DA in rats with SNL but not in animals with incisional, injury."1.40Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: a potential biomarker of efficacy. ( Becerra, L; Borsook, D; Navratilova, E; Ossipov, MH; Patwardhan, A; Porreca, F; Qu, C; Xie, JY, 2014)
"6 h, oral bioavailability of 37% and 90%) with anti-inflammatory activity (ED 50 = 37 micromol/kg, mouse) and efficacy in pain models (thermal hyperalgesia, ED 50 = 72 micromol/kg, rat)."1.35Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. ( Adair, RM; Altenbach, RJ; Bettencourt, BM; Brioni, JD; Cowart, MD; Drizin, I; Esbenshade, TA; Fix-Stenzel, SR; Honore, P; Hsieh, GC; Liu, H; Marsh, KC; McPherson, MJ; Milicic, I; Miller, TR; Sullivan, JP; Wetter, JM; Wishart, N; Witte, DG, 2008)
"Gabapentin and R-PIA were administered to obtain the dose-response curve and the 50% effective dose (ED(50))."1.35The interaction of gabapentin and N6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA) on mechanical allodynia in rats with a spinal nerve ligation. ( Jun, IG; Park, JY, 2008)
"Here, we tested the effect of FK1706 on painful diabetic neuropathy in rat model of diabetes induced by streptozotocin (STZ)."1.35FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy. ( Matsuoka, N; Murai, N; Mutoh, S; Price, RD; Yamaji, T; Yamamoto, H; Yamazaki, S, 2008)
"Pain is the result of an emotional and sensory experience and preclinical models of OA can thus be useful to better understand the underlying mechanisms of the disease and test new therapeutic options."1.35Differential analgesic effects of morphine and gabapentin on behavioural measures of pain and disability in a model of osteoarthritis pain in rats. ( Dickenson, AH; Ghandehari, J; Vonsy, JL, 2009)
" Here we determined the antinociceptive effect of chronic administration of neramexane and compared its effect with that of memantine and gabapentin in a rat model of diabetic neuropathic pain."1.35Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain. ( Chen, SR; Pan, HL; Samoriski, G, 2009)
"Primary erythermalgia (erythromelalgia) is a rare autosomal dominant condition characterized by intermittent attacks of erythema, increased skin temperature and severe burning pain in the extremities, in a bilateral symmetrical distribution."1.35Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel. ( Atherton, D; Elmslie, F; Mansour, S; Mortimer, P; Natkunarajah, J, 2009)
"Both indomethacin and morphine were able to block or reverse thermal hyperalgesia and normalize gait in the CARR model."1.35Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models. ( Cummons, TA; Harrison, JE; Leventhal, L; Lu, P; Piesla, MJ; Strassle, BW; Whiteside, GT, 2009)
"Cilnidipine is a 1,4-dihydropyridine-derived voltage-dependent calcium channel (VDCC) blocker and suppresses N-type VDCC currents in addition to L-type VDCC currents."1.35Suppression of formalin-induced nociception by cilnidipine, a voltage-dependent calcium channel blocker. ( Iwata, S; Koganei, H; Shoji, M, 2009)
"Gabapentin has established efficacy in the reduction of burn-induced hyperalgesia and allodynia in animal and human experimental burn models."1.35Successful use of gabapentin in acute pain management following burn injury: a case series. ( Cramond, T; Gray, P; Williams, B, 2008)
"Chronic muscle pain is a problem with high prevalence in clinical practice and its pharmacological treatment is difficult."1.34Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. ( Beyreuther, BK; Geis, C; Sommer, C; Stöhr, T, 2007)
"GBP increases the risk of myoclonus in ESRD."1.33Gabapentin-induced myoclonus in end-stage renal disease. ( Bell, WL; Glenn, DG; O'Donovan, CA; Zhang, C, 2005)
"In contrast, analgesia, sedation and catalepsy were not observed in this dose range, but were apparent at 100 mg/kg."1.33Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. ( Boulet, JM; Chaffer, SM; Elsemore, DA; Gottshall, SL; Harrison, JE; Koetzner, L; Lee, G; Mark, L; Miller, W; Pearson, MS; Rabadi, L; Rotshteyn, Y; Shan, S; Tafesse, L; Toth, M; Turchin, PI; Valenzano, KJ; Whiteside, GT, 2005)
"Neuropathic pain is a clinical manifestation characterized by the presence of spontaneous pain, allodynia and hyperalgesia."1.33Development and expression of neuropathic pain in CB1 knockout mice. ( Castañé, A; Célérier, E; Ledent, C; Maldonado, R; Martín, M; Parmentier, M; Valverde, O, 2006)
"Ambroxol's effects were compared with those of gabapentin."1.33Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. ( Arndt, K; Gaida, W; Klinder, K; Weiser, T, 2005)
"Pinacidil activity was not blocked by L-NAME, D-NAME, 7-nitroindazole, ODQ, KT-5823 or okadaic acid."1.33The nitric oxide-cyclic GMP-protein kinase G-K+ channel pathway participates in the antiallodynic effect of spinal gabapentin. ( Flores-Murrieta, FJ; Granados-Soto, V; Mixcoatl-Zecuatl, T, 2006)
"The severe burning pain, deep pressure-like pain, and deep mechanical allodynia, which presented over the contralateral side to the TBI, were successfully relieved with motor cortex stimulation (MCS)."1.33Motor cortex stimulation for central pain following a traumatic brain injury. ( Choi, ES; Hong, JT; Lee, SW; Son, BC; Sung, JH, 2006)
"Paclitaxel (Taxol) is a widely used chemotherapeutic agent in the treatment of several tumors."1.33Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. ( Hald, A; Inoue, M; Matsumoto, M; Ueda, H; Xie, W, 2006)
" This dosage produced a substantial but non-significant decrease in the incidence of postherpetic pain-related responses."1.32Effects of the suppression of acute herpetic pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice. ( Kuraishi, Y; Nojima, H; Shiraki, K; Takahata, H; Takasaki, I, 2004)
"Gabapentin (GBP) is a new antiepileptic agent with an original spectrum of activity."1.32[Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004)
"The initial hyperalgesia induced by 0."1.31Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia. ( Assié, MB; Bardin, L; Carilla-Durand, E; Colpaert, FC; Cosi, C; Koek, W; Pauwels, PJ; Tarayre, JP; Vacher, B; Wiesenfeld-Hallin, Z; Xu, XJ, 2002)
"Allodynia and hyperalgesia appeared on day 5 post-inoculation."1.31Pharmacological and immunohistochemical characterization of a mouse model of acute herpetic pain. ( Andoh, T; Kuraishi, Y; Nemoto, H; Nitta, M; Nojima, H; Shiraki, K; Takahata, H; Takasaki, I, 2000)
"Gabapentin treatment significantly and reversibly changed the responses, consistent with the attenuation of the abnormal sensory behavior, and the attenuated responses lasted for the duration of the drug effect (up to 6 h)."1.31Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. ( Hulsebosch, CE; McAdoo, DJ; Perez-Polo, JR; Taylor, CP; Westlund, KN; Xu, GY, 2000)
"SCI gabapentin-treated rats did not display differences in total rearing time until PSD 28 and a significant difference in total activity of all measured parameters was not seen until PSD 60."1.31Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury. ( Grady, JJ; Hulsebosch, CE; Mills, CD, 2001)
"Acyclovir treatment healed all skin lesions by day 15 after inoculation."1.31Effects of analgesics on delayed postherpetic pain in mice. ( Andoh, T; Kuraishi, Y; Nojima, H; Sasaki, A; Shiraki, K; Takasaki, I, 2002)
"Gabapentin (GBP) is a gamma-aminobutyric acid analog originally synthesized for its anticonvulsant actions."1.30Gabapentin reverses the allodynia produced by the administration of anti-GD2 ganglioside, an immunotherapeutic drug. ( Gillin, S; Sorkin, LS, 1998)
"Gabapentin is an anticonvulsant that may represent a novel class of drugs, which has novel spinal antihyperalgesic activity."1.30The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat. ( Jun, JH; Yaksh, TL, 1998)
"Gabapentin (GP) has been shown to have antihyperalgesic properties and the site of drug action is reported to be the central nervous system."1.30Attenuation of formalin-induced nociceptive behaviors following local peripheral injection of gabapentin. ( Carlton, SM; Zhou, S, 1998)
"A variety of treatments for the pain were ineffective."1.30Gabapentin for treatment of neuropathic pain in a 12-year-old girl. ( McGraw, T; Stacey, BR, 1998)

Research

Studies (418)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's36 (8.61)18.2507
2000's232 (55.50)29.6817
2010's111 (26.56)24.3611
2020's39 (9.33)2.80

Authors

AuthorsStudies
Hong-Ju, Y1
He, L1
Wei-Guo, S1
Nan, Z1
Wei-Xiu, Y1
Zhong-Wei, J1
Jun-Wei, W1
Zheng-Hua, G1
Bo-Hua, Z1
Zhi-Pu, L1
Zhe-Hui, G1
Mortell, KH1
Anderson, DJ1
Lynch, JJ1
Nelson, SL1
Sarris, K1
McDonald, H1
Sabet, R1
Baker, S1
Honore, P3
Lee, CH1
Jarvis, MF2
Gopalakrishnan, M1
Yogeeswari, P1
Ragavendran, JV1
Sriram, D1
Nageswari, Y1
Kavya, R1
Sreevatsan, N1
Vanitha, K1
Stables, J1
Shieh, CC1
Chapman, M1
Joshi, S1
Zhang, XF1
Kort, M1
Carroll, W1
Marron, B1
Atkinson, R1
Thomas, J1
Liu, D1
Krambis, M1
Liu, Y2
McGaraughty, S1
Chu, K1
Roeloffs, R1
Zhong, C1
Mikusa, JP1
Hernandez, G2
Gauvin, D1
Wade, C1
Zhu, C1
Pai, M1
Scanio, M1
Shi, L1
Drizin, I2
Gregg, R1
Matulenko, M1
Hakeem, A1
Gross, M1
Johnson, M1
Marsh, K1
Wagoner, PK1
Sullivan, JP2
Faltynek, CR1
Krafte, DS1
Field, MJ3
Li, Z1
Schwarz, JB1
Cowart, MD1
Altenbach, RJ1
Liu, H2
Hsieh, GC1
Milicic, I1
Miller, TR1
Witte, DG1
Wishart, N1
Fix-Stenzel, SR1
McPherson, MJ1
Adair, RM1
Wetter, JM1
Bettencourt, BM1
Marsh, KC1
Esbenshade, TA1
Brioni, JD1
Rephaeli, A1
Gil-Ad, I1
Aharoni, A1
Tarasenko, I1
Tarasenko, N1
Geffen, Y1
Halbfinger, E1
Nisemblat, Y1
Weizman, A1
Nudelman, A1
Payne, JE1
Bonnefous, C1
Symons, KT1
Nguyen, PM1
Sablad, M1
Rozenkrants, N1
Zhang, Y1
Wang, L1
Yazdani, N1
Shiau, AK1
Noble, SA1
Rix, P1
Rao, TS1
Hassig, CA1
Smith, ND1
Rawson, DJ1
Brugier, D1
Harrison, A1
Hough, J1
Newman, J1
Otterburn, J1
Maw, GN1
Price, J1
Thompson, LR1
Turnpenny, P1
Warren, AN1
Valhondo, M1
Marco, I1
Martín-Fontecha, M1
Vázquez-Villa, H1
Ramos, JA1
Berkels, R1
Lauterbach, T1
Benhamú, B1
López-Rodríguez, ML1
Lebedyeva, IO1
Ostrov, DA1
Neubert, J1
Steel, PJ1
Patel, K1
Sileno, SM1
Goncalves, K1
Ibrahim, MA1
Alamry, KA1
Katritzky, AR1
Li, Y1
Liu, YB1
Zhang, JJ1
Ma, SG1
Qu, J1
Lv, HN1
Yu, SS1
Healy, MP1
Allan, AC1
Bailey, K1
Billinton, A1
Chessell, IP1
Clayton, NM1
Giblin, GMP1
Kay, MA1
Khaznadar, T1
Michel, AD1
Naylor, A1
Price, H1
Spalding, DJ1
Stevens, DA1
Swarbrick, ME1
Wilson, AW1
Cook, A1
Modh, A1
Ali, H1
Sheqwara, J1
Chang, S1
Ghanem, T1
Momin, S1
Wu, V1
Tam, S1
Money, S1
Han, X1
Fakhoury, L1
Movsas, B1
Siddiqui, F1
Oliveira, ADP1
Silva-Néto, RP1
Gold, JR1
Grubb, TL1
Cox, S1
Malavasi, L1
Villarino, NL1
McDowell, L1
Bossi, P1
Zhou, X1
Zhu, Y1
Wang, Z1
Lin, Z1
Zhu, D1
Xie, C1
Calcutt, NA2
Guan, Y1
Welch, EK1
Dengler, KL1
DiCarlo-Meacham, AM1
Wheat, JE1
Stone, GW1
Olsen, C1
Von Pechmann, W1
Zhang, XY1
Barakat, A1
Diaz-delCastillo, M1
Vollert, J1
Sena, ES1
Heegaard, AM1
Rice, ASC1
Soliman, N1
Ma, SJ2
Wang, K2
Iovoli, AJ3
Attwood, K3
Hermann, G2
Farrugia, M2
Singh, AK3
Kim, TW1
Samet, JH1
Lodi, S1
Kimmel, SD1
Forman, LS1
Lira, MC1
Liebschutz, JM1
Williams, EC1
Walley, AY1
Asgardoon, MH1
Jazayeri, SB1
Behkar, A1
Dabbagh Ohadi, MA1
Yarmohammadi, H1
Ghodsi, Z1
Pomerani, TI1
Mojtahedzadeh, M1
Rahimi-Movaghar, V1
Pan, Y1
Davis, PB1
Kaebler, DC1
Blankfield, RP1
Xu, R1
Toma, W1
Paris, JJ1
Warncke, UO1
Nass, SR1
Caillaud, M1
McKiver, B1
Ondo, O1
Bagdas, D1
Bigbee, J1
Knapp, PE1
Hauser, KF1
Damaj, MI1
Brant, AR1
Reeves, MF1
Ye, PP1
Scott, RK1
Floyd, S1
Tefera, E1
Lotke, PS1
Candon, M1
Strominger, J1
Gerlach, LB1
Maust, DT1
Ellis, MS4
Qureshi, R3
Buttram, ME5
Williams, CD1
Al-Jammali, Z1
Herink, MC1
Neimanis, D1
Smith, KA1
Banks, C1
A Bowman, L1
Merrey, J1
Waldfogel, JM1
Yang, HH1
Wu, TJ1
Suh, JD1
Wang, MB1
Holliday, M1
Beswick, D1
Zhang, H1
Wells, C1
McCormick, J1
Maxim, T1
Regev, A1
Chandy, ZK1
Lee, JT1
Onal, O1
Onal, M1
Smith, LE1
Murphy, BA2
Smith, DK2
Lopez, MR1
VanCott, AC1
Amuan, ME1
Panahi, S1
Henion, A1
Pugh, MJ1
Ferron, L1
Gandini, MA1
Zamponi, GW1
Alberola-Amores, FJ1
Moral-Rubio, J1
Cao, J1
An, Q1
Han, F1
Kurtz, SP2
Cicero, TJ2
Havens, JR2
Goodman, CW2
Brett, AS2
Hermann, GM1
Platek, AJ1
Wang, C1
Miller, A2
Bourgeois, DJ1
Ala, S1
Zamani, N1
Akbari, J1
Salehifar, E1
Janbabai, G1
Koulaeinejad, N1
Waddy, SP1
Becerra, AZ1
Ward, JB1
Chan, KE1
Fwu, CW1
Eggers, PW1
Abbott, KC1
Kimmel, PL1
Gallego, H1
Aleshaki, JS1
Cmelak, A1
Niermann, K1
Ghiam, M1
Lou, D1
Gilbert, J1
Gibson, MK1
Hawkins, D1
Aksan, F1
Nelson, EA1
Swedish, KA1
Chinnadurai, R1
Sinha, S1
Lowney, AC1
Miller, M1
Zhou, L1
Bhattacharjee, S1
Kwoh, CK1
Malone, DC1
Tighe, PJ1
Reisfield, GM1
Slack, M1
Wilson, DL1
Lo-Ciganic, WH1
Slovak, JE1
Costa, AP1
McPherson, C1
Tu, TG1
Sadeghi, S1
Atayee, R1
Lee, K3
Harvey, A1
Waugh, MC1
Rice, J1
Antolovich, G1
Copeland, L1
Orsini, F1
Scheinberg, A1
McKinnon, C1
Thorley, M1
Baker, F1
Chalkiadis, G1
Stewart, K1
Gomes, T1
Juurlink, DN1
Antoniou, T1
Mamdani, MM1
Paterson, JM1
van den Brink, W1
Vickers Smith, R1
Boland, EM1
Young, AM1
Lofwall, MR1
Quiroz, A1
Staton, M1
Jordan, RI1
Mulvey, MR1
Bennett, MI2
Brown, CS1
Bachmann, GA1
Wan, J1
Foster, DC1
Wong, JW1
Chin, JM1
Schlueter, RJ1
Guglielmi, G1
Novick, TK1
Surapaneni, A1
Shin, JI1
Ballew, SH1
Alexander, GC1
Inker, LA1
Chang, AR1
Grams, ME1
Alexander, J1
Edwards, RA1
Brodsky, M1
Manca, L1
Grugni, R1
Savoldelli, A1
Bonfanti, G1
Emir, B1
Whalen, E1
Watt, S1
Parsons, B1
Monteiro, BP1
de Lorimier, LP1
Moreau, M1
Beauchamp, G1
Blair, J1
Lussier, B1
Pelletier, JP1
Troncy, E1
Sriperumbuduri, S1
Hiremath, S1
Gross, JL1
Perate, AR1
Elkassabany, NM1
Wampole, CR1
Smith, KE1
Polaner, DM1
Shafer, SL1
Enteshari-Moghaddam, A1
Azami, A1
Isazadehfar, K1
Mohebbi, H1
Habibzadeh, A1
Jahanpanah, P1
Okamoto, M1
Takahagi, S1
Kamegashira, A1
Yanase, Y1
Hide, M1
Ongun, N1
Ongun, GT1
Burnsed, JC1
Heinan, K1
Letzkus, L1
Zanelli, S1
Kardeş, S1
Fraccaro, E1
Coetzee, JF2
Odore, R1
Edwards-Callaway, LN1
Kukanich, B1
Badino, P1
Bertolotti, L1
Glynn, H1
Dockweiler, J1
Allen, K1
Bergamasco, L1
García-Hernández, L1
Navarrete-Vázquez, G1
González-Trujano, ME1
López-Muñoz, FJ2
Déciga-Campos, M1
Ramirez-Fort, MK1
Doan, HQ1
Nguyen, HP1
Khan, F1
Kauffman, J1
Campbell, LS1
Taneja, A1
Troconiz, IF1
Danhof, M1
Della Pasqua, O1
Liu, J2
Wang, LN2
McNicol, ED2
Yan, PZ1
Butler, PM1
Kurowski, D1
Perloff, MD1
Scheinfeld, N2
Haviv, Y1
Zadik, Y1
Sharav, Y1
Benoliel, R1
Starmer, HM1
Yang, W1
Raval, R1
Gourin, CG1
Richardson, M1
Kumar, R1
Jones, B1
McNutt, T1
Cheng, Z1
Cheng, S1
Quon, H3
Xie, JY1
Qu, C1
Patwardhan, A1
Ossipov, MH1
Navratilova, E1
Becerra, L2
Borsook, D3
Porreca, F1
Zhang, MM1
Liu, SB1
Chen, T1
Koga, K1
Zhang, T1
Li, YQ1
Zhuo, M1
Işik, B1
Yaman, S1
Aktuna, S1
Turan, A2
Suzuki, T1
Hashimoto, Y1
Anzai, S1
Nagasawa, K1
Shinde, S1
Gordon, P1
Sharma, P1
Gross, J1
Davis, MP1
Wodarski, R2
Schuh-Hofer, S1
Yurek, DA1
Wafford, KA1
Gilmour, G1
Treede, RD1
Kennedy, JD1
Boyle, Y1
Fernando, D1
Kurz, H1
Miller, SR1
Zucchetto, M1
Storey, J1
Sarıtaş, TB1
Korkmaz, M1
Sevimli, A1
Sarıtaş, ZK1
Scholl, JH1
van Eekeren, R1
van Puijenbroek, EP1
Matsumura, S1
Taniguchi, W1
Nishida, K2
Nakatsuka, T1
Ito, S1
Hauer, JM1
Solodiuk, JC1
Zhu, CZ1
Bannon, AW1
Joshi, SK1
Inkpen, H1
North, JM1
Hong, KS1
Rauck, RL1
Farmakidis, C1
Inan, S1
Milstein, M1
Herskovitz, S1
Bassani, AS1
Banov, D1
Gould, SA1
Doods, H1
Lamla, T1
Pekcec, A1
Lee-Kubli, CA1
Ingves, M1
Henry, KW1
Shiao, R1
Collyer, E1
Tuszynski, MH1
Campana, WM1
Mimenza Alvarado, A1
Aguilar Navarro, S1
Alrawashdeh, O1
Kataoka, T1
Kiyota, N1
Shimada, T1
Funakoshi, Y1
Chayahara, N1
Toyoda, M1
Fujiwara, Y1
Nibu, K1
Komori, T1
Sasaki, R1
Mukohara, T1
Minami, H1
Hopkins, HL1
Duggett, NA1
Flatters, SJL1
van den Beuken-van Everdingen, MH1
de Graeff, A1
Jongen, JL1
Dijkstra, D1
Mostovaya, I1
Vissers, KC1
Yoshikawa, N1
Naito, T1
Yagi, T1
Kawakami, J1
Yin, K1
Deuis, JR1
Lewis, RJ1
Vetter, I1
Ehieli, E1
Yalamuri, S1
Brudney, CS1
Pyati, S1
Milazzo-Kiedaisch, CA1
Itano, J1
Dutta, PR3
Kaufmann, D1
West, PJ1
Smith, MD1
Yagen, B1
Bialer, M1
Devor, M2
White, HS1
Brennan, KC1
Ding, W1
You, Z1
Shen, S1
Yang, J2
Lim, G1
Doheny, JT1
Chen, L1
Zhu, S1
Mao, J2
Caraceni, A2
Zecca, E2
Martini, C2
Pigni, A1
Bracchi, P1
Wood, PL1
Mahmood, SA1
Moskal, JR1
Forde, G2
Stanos, S1
Price, G1
Park, JY1
Jun, IG1
Boardman, LA1
Cooper, AS1
Blais, LR1
Raker, CA1
Yamazaki, S1
Yamaji, T1
Murai, N1
Yamamoto, H1
Price, RD1
Matsuoka, N1
Mutoh, S1
Hayashida, K3
Eisenach, JC5
Bannwarth, B1
Vonsy, JL1
Ghandehari, J1
Dickenson, AH5
Fürst, Z1
Clark, AK1
Grist, J1
Marchand, F1
Malcangio, M1
Pigatto, PD1
Guzzi, G1
Carlsson, KC1
van de Schootbrugge, M1
Eriksen, HO1
Moberg, ER1
Karlsson, MO1
Hoem, NO1
Yalcin, I1
Tessier, LH1
Petit-Demoulière, N1
Doridot, S1
Hein, L1
Freund-Mercier, MJ1
Barrot, M1
Dworkin, RH1
Barbano, RL1
Tyring, SK1
Betts, RF1
McDermott, MP1
Pennella-Vaughan, J1
Bennett, GJ1
Berber, E1
Gnann, JW1
Irvine, C1
Kamp, C1
Kieburtz, K1
Max, MB2
Schmader, KE1
Quilici, S1
Chancellor, J1
Löthgren, M1
Simon, D1
Said, G1
Le, TK1
Garcia-Cebrian, A1
Monz, B1
Chiechio, S1
Zammataro, M1
Caraci, F1
Rampello, L1
Copani, A1
Sabato, AF2
Nicoletti, F1
Lin, CF1
Tsaur, ML1
Lin, CS1
Chen, CC1
Huang, YJ1
Cheng, JK2
Gauchan, P1
Andoh, T5
Ikeda, K1
Fujita, M1
Sasaki, A3
Kato, A1
Kuraishi, Y7
Omori, Y1
Kagaya, K1
Enomoto, R1
Nojima, H6
Takahata, H4
Chen, SR3
Samoriski, G1
Pan, HL3
Gatti, A1
Carucci, A1
Bertini, L1
Mammucari, M1
Occhioni, R1
De la O-Arciniega, M1
Díaz-Reval, MI1
Cortés-Arroyo, AR1
Domínguez-Ramírez, AM1
Marino, F1
Takasu, K4
Kinoshita, Y1
Ono, H4
Tanabe, M4
Davis, AM2
Bruce, AS1
Mangiaracina, C1
Schulz, T1
Hyman, P1
Natkunarajah, J1
Atherton, D1
Elmslie, F1
Mansour, S1
Mortimer, P1
Bar Ad, V3
Weinstein, G2
Chalian, A2
Both, S2
Haney, AL1
Garner, SS1
Cox, TH1
Piesla, MJ1
Leventhal, L1
Strassle, BW1
Harrison, JE2
Cummons, TA1
Lu, P1
Whiteside, GT3
Fleckenstein, J1
Kramer, S1
Hoffrogge, P1
Thoma, S1
Lang, PM1
Lehmeyer, L1
Schober, GM1
Pfab, F1
Ring, J1
Weisenseel, P1
Schotten, KJ1
Mansmann, U1
Irnich, D1
Takatani, J1
Takeshima, N1
Okuda, K1
Miyakawa, H1
Noguchi, T1
Koganei, H1
Shoji, M1
Iwata, S1
Vedula, SS1
Bero, L1
Scherer, RW1
Dickersin, K1
Morris-Stiff, G1
Lewis, MH1
Takahashi, H1
Shimoyama, N2
Filler, AG1
Bacon, M1
Frederickson, M1
Howe, FA1
Rabinowitz, MD1
Sokoloff, AJ1
Deacon, TW1
Abell, C1
Munglani, R1
Griffiths, JR1
Bell, BA1
Lever, AM1
Toth, C1
Arai, YC1
Matsubara, T1
Shimo, K1
Suetomi, K1
Nishihara, M1
Ushida, T1
Kobayashi, K1
Suzuki, C1
Kinoshita, A1
Kondo, M1
Matsubara, S1
Hayashi, R1
Tohyama, Y1
Arakawa, M1
Wolfe, KC1
Poma, R1
Liao, XZ1
Zhou, MT1
Mao, YF1
Xu, H2
Chen, H1
Sun, JH1
Xiong, YC1
Tran, DQ1
Duong, S1
Finlayson, RJ1
Kolosov, A1
Goodchild, CS1
Cooke, I1
Tuchman, M1
Barrett, JA1
Donevan, S1
Hedberg, TG1
Taylor, CP3
Scrivani, S1
Wallin, D1
Moulton, EA1
Cole, S1
Wasan, AD1
Lockerman, L1
Bajwa, Z1
Upadhyay, J1
Heidelbaugh, JJ1
Llanes, M1
Weadock, WJ1
Munro, G3
Dyhr, H2
Grunnet, M1
Dosoretz, A1
Raffa, RB1
Pergolizzi, JV1
Segarnick, DJ1
Tallarida, RJ2
Peters, CM1
Ewan, EE1
Nakajima, K1
Obata, H2
Xu, Q1
Yaksh, TL5
Ko, SH1
Kwon, HS1
Yu, JM1
Baik, SH1
Park, IB1
Lee, JH1
Ko, KS1
Noh, JH1
Kim, DS1
Kim, CH1
Mok, JO1
Park, TS1
Son, HS1
Cha, BY1
Christianson, CA1
Corr, M1
Firestein, GS1
Mobargha, A1
Svensson, CI2
Tzellos, TG1
Toulis, KA1
Goulis, DG1
Papazisis, G1
Zampeli, VA1
Vakfari, A1
Kouvelas, D1
Takasaki, I5
Schleich, A1
Baumann, H1
Touchette, D1
Gessler, EM1
Ogino, Y1
Lantos, PM1
Vettorato, E1
Corletto, F1
Jamshidian, F1
Hubbard, AE1
Jewell, NP1
Oshita, K1
Saeki, N1
Niinai, H1
Hamada, H1
Kawamoto, M1
Galkin, VV1
Nesterova, MV1
Emel'ianov, VV1
Panah Khahi, M1
Yaghooti, AA1
Marashi, SH1
Nadjafi, A1
Udall, M1
Harnett, J1
Mardekian, J1
Storm, A1
Hansen, MK1
Marcher, L1
Erichsen, HK2
Sheykhzade, M1
Andrews, N1
Legg, E1
Lisak, D1
Issop, Y1
Richardson, D1
Harper, S1
Pheby, T2
Huang, W1
Burgess, G1
Machin, I1
Rice, AS2
Neelakantan, H1
Walker, EA1
Yang, JL1
Xu, B1
Li, SS1
Zhang, WS1
Deng, XM1
Zhang, YQ1
Inceoglu, B1
Wagner, KM1
Bettaieb, A1
Schebb, NH1
Hwang, SH1
Morisseau, C1
Haj, FG1
Hammock, BD1
Kawasaki, M1
Hatashima, S1
Matsuda, T1
Kilic, FS1
Sirmagul, B1
Yildirim, E1
Oner, S1
Erol, K1
Hauer, J1
Mackey, D1
Hansen, RR1
Brown, DT1
Mirza, NR1
Arcos, M1
Palanca, JM1
Montes, F1
Barrios, C1
Oya, H1
Matoba, M1
Murakami, S1
Ohshiro, T1
Kishino, T1
Satoh, Y1
Tsukahara, T1
Hori, S1
Maeda, M1
Makino, T1
Maeda, T1
Clarke, H1
Kirkham, KR1
Orser, BA1
Katznelson, R1
Mitsakakis, N1
Ko, R1
Snyman, A1
Ma, M1
Katz, J1
Abe, M1
Kurihara, T1
Han, W1
Shinomiya, K1
Tanabe, T1
Pelham, A1
Lee, MA1
Regnard, CB1
Wallin, J1
Cui, JG1
Yakhnitsa, V1
Schechtmann, G1
Meyerson, BA1
Linderoth, B1
Hunt, CH1
Dodick, DW1
Bosch, EP1
Chen, B1
Stitik, TP1
Foye, PM1
Nadler, SF1
DeLisa, JA1
Laughlin, TM1
Tram, KV1
Wilcox, GL1
Birnbaum, AK1
Gilron, I5
Backonja, MM1
Gonzalez, MI2
Singh, L3
Bortalanza, LB1
Ferreira, J1
Hess, SC1
Delle Monache, F1
Yunes, RA1
Calixto, JB3
Serpell, MG1
Vitek, L1
Tettenborn, B1
Colpaert, FC2
Tarayre, JP2
Koek, W2
Pauwels, PJ1
Bardin, L1
Xu, XJ3
Wiesenfeld-Hallin, Z3
Cosi, C1
Carilla-Durand, E1
Assié, MB1
Vacher, B1
Luo, ZD2
Higuera, ES2
Valder, CR1
Song, YH1
Myers, RR1
Garcia-Borreguero, D1
Larrosa, O1
de la Llave, Y1
Verger, K1
Masramon, X1
Pandey, CK2
Bose, N1
Garg, G1
Singh, N1
Baronia, A1
Agarwal, A1
Singh, PK1
Singh, U1
Eisenberg, E1
Brecker, C1
Feng, Y2
Cui, M2
Willis, WD2
Nicolas, X1
Vaillant, PY1
Bellard, S1
Backonja, M2
Glanzman, RL1
Iida, Y1
Zhang, HW1
Uehara, S1
Murata, J1
Saiki, I1
Ouchi, H1
Neumeier, S1
Brinkschmidt, T1
Jensen, U1
Boyce, JR1
Peters, GE1
Biederman, J1
Jhamandas, K1
Hong, M1
Yen, HL1
Chan, W1
Sarantopoulos, C2
McCallum, B1
Sapunar, D1
Kwok, WM1
Hogan, Q2
Maneuf, YP3
Sutton, KS1
Chung, FZ1
Pinnock, RD1
Twaddle, ML1
Scheschonka, A1
Beuche, W1
Kassuya, CA1
Silvestre, AA1
Rehder, VL1
Paradowski, B1
Bilinska, M1
Oneschuk, D1
al-Shahri, MZ1
Kumar, P1
Jain, MK1
Sloan, PA1
Kancharla, A1
Chesler, EJ1
Ritchie, J1
Kokayeff, A1
Lariviere, WR1
Wilson, SG1
Mogil, JS1
Lockwood, PA1
Cook, JA1
Ewy, WE1
Mandema, JW1
Wu, WP1
Hao, JX2
Ongini, E1
Impagnatiello, F1
Presotto, C1
von Orelli, F1
Scullin, P1
Sheahan, P1
Sheila, K1
Reyes-García, G2
Medina-Santillán, R2
Rocha-González, HI2
Granados-Soto, V4
Blake, R1
Andrews, NA1
McKnight, AT1
White, WT1
Patel, N1
Drass, M1
Nalamachu, S1
Simpson, KH1
Kanai, A1
McCallum, JB1
Shiraki, K4
Baron, R1
Lotery, HE1
McClure, N1
Galask, RP1
Villarejo, A1
Porta-Etessam, J3
Camacho, A1
González De La Aleja, J1
Martínez-Salio, A3
Penas, M1
Keskinbora, K1
Pekel, AF1
Aydinli, I1
Stahl, SM1
Hobgood, C1
Hevia, A1
Hinchey, P1
Bonezzi, C1
Arcuri, E1
Yaya Tur, R1
Maltoni, M1
Visentin, M1
Gorni, G1
Tirelli, W1
Barbieri, M1
De Conno, F1
Iyengar, S1
Webster, AA1
Hemrick-Luecke, SK1
Xu, JY1
Simmons, RM1
Ilag, VL1
Decosterd, I1
Allchorne, A1
Woolf, CJ1
Rasmussen, PV1
Sindrup, SH1
Jensen, TS2
Bach, FW1
Lim, LS1
Takahashi, PY1
Zamiri, M1
Bilsland, D1
Smiley, MM1
Lu, Y1
Vera-Portocarrero, LP1
Zidan, A1
Westlund, KN2
van de Vusse, AC1
Stomp-van den Berg, SG1
Kessels, AH1
Weber, WE1
Jones, CK1
Peters, SC1
Shannon, HE1
Lossignol, DA1
Plehiers, B1
Body, JJ1
Donovan-Rodriguez, T1
Urch, CE1
Yoon, MH2
Choi, JI1
Park, HC1
Bae, HB1
Jeong, SW1
Jeong, CY1
Derbyshire, E1
Martin, D1
Morales-Franco, G1
Espinoza-Raya, J1
Braune, S1
Zhang, C1
Glenn, DG1
Bell, WL1
O'Donovan, CA1
Urban, MO1
Ren, K1
Park, KT1
Campbell, B1
Anker, N1
Stearns, B1
Aiyar, J1
Belley, M1
Cohen, C1
Bristow, L1
Criscuolo, S1
Auletta, C1
Lippi, S1
Brogi, F1
Brogi, A1
Valenzano, KJ1
Tafesse, L1
Lee, G1
Boulet, JM1
Gottshall, SL1
Mark, L1
Pearson, MS1
Miller, W1
Shan, S1
Rabadi, L1
Rotshteyn, Y1
Chaffer, SM1
Turchin, PI1
Elsemore, DA1
Toth, M1
Koetzner, L1
Hong, HB1
Xu, RJ1
Hama, AT1
Raza, M1
Tripathi, M1
Navkar, DV1
Kumar, A1
Singh, UK1
Nordmann, GR1
Lauder, GR1
Grier, DJ1
Wiffen, P1
Collins, S1
McQuay, H1
Carroll, D1
Jadad, A1
Moore, A1
Wiffen, PJ1
McQuay, HJ1
Edwards, JE1
Moore, RA1
Kroin, JS1
Buvanendran, A1
Cochran, E1
Tuman, KJ1
Bassani, F1
Bergamaschi, M1
Tonino Bolzoni, P1
Villetti, G1
Pedersen, LH1
Nielsen, AN1
Blackburn-Munro, G2
Suzuki, R1
Rahman, W1
Rygh, LJ1
Webber, M1
Hunt, SP1
Castañé, A1
Célérier, E1
Martín, M1
Ledent, C1
Parmentier, M1
Maldonado, R1
Valverde, O1
Gaida, W1
Klinder, K1
Arndt, K1
Weiser, T1
Quintão, NLM1
Medeiros, R1
Santos, ARS1
Campos, MM1
Iannetti, GD2
Zambreanu, L1
Wise, RG2
Buchanan, TJ1
Huggins, JP1
Smart, TS2
Vennart, W1
Tracey, I2
Ross, JR1
Goller, K1
Hardy, J1
Riley, J1
Broadley, K1
A'hern, R1
Williams, J1
Baillie, JK1
Power, I1
Mixcoatl-Zecuatl, T1
Flores-Murrieta, FJ1
Chiou, LC1
Ebell, M1
Kripke, C1
Guay, DR1
Son, BC1
Lee, SW1
Choi, ES1
Sung, JH1
Hong, JT1
Matsumoto, M1
Inoue, M1
Hald, A1
Xie, W1
Ueda, H1
Bekkelund, SI1
Lilleng, H1
Tønseth, S1
Rode, F1
Broløs, T1
Bjerrum, OJ1
Mathiesen, O1
Imbimbo, BP1
Hilsted, KL1
Fabbri, L1
Dahl, JB1
Moulin, D1
Meymandi, MS2
Sepehri, G2
Mobasher, M1
Nikolajsen, L1
Finnerup, NB1
Kramp, S1
Vimtrup, AS1
Keller, J1
Cuignet, O1
Pirson, J1
Soudon, O1
Zizi, M1
Felicio, AC1
Godeiro, Cde O1
Borges, V1
Silva, SM1
Ferraz, HB1
Takeuchi, Y1
Honda, M1
White, PF1
Karamanlioglu, B1
Pamukçu, Z1
Rashid, RM1
Ibrahim, S1
Patel, V1
Barsukov, IN1
Kashin, AV1
Kostiuk, GP1
Coderre, TJ1
Kumar, N1
Lefebvre, CD1
Yu, JS1
Norman, P1
Beyreuther, BK1
Geis, C1
Stöhr, T1
Sommer, C1
Ortega-Varela, LF1
Herrera, JE1
Caram-Salas, NL1
Arnold, LM1
Goldenberg, DL2
Stanford, SB1
Lalonde, JK1
Sandhu, HS1
Keck, PE1
Welge, JA1
Bishop, F1
Stanford, KE1
Hess, EV1
Hudson, JI1
Harris, G1
Horowitz, B1
Borgida, A1
Terneus, W1
Parker, R1
Wallace, VC1
Segerdahl, AR1
Lambert, DM1
Vandevoorde, S1
Blackbeard, J1
Hasnie, F1
Sinclair, AM1
Miller, B1
Lee, LK1
Gil, DW1
Cheevers, CV1
Donello, JE1
Rodríguez, MJ1
Díaz, S1
Vera-Llonch, M1
Dukes, E1
Rejas, J2
Savica, R1
Beghi, E1
Mazzaglia, G1
Innocenti, F1
Brignoli, O1
Cricelli, C1
Caputi, AP1
Musolino, R1
Spina, E1
Trifirò, G1
Spiller, J1
Niscola, P1
Perrotti, AP1
del Poeta, G1
Romani, C1
Palombi, M1
Piccioni, D1
Scaramucci, L1
Tolu, B1
Tendas, A1
Cupelli, L1
Abruzzese, E1
D'Elia, GM1
Brunetti, GA1
Maurillo, L1
Giovannini, M1
Cartoni, C1
de Fabritiis, P1
Christie, J1
Rintala, DH1
Holmes, SA1
Courtade, D1
Fiess, RN1
Tastard, LV1
Loubser, PG1
Aizawa, H1
Mitsis, GD1
Governo, RJ1
Morris, PG1
Marsden, CA1
Chapman, V1
Celebi, N1
Canbay, O1
Aycan, IO1
Sahin, A1
Aypar, U1
Pardo, A1
Ruiz, MA1
Gray, P1
Williams, B1
Cramond, T1
Kavalieratos, CS1
Dimou, T1
Bras, M1
Haugen, RN1
Tharp, MD1
Haslam, C1
Nurmikko, T1
Iyer, R1
Egloff, L1
Fraas, J1
Harris, JD1
Coste, O1
Pierre, S1
Marian, C1
Brenneis, C1
Angioni, C1
Schmidt, H1
Popp, L1
Geisslinger, G1
Scholich, K1
Stepanovic-Petrovic, RM1
Tomic, MA1
Vuckovic, SM1
Paranos, S1
Ugresic, ND1
Prostran, MS1
Milovanovic, S1
Boskovic, B1
Zapp, JJ1
McGraw, T2
Kosek, P1
Shimoyama, M1
Inturrisi, CE1
Elliott, KJ1
Hunter, JC2
Gogas, KR1
Hedley, LR2
Jacobson, LO1
Kassotakis, L1
Thompson, J1
Fontana, DJ1
Sist, T1
Filadora, V1
Miner, M1
Lema, M1
Samkoff, LM1
Daras, M1
Tuchman, AJ1
Koppel, BS1
Wetzel, CH1
Connelly, JF1
Rosenberg, JM1
Harrell, C1
Ristic, H1
Werner, RA1
de Rosayro, AM1
Khatri, A1
Pearlstein, L1
Houtchens, MK1
Richert, JR1
Sami, A1
Rose, JW1
Gillin, S1
Sorkin, LS1
Jun, JH1
Gould, HJ1
Gee, NS1
Su, TZ1
Kocsis, JD1
Welty, DF1
Brown, JP1
Dooley, DJ1
Boden, P1
McCaffery, M1
Carlton, SM1
Zhou, S1
Merren, MD1
Ness, TJ1
San Pedro, EC1
Richards, SJ1
Kezar, L1
Liu, HG1
Mountz, JM1
Beydoun, A2
Edwards, KR1
Schwartz, SL1
Fonseca, V1
Hes, M1
LaMoreaux, L1
Garofalo, E1
Low, PA1
Dotson, RM1
Stacey, BR1
Gorson, KC1
Schott, C1
Herman, R1
Ropper, AH1
Rand, WM1
Seidl, JJ1
Slawson, JG1
McCleary, S1
Hughes, J1
Schiebel, NE1
Ebbert, J1
Margolis, K1
Hansen, HC2
Jett, MF1
Dillon, MP1
Eglen, RM1
van Deventer, H1
Bernard, S1
Chizh, BA1
Wnendt, S1
Morello, CM1
Leckband, SG1
Stoner, CP1
Moorhouse, DF1
Sahagian, GA1
Maurer, I1
Volz, HP1
Sauer, H1
Urban, L1
McCaslin, PP1
Holtom, N1
Solaro, C1
Uccelli, MM1
Guglieri, P1
Uccelli, A1
Mancardi, GL1
Nicholson, B1
García-Morales, I1
Berbel, A2
Benito-León, J2
Pérez, HE1
Sánchez, GF1
Chen, LL1
Nitta, M1
Nemoto, H1
Zylicz, Z1
Dallocchio, C1
Buffa, C1
Mazzarello, P1
Chiroli, S1
Kapadia, NP1
Harden, N1
Chandler, A1
Williams, JE1
Kayser, V1
Christensen, D1
Derk, CT1
Cynwyd, B1
Hulsebosch, CE2
Xu, GY1
Perez-Polo, JR1
McAdoo, DJ1
Block, F1
Sasaki, K1
Smith, CP1
Chuang, YC1
Lee, JY1
Kim, JC1
Chancellor, MB1
Rovetta, G1
Baratto, L1
Farinelli, G1
Monteforte, P1
Mercadante, S1
Villari, P1
Fulfaro, F1
Nozaki-Taguchi, N1
Chaplan, SR1
Ajakwe, RC1
Behm, MO1
Kearns, GL1
La Spina, I1
Porazzi, D1
Maggiolo, F1
Bottura, P1
Suter, F1
Devulder, J1
Lambert, J1
Naeyaert, JM1
Mills, CD1
Grady, JJ1
Brooks-Rock, K1
Azulay, JP1
Pouget, J1
Alam, M1
Rabinowitz, AD1
Engler, DE1
Matthews, EA1
Schapiro, RT1
Heughan, CE1
Sawynok, J1
Rose, MA1
Kam, PC1
Gu, Y1
Huang, LY1
Bosnjak, S1
Jelic, S1
Susnjar, S1
Luki, V1
Sussman, N1
To, TP1
Lim, TC1
Hill, ST1
Frauman, AG1
Cooper, N1
Kirsa, SW1
Brown, DJ1
Wheeler, G1
Bruins Slot, LA1
Ribet, JP1

Clinical Trials (42)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma[NCT03269344]Phase 365 participants (Actual)Interventional2017-06-05Completed
Gabapentin as an Adjunct for Pain Management During Dilation and Evacuation: A Double-blind Randomized Controlled Trial[NCT03635905]Phase 4130 participants (Actual)Interventional2017-05-26Completed
A Controlled Trial of Gabapentin in Vulvodynia: Biological Correlates of Response[NCT01301001]230 participants (Actual)Interventional2012-08-31Completed
A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy[NCT00159679]Phase 4167 participants (Actual)Interventional2004-09-30Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy[NCT00143156]Phase 3450 participants Interventional2005-03-31Completed
A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN).[NCT00156078]Phase 4450 participants Interventional2005-01-31Completed
Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic Peripheral Neuropathy[NCT00553475]Phase 3314 participants (Actual)Interventional2007-10-31Completed
Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial[NCT03080493]Phase 4121 participants (Actual)Interventional2017-03-20Completed
Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain[NCT02339662]Phase 450 participants (Anticipated)Interventional2015-02-28Recruiting
A Randomized, Double Blind, Placebo Controlled Study to Investigate the Effect of Donepezil and Gabapentin Combination on an Experimental Pain Model in Healthy Subjects[NCT01485185]Phase 148 participants (Actual)Interventional2011-10-11Completed
Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain[NCT01364298]Phase 4353 participants (Actual)Interventional2011-04-30Completed
Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management: A Randomized Controlled Trial of Efficacy and Safety[NCT05427058]36 participants (Anticipated)Interventional2022-08-01Not yet recruiting
Persistent Postoperative Pain Incidence With Long Term Perioperative Gabapentin Used[NCT02693821]Phase 4122 participants (Actual)Interventional2015-12-31Completed
Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia[NCT03120962]140 participants (Anticipated)Interventional2017-05-31Not yet recruiting
Efficacy of Duloxetine in Conjunction With Tramadol for Chronic Cancer Pain[NCT05311774]400 participants (Anticipated)Interventional2022-04-30Not yet recruiting
Analgetic Effectiveness of Acupuncture When Compared to a Standardised Analgesic Regimen in the Treatment of Herpes Zoster Neuralgia[NCT00885586]Phase 468 participants (Actual)Interventional2008-11-30Completed
The Efficacy and Safety of Intradermal Acupuncture for Acute Herpes Zoster: Study Protocol for a Randomized Controlled Trial[NCT05348382]72 participants (Anticipated)Interventional2022-07-04Recruiting
Double Blind Trial Investigating the Role of Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients[NCT03847311]Phase 240 participants (Anticipated)Interventional2021-05-03Recruiting
Self-Management to Improve Walking Ability in Degenerative Lumbar Spinal Stenosis: the Evaluation of Four Novel Strategies.[NCT02592642]104 participants (Actual)Interventional2014-09-30Completed
Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI[NCT00243152]6 participants (Actual)Interventional2005-10-31Completed
Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients[NCT02160301]Phase 40 participants (Actual)Interventional2017-11-30Withdrawn (stopped due to Insufficient infrastructure/funding for enrollment)
The Effect of Preoperative Anxiety Level to Postoperative Pain and Analgesic Consumption in Patients Who Had Laparoscopic Sleeve Gastrectomy[NCT04432558]42 participants (Actual)Observational [Patient Registry]2017-04-12Completed
Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures[NCT02957097]Phase 40 participants (Actual)Interventional2019-09-30Withdrawn (stopped due to Original PI left institution and the PI who took over was not able to initiate the study so it was never started.)
Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain[NCT00637975]Phase 280 participants (Anticipated)Interventional2007-09-30Completed
Pregabalin for Pain Reduction in Critical Limb Ischemia - A Double Blind, Randomized Controlled Study[NCT00403780]Phase 418 participants (Actual)Interventional2006-06-30Terminated (stopped due to low inclusion rate)
Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)[NCT01623271]5 participants (Actual)Interventional2013-05-31Terminated (stopped due to Due to limited population of research participants.)
Randomized Controlled Pilot Trial of Adjunct Group Acupuncture vs Usual Care Among Patients With Painful Diabetic Neuropathy[NCT02104466]40 participants (Actual)Interventional2015-03-31Completed
Effect of Ambroxol on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy[NCT05558878]80 participants (Anticipated)Interventional2022-10-01Not yet recruiting
Effect of Two Different Doses of Oral Pregabalin Premedication for Postoperative Pain Relief After Gynecological Surgeries[NCT04708353]90 participants (Anticipated)Interventional2020-08-20Recruiting
Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187]8 participants (Actual)Interventional2009-11-30Terminated (stopped due to PI left institution)
Comparison of Oral Lamotrigine Versus Pregabalin for Control of Acute and Chronic Pain Following Modified Radical Mastectomy: Controlled Double-blind Study[NCT03419949]0 participants Expanded AccessAvailable
The Effect of Neurontin on Pain Management in the Acutely Burned Patient[NCT01265056]53 participants (Actual)Interventional2010-02-28Completed
Open Labeled, Non-randomized, Study of Efficacy and Safety of Gralise in Fibromyalgia Patients.[NCT02052414]34 participants (Actual)Interventional2012-07-31Completed
Phase III Study of the Use of Gabapentin and Osteopathic Manipulative Medicine to Treat Fibromyalgia[NCT01107574]Phase 341 participants (Actual)Interventional2004-04-30Completed
Evaluation of the Efficiency of a Therapeutic Education Program in Standardized Thermal Cure for Fibromyalgia Patients[NCT02406313]152 participants (Actual)Interventional2015-03-31Active, not recruiting
Fibromyalgia of Less Than One Year Duration in Primary Care: Treatment Response in a Double Blind, Placebo Controlled Study of Pregabalin[NCT01397006]Phase 40 participants (Actual)Interventional2011-09-30Withdrawn
Analgesic Effect of Pregabalin in Patients Undergoing Total Abdominal Hysterectomy[NCT01466101]0 participants (Actual)Interventional2011-01-31Withdrawn (stopped due to PI left the institution. No subjects screened or enrolled.)
Effect of Preoperative Pregabalin on Propofol Induction Dose[NCT01158859]Phase 450 participants (Anticipated)Interventional2010-04-30Completed
Perioperative Administration of Pregabalin in Laparoscopic Living Donor Nephrectomy (L-LDN) - an Adjuvance to Peroral Analgetic Treatment - a Randomized Controlled Study[NCT01059331]Phase 480 participants (Actual)Interventional2010-02-28Completed
A Phase III, Double Blind, Randomized, Placebo-controlled Study to Assess the Efficacy of Adjunct Monochromatic Near-infrared Photoenergy (MIRE) in Patients With Painful Axonal Peripheral Neuropathy[NCT00125268]Phase 330 participants (Actual)Interventional2005-07-31Terminated (stopped due to Unable to enroll enough patients)
Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297]301 participants (Anticipated)Interventional2022-11-01Recruiting
Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776]Phase 254 participants (Actual)Interventional2017-08-07Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Average Opioid Use, Measured in Morphine Equivalents Per Day.

(NCT03269344)
Timeframe: Over the entire study period from baseline to follow-up, approximately 13 weeks

InterventionDaily morphine equivalents (Median)
Control Arm15.6
Experimental Arm22.2

Change in PRO-CTCAE Scores From Baseline to Follow-up

Scale: Patient-reported outcomes of Common Terminology Criteria for Adverse Events (PRO-CTCAE), 5-point Likert scale, higher scores indicate worse outcomes. Range of scores 0-40 (min-max). (NCT03269344)
Timeframe: Evaluated change in scores from baseline to 6 weeks post-treatment, approximately 13 weeks

Interventionunits on a scale (Median)
Control Arm1.0
Experimental Arm6.5

Change in Quality of Life From Mucositis-related Pain Measured by the Patient-Reported Oral Mucositis Symptoms (PROMS) Scale From Baseline to Follow-up

Scale tile: Patient Reported Oral Mucositis Symptoms scale, range 0-1000, higher scores indicate worse outcomes (NCT03269344)
Timeframe: Evaluated change in scores from baseline to 6 weeks post-treatment, approximately 13 weeks

Interventionscore on a scale (Mean)
Control Arm20.1
Experimental Arm29.1

Change in Total FACT-HN Scores From Baseline to Follow-up

Scale: Functional Assessment of Cancer Therapy-Trial Outcome (FACT-HN), range 0-148, higher scores indicate better outcomes (NCT03269344)
Timeframe: Administered at baseline and at 6-week follow-up endpoint, approximately 13 weeks

Interventionunits on a scale (Median)
Control Arm-15.0
Experimental Arm-20.0

Feeding Tube Placement

Measure of number of patients who required feeding tube placement at any time during the study period (NCT03269344)
Timeframe: Evaluated placement of feeding tube from baseline (start of radiation) to 6 weeks post-treatment, approximately 13 weeks

InterventionParticipants (Count of Participants)
Control Arm6
Experimental Arm18

Percent Weight Lost

Percent weight lost from baseline to week 7 of treatment (end of treatment) (NCT03269344)
Timeframe: Percent change from baseline to week 7 of treatment

InterventionPercent change (Median)
Control Arm-10.7
Experimental Arm-11.4

Coital Pain

Coital pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever), assessed after each sexual intercourse event. The number of sexual intercourse events was averaged during final week of each treatment arm. (NCT01301001)
Timeframe: Week 6 of each treatment arm

Interventionunits on a scale (Mean)
Placebo3.97
Gabapentin3.85

Tampon Test Pain Intensity

Tampon pain on a 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). One tampon was inserted each week. Tampon pain was assessed during last week of maintenance phase (7 days). (NCT01301001)
Timeframe: Week 6 for each treatment arm

Interventionunits on a scale (Mean)
Placebo4.29
Gabapentin3.96

Vulvodynia Pain

Overall vulvodynia pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). Pain was assessed daily during the last week of treatment. Daily scores were averaged. (NCT01301001)
Timeframe: Week 6 for each treatment arm

Interventionunits on a scale (Mean)
Placebo2.88
Gabapentin2.71

Change From Baseline at Week 1 in Mean Weekly Pain Scores

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 1.~Change from baseline: Score at Week 1 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 1

Interventionscore on scale (Least Squares Mean)
Placebo-0.39
Pregabalin 300 mg/Day-0.82
Pregabalin 600 mg/Day-1.14

Change From Baseline at Week 10 in Mean Weekly Pain Scores

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 10.~Change from baseline: Score at Week 10 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 10

Interventionscore on scale (Least Squares Mean)
Placebo-1.23
Pregabalin 300 mg/Day-1.93
Pregabalin 600 mg/Day-2.10

Change From Baseline at Week 11 in Mean Weekly Pain Scores

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 11.~Change from baseline: Score at Week 11 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 11

Interventionscore on scale (Least Squares Mean)
Placebo-1.32
Pregabalin 300 mg/Day-1.95
Pregabalin 600 mg/Day-2.09

Change From Baseline at Week 12 in Mean Weekly Pain Scores

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 12.~Change from baseline: Score at Week 12 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 12

Interventionscore on scale (Least Squares Mean)
Placebo-1.36
Pregabalin 300 mg/Day-2.01
Pregabalin 600 mg/Day-2.13

Change From Baseline at Week 13 in Mean Weekly Pain Scores

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 13.~Change from baseline: Score at Week 13 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 13

Interventionscore on scale (Least Squares Mean)
Placebo-1.38
Pregabalin 300 mg/Day-2.04
Pregabalin 600 mg/Day-2.12

Change From Baseline at Week 2 in Mean Weekly Pain Scores

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 2.~Change from baseline: Score at Week 2 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 2

Interventionscore on scale (Least Squares Mean)
Placebo-0.57
Pregabalin 300 mg/Day-1.17
Pregabalin 600 mg/Day-1.80

Change From Baseline at Week 3 in Mean Weekly Pain Scores

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 3.~Change from baseline: Score at Week 3 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 3

Interventionscore on scale (Least Squares Mean)
Placebo-0.80
Pregabalin 300 mg/Day-1.40
Pregabalin 600 mg/Day-1.93

Change From Baseline at Week 4 in Mean Weekly Pain Scores

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 4.~Change from baseline: Score at Week 4 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 4

Interventionscore on scale (Least Squares Mean)
Placebo-0.89
Pregabalin 300 mg/Day-1.53
Pregabalin 600 mg/Day-2.00

Change From Baseline at Week 5 in Mean Weekly Pain Scores

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 5.~Change from baseline: Score at Week 5 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 5

Interventionscore on scale (Least Squares Mean)
Placebo-0.91
Pregabalin 300 mg/Day-1.57
Pregabalin 600 mg/Day-2.07

Change From Baseline at Week 6 in Mean Weekly Pain Scores

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 6.~Change from baseline: Score at Week 6 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 6

Interventionscore on scale (Least Squares Mean)
Placebo-0.94
Pregabalin 300 mg/Day-1.72
Pregabalin 600 mg/Day-2.06

Change From Baseline at Week 7 in Mean Weekly Pain Scores

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 7.~Change from baseline: Score at Week 7 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 7

Interventionscore on scale (Least Squares Mean)
Placebo-1.04
Pregabalin 300 mg/Day-1.76
Pregabalin 600 mg/Day-2.13

Change From Baseline at Week 8 in Mean Weekly Pain Scores

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 8.~Change from baseline: Score at Week 8 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 8

Interventionscore on scale (Least Squares Mean)
Placebo-1.18
Pregabalin 300 mg/Day-1.85
Pregabalin 600 mg/Day-2.12

Change From Baseline at Week 9 in Mean Weekly Pain Scores

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 9.~Change from baseline: Score at Week 9 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 9

Interventionscore on scale (Least Squares Mean)
Placebo-1.20
Pregabalin 300 mg/Day-1.93
Pregabalin 600 mg/Day-2.06

Change From Baseline in Mean Sleep Interference Scores

The mean change from baseline in the weekly mean sleep interference score at study endpoint. Score range is from 0-10. Higher scores indicate more severe interference with sleep. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo-0.74
Pregabalin 300 mg/Day-1.59
Pregabalin 600 mg/Day-1.36

Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Overall Sleep Problems Index

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for overall sleep problems index ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo-7.91
Pregabalin 300 mg/Day-11.45
Pregabalin 600 mg/Day-9.73

Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Quantity of Sleep

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for quantity of sleep ranges from 0-24. Higher scores indicate more of the attribute named in the subscale. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo0.37
Pregabalin 300 mg/Day0.69
Pregabalin 600 mg/Day0.54

Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Adequacy

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep adequacy ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo12.08
Pregabalin 300 mg/Day17.69
Pregabalin 600 mg/Day21.73

Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Disturbance

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep disturbance ranges from 0-100. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo-9.03
Pregabalin 300 mg/Day-15.40
Pregabalin 600 mg/Day-12.81

Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Shortness of Breath or Headache

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep shortness of breath or headache ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo-1.63
Pregabalin 300 mg/Day-3.02
Pregabalin 600 mg/Day-4.47

Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Snoring

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for snoring ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo-6.00
Pregabalin 300 mg/Day-5.96
Pregabalin 600 mg/Day-1.56

Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Somnolence

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for somnolence ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo-2.96
Pregabalin 300 mg/Day0.83
Pregabalin 600 mg/Day4.83

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Bodily Pain

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo10.34
Pregabalin 300 mg/Day11.84
Pregabalin 600 mg/Day12.89

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: General Health Perception

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo2.31
Pregabalin 300 mg/Day3.29
Pregabalin 600 mg/Day4.40

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Mental Health

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo3.84
Pregabalin 300 mg/Day5.33
Pregabalin 600 mg/Day7.81

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Physical Functioning

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo2.70
Pregabalin 300 mg/Day2.43
Pregabalin 600 mg/Day3.86

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Emotional

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo4.13
Pregabalin 300 mg/Day5.05
Pregabalin 600 mg/Day6.35

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Physical

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo4.38
Pregabalin 300 mg/Day2.28
Pregabalin 600 mg/Day3.97

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Social Functioning

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo3.00
Pregabalin 300 mg/Day8.06
Pregabalin 600 mg/Day11.16

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Vitality

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo5.28
Pregabalin 300 mg/Day4.20
Pregabalin 600 mg/Day12.87

Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo-0.83
Pregabalin 300 mg/Day-1.43
Pregabalin 600 mg/Day-1.39

Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo-0.59
Pregabalin 300 mg/Day-0.80
Pregabalin 600 mg/Day-0.96

Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo-2.82
Pregabalin 300 mg/Day-4.60
Pregabalin 600 mg/Day-4.95

Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo-3.68
Pregabalin 300 mg/Day-6.03
Pregabalin 600 mg/Day-6.36

Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionmm (Least Squares Mean)
Placebo-16.92
Pregabalin 300 mg/Day-24.19
Pregabalin 600 mg/Day-24.41

Change From Baseline to Study Endpoint in Mean Weekly Pain Scores

Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo-1.20
Pregabalin 300 mg/Day-1.82
Pregabalin 600 mg/Day-1.94

Change From Baseline to Study Endpoint in Mean Weekly Pain Scores by Groups of Subjects With Expected Similar Plasma Concentrations

Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. Subjects are classified by exposure to pregabalin, which is estimated by creatinine clearance (CLcr). (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionscore on scale (Least Squares Mean)
Placebo-1.27
Expected Exposure Pregabalin 300 mg/Day-1.93
Expected Exposure Pregabalin 600 mg/Day-1.90

Clinical Global Impression of Change

Clinical Global Impression of Change is a clinician-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00553475)
Timeframe: Week 13 or up to discontinuation

Interventionscore on scale (Mean)
Placebo3.3
Pregabalin 300 mg/Day2.9
Pregabalin 600 mg/Day2.7

Number of Responders

A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to study endpoint. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Interventionparticipants (Number)
Placebo29
Pregabalin 300 mg/Day39
Pregabalin 600 mg/Day16

Patient Global Impression of Change

The Patient Global Impression of Change is a patient-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00553475)
Timeframe: Week 13 or up to discontinuation

Interventionscore on scale (Mean)
Placebo3.4
Pregabalin 300 mg/Day3.2
Pregabalin 600 mg/Day2.8

Mean Change From Baseline in NRS Pain Score at 2 Hours After Dilator Insertion

Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message. (NCT03080493)
Timeframe: 2 hours after insertion of last osmotic dilator

InterventionNumeric rating scale pain score change (Median)
Gabapentin3.5
Placebo Oral Capsule4

Mean Change From Baseline in NRS Pain Score at 4 Hours After Dilator Insertion

Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message. (NCT03080493)
Timeframe: 4 hours after insertion of last osmotic dilator

InterventionNumeric rating scale pain score change (Mean)
Gabapentin3
Placebo Oral Capsule3.5

Mean Change From Baseline in NRS Pain Score at 5 Minutes After Last Dilator Insertion

Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person before subject leaves clinic appointment. (NCT03080493)
Timeframe: 5 minutes after insertion of last osmotic dilator

InterventionNumeric rating scale pain score change (Median)
Gabapentin1
Placebo Oral Capsule2

Mean Change From Baseline in NRS Pain Score at 8 Hours After Dilator Insertion

Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message. (NCT03080493)
Timeframe: 8 hours after insertion of last osmotic dilator

InterventionNumeric rating scale pain score change (Median)
Gabapentin2
Placebo Oral Capsule2.5

Mean Change From Baseline in NRS Pain Score at Time of Presentation for D&E Procedure (Day Following Dilator Insertion)

Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person upon presentation for D&E procedure. (NCT03080493)
Timeframe: Time of presentation for D&E (day after dilator insertion)

InterventionNumeric rating scale pain score change (Median)
Gabapentin0.5
Placebo Oral Capsule1

Number of Participants Using Narcotic Pain Medication (Acetaminophen/Codeine)

Subject account of how many used acetaminophen/codeine (standard medications given for supplement NSAID as needed after dilator insertion) (NCT03080493)
Timeframe: Collected between each subject contact (2 hours, 4 hours, 8 hours after dilator insertion and at time of presentation for D&E procedure)

InterventionParticipants (Count of Participants)
Gabapentin35
Placebo Oral Capsule40

Number of Participants With Adverse Events (AEs)

An adverse event (AE) is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to Baseline during a clinical study with an investigational medicinal product (IMP), regardless of causal relationship and even if no IMP has been administered. (NCT01364298)
Timeframe: Day 7 up to Day 84 (+7 days)

Interventionparticipants (Number)
Gabapentin/B-complex80
Pregabalin93

Profile of Mood States (POMS) Score

"POMS is a rating scale, which comprises of 65 items that are evaluated in a 0-4 scale, where 0 means not at all and 4 extremely. The scores for the 65 items are added in various combinations to throw six validated factors which are used to calculate total POMS score: (tension-anxiety) + (depression-dejection) + (anger-hostility)+ (fatigue-Inertia) + (confusion-bewilderment) - (vigor-activity). Score range (-40 to 192). Score -40 denotes the best score and score 192 denotes the worst score." (NCT01364298)
Timeframe: Day 84 (Week 12)

Interventionunits on a scale (Mean)
Gabapentin/B-complex1.3
Pregabalin3.4

Change From Baseline in Average Numeric Pain Intensity Scale (NPIS) Score at Day 84

An average NPIS pain score (daily average records of the past seven days) was evaluated. Numeric pain intensity scale (NPIS) is a 11-point scale, with 0 representing no pain and 10 representing the worst possible pain. The participants were asked to mark the number that best represents the current level of pain they have experienced during the previous 24 hours. Change from baseline data has been calculated as value at baseline minus value at Day 84. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)

,
Interventionunits on a scale (Mean)
Baseline (n=147, 123)Change at Day 84 (n=146, 122)
Gabapentin/B-complex6.73.905
Pregabalin6.84.260

Change From Baseline in Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) Scale Score at Day 84

The LANSS scale score is 7-item pain scale that consists of grouped sensory description and sensory examination with simple scoring system. Evaluations in two main areas: pain and sensorial exploration. The first 5 questions asks for presence of unpleasant skin sensations (pricking, tingling, pins and needles), appearance of skin (mottled, red, or pink), increased sensitivity of skin to touch, sudden bursts of electric shock sensations, and hot or burning skin sensations. Last 2 questions involve sensory testing for the presence of allodynia and altered pinprick threshold. Different numbers of points, relative to their significance to neuropathic pain, are given to positive answers for maximum of 24 points. A score less than 12 makes unlikely that participant's symptoms are neuropathic in nature, whereas score more than 12 make neuropathic mechanisms likely to be contributing to participant's pain. Change from baseline data has been calculated as value at baseline minus value at Day 84. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)

,
Interventionunits on a scale (Mean)
Baseline (n=147, 123)Change at Day 84 (n=146, 122)
Gabapentin/B-complex16.28.082
Pregabalin15.86.967

Change From Baseline in Visual Analogue Scale (VAS) Score at Day 84

VAS is used to rate the pain as per 10 centimeter (cm) line. The pain intensity score ranges from '0=no pain' to '10=worst possible pain'. Change from baseline data has been calculated as value at baseline minus value at Day 84. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)

,
Interventioncentimeter (Mean)
Baseline (n=147, 123)Change at Day 84 (n=146, 122)
Gabapentin/B-complex7.04.182
Pregabalin7.14.529

Number of Participants With Various Health Conditions Based on Clinical Global Impression of Change (CGIC) Scale

CGIC is an assessment that the physician performs to assess the participant's global change in health condition from start of the study on a 7-point scale (1 = extremely improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse 6 = much worse, 7 = extremely worse). (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)

,
Interventionparticipants (Number)
Health: extremely improvedHealth: much improvedHealth: minimally improved
Gabapentin/B-complex557911
Pregabalin47696

Number of Participants With Various Health Conditions Based on Global Impression of Patient Change (GIPC) Scale

GIPC is an assessment that the participant's global change in health condition from start of the study on a 7-point scale (1 = extremely improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse 6 = much worse, 7 = extremely worse). (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)

,
Interventionparticipants (Number)
Health: extremely improvedHealth: much improvedHealth: minimally improved
Gabapentin/B-complex627310
Pregabalin476510

Percentage of Participants With at Least 30 and 50 Percent (%) Improvement in Numeric Pain Intensity Scale (NPIS) From Baseline at Day 84 (Week 12)

NPIS is a 11-point scale, with 0 representing no pain and 10 representing the worst possible pain. The participants were asked to mark the number that best represents the current level of pain they have experienced during the previous 24 hours. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)

,
Interventionpercentage of participants (Number)
At least 30% improvementAt least 50% improvement
Gabapentin/B-complex76.966.0
Pregabalin85.472.4

Sleep Evaluation: Number of Participants Who Fell Asleep in Pre-specified Time Duration

Sleep evaluation was performed by assessing number of participants who fell asleep in a particular pre-specified range of time duration, that is, 0-15 minutes, 16-30 minutes, 31-45 minutes, 46-60 minutes and greater than 60 minutes at Day 84 (Week 12). (NCT01364298)
Timeframe: Day 84 (Week 12)

,
Interventionparticipants (Number)
0 to 15 minutes16 to 30 minutes31 to 45 minutes46 to 60 minutesGreater than 60 minutes
Gabapentin/B-complex85331388
Pregabalin72331242

Blood Oxygenation Level-dependent (BOLD) Changes in Neural Pain Circuitry Following Treatment With Lamotrigine During Experimentally Induced Pain States

fMRI scans acquired Stimuli Type: Brush Stimulation Regions: Face (V2) Right and Left Sides Rating: Pain/ unpleasantness fMRI scans acquired Stimuli Type: Cold, threshold -1°C Stimulation Regions: Face (V2) Right and Left Sides Rating: Pain/ unpleasantness **Extra time allotted for probe repositioning** fMRI scans acquired Stimuli Type: Heat, threshold +1°C Stimulation Regions: Face (V2) Right and Left Sides Rating: Pain/ unpleasantness **Extra time allotted for probe repositioning** Cortical, subcortical, and brain stem sensory regions Z-scores Increase or decrease in activation as affected by the drug (NCT00243152)
Timeframe: Week 10 during scanning session

InterventionZ-statistic (Number)
Heat Affected Thalamus (10,-14,8)Heat Affected Post-Central (-56,-12,28)Cold Affected Post-Central (68, -8, 32)Cold Affected Thalamus (-4, -8, 0)Brush Affected Post-Central (66,-16,14)Brush Affected Thalamus (-14,-22, 4)Brush Affected Spinal Trigeminal Nucles(2,-48,-68)
Lamotrigine vs Placebo-2.9294-2.7323-2.5114-3.0333.905-3.7912.9058

Subjective Ratings of Pain During Magnetic Resonance Scanning

"Quantitative Sensory Testing (QST)~Stimuli Type: Heat, Cold, Brush Stimulation Regions: Face Affected and contralateral Unaffected mirror area Rating: Pain/ unpleasantness Stimuli Type: Cold, threshold -1°C Stimulation Regions: Face Affected and contralateral Unaffected mirror area Rating: Pain/ unpleasantness Stimuli Type: Heat, threshold +1°C Stimulation Regions: Face Affected and contralateral Unaffected mirror area Rating: Pain/ unpleasantness~Ratings on a likert scale of 0-10 with 0 being defined as no pain and 10 being defined as worst possible pain" (NCT00243152)
Timeframe: week 10 (during the scan)

,
Interventionscores on a pain scale (Mean)
Heat AffectedHeat UnaffectedCold AffectedCold UnaffectedBrush AffectedBrush Unaffected
Lamotrigine3.232.12.22.81.2
Placebo5.542.51.13.9.4

Visual Analog Scale (VAS) at Visit 3

Subjects rated their pain using the VAS at visit 3, which was the last day of their maintenance phase. After this visit, subjects begin to taper the gralise. The VAS is subject reported on a scale of 0-10 with 0 being no pain and 10 being the worst pain they can imagine. Results reported are an average of the 3 subjects who completed visit 3. (NCT01623271)
Timeframe: At visit 3

Interventionunits on the VAS (Mean)
CRPS I Pain Subjects3.67

Difference in Psychological Outcomes on the Sickness Inventory Profile (SIP)

The sickness inventory profile (SIP) is a behaviorally based measure of health status. Scores range from 0-68 with higher numbers indicating worse outcomes. The study report total SIP score. The higher the score the worse the function. (NCT01265056)
Timeframe: First Clinic Follow Up After Discharge

Interventionunits on a scale (Mean)
Placebo34.9
Gabapentin36.0

Opioid Consumption Between the Treatment and the Control Groups (Morphine Equivalents)

(NCT01265056)
Timeframe: From time of enrollment to 2 weeks after being discharged

Interventionmorphine equivalents (Mean)
Placebo7.0
Gabapentin6.7

Psychological Functioning as Evaluated by the Brief Symptom Inventory (BSI) Between Treatment and Placebo Groups

The Brief Symptom Inventory 18 (BSI 18) is designed with reliability in mind. The BSI 18 assessment gathers patient-reported data to help measure psychological distress and psychiatric disorders in medical and community populations. As the latest in an integrated series of test instruments that include the SCL-90-R®, BSI® (53 questions), and DPRS® instruments, the BSI 18 test offers a more effective, easy-to-administer tool to help support clinical decision-making and monitor progress throughout treatment. BSI-18 measures three dimensions with 6 questions a piece (somatization , depression , anxiety) and overall psychological distress scores (Global severity index, GSI). Each of the 18 items range from a score of 0-4; total score ranges from 0-72 with higher scores indicating worse function. The GSI score is calculated as the mean of the three subscales. The study reported the GSI score. Higher score is worse. (NCT01265056)
Timeframe: First Clinic Follow Up After Discharge

Interventionunits on a scale (Mean)
Placebo9
Gabapentin7.3

Fibromyalgia Impact Questionnaire (FIQ)

The Fibromyalgia Impact Questionnaire (FIQ) is an instrument designed to quantitate the overall impact of fibromyalgia over many dimensions (e.g. function, pain level, fatigue, sleep disturbance, psychological distress etc.). It is scored from 0 to 100 with the latter number being the worst case. The average score for patients seen in tertiary care settings is about 50. The FIQ is widely used to assess change in fibromyalgia status. (NCT02052414)
Timeframe: 15 weeks.

Interventionunits on a scale (Mean)
FIQ BaselineFIQ Week 4FIQ Week 8FIQ Week 12FIQ Week 15
Gralise (Gabapentin ER)71.0441.8240.7939.2761.86

Medical Outcome Study (MOS) Sleep Questionnaires

"Medical Outcomes Study (MOS) sleep questionnaires to assess how Fibromyalgia impacts patients' sleep in various areas.~Specifically, Data reported below measured number of hours subjects spent per night sleeping. MOS sleep questionnaires were assessed at each follow up visits. (visits 1, 2, 3, 4, and 5)." (NCT02052414)
Timeframe: 15 weeks

InterventionHours (Mean)
Sleep Quantity BaselineSleep Quantity week 4Sleep quantity week 8Sleep quantity week 12Sleep quantity week 15
Gralise (Gabapentin ER)5.867.176.817.046.23

Numeric Pain Rating System (NPRS)

Fibromyalgia pain experienced by study subjects will be captured using NPRS at baseline visit, at each follow visits that are scheduled to occur every 4 weeks over 12 weeks of treatment period, and at the end of treatment visit that will occur 3 weeks after treatment period (12 weeks treatment period + 3 weeks = 15 weeks). Any difference in NPRS scores between baseline and any subsequent visits will indicate the magnitude of pain relief as reflected in digital scale of 0-10 (0=no pain, 10=worst pain imaginable). (NCT02052414)
Timeframe: 15 weeks

Interventionunits on a scale (Mean)
NPRS Baseline (Visit 1)NPRS on Week 4 (Visit 2)NPRS on week 8 (Visit 3)NPRS on Week 12 (Visit 4)NPRS on week 15 (Visit 5)
Gralise (Gabapentin ER)7.294.723.953.836.94

Patient Global Impression of Change (PGIC)

Patient Global impression of Change (PGIC) is an outcome commonly used measure of the efficacy of treatments. PGIC is a 7 point scale that requires the subjects to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT02052414)
Timeframe: 15 Weeks.

Interventionunits on a scale (Mean)
PGIC After 4 weeksPGIC After 8 weeksPGIC After 12 weeksPGIC After 15 weeks
Gralise (Gabapentin ER)4.965.405.374.44

Self Reported Side Effects.

Side / adverse effects were assessed at each follow up visits and resulted are as follows. (NCT02052414)
Timeframe: 15 Weeks

Interventionparticipants (Number)
Extremity SwellingWeight GainDrowsyDizzyIrritabilityDry EyesPainMood ChangesDifficulty ConcentratingDry MouthSuspected Drug interactionAcute DeleriumAdhesionNone
Gralise (Gabapentin ER)228332122111112

Prefrontal GABA+ Concentrations

Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition

Interventionmmol/kg (Mean)
N-Acetylcysteine3.90
Gabapentin3.93
Placebo Oral Tablet3.73

Prefrontal Glx Concentrations

Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition

Interventionmmol/kg (Mean)
N-Acetylcysteine21.59
Gabapentin21.69
Placebo Oral Tablet22.25

Reviews

69 reviews available for gabapentin and Ache

ArticleYear
Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain.
    Journal of medicinal chemistry, 2007, May-31, Volume: 50, Issue:11

    Topics: Amines; Analgesics; Animals; Anticonvulsants; Calcium Channels; Carboxylic Acids; Cyclohexanecarboxy

2007
Systematic review and meta-analysis of studies in which burrowing behaviour was assessed in rodent models of disease-associated persistent pain.
    Pain, 2022, 11-01, Volume: 163, Issue:11

    Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; Disease M

2022
Pharmacologic therapies of pain in patients with spinal cord injury: a systematic review.
    Spinal cord series and cases, 2022, 07-04, Volume: 8, Issue:1

    Topics: Amitriptyline; Anticonvulsants; Gabapentin; Humans; Ketamine; Pain; Pregabalin; Spinal Cord Injuries

2022
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval.
    Drugs, 2023, Volume: 83, Issue:1

    Topics: Analgesics; Gabapentin; Humans; Pain; Pregabalin; United States; United States Food and Drug Adminis

2023
Prophylactic gabapentin during head and neck cancer therapy: a systematic review and meta-analysis.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023, Mar-17, Volume: 31, Issue:4

    Topics: Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric

2023
A critical appraisal of gabapentinoids for pain in cancer patients.
    Current opinion in supportive and palliative care, 2018, Volume: 12, Issue:2

    Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Drug Therapy, Combination; Gabapentin; Humans; Pain; Pa

2018
The case for cautious consumption: NSAIDs in chronic kidney disease.
    Current opinion in nephrology and hypertension, 2019, Volume: 28, Issue:2

    Topics: Acute Kidney Injury; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Baclofen; Cost-Ben

2019
Pain Management in Trauma in the Age of the Opioid Crisis.
    Anesthesiology clinics, 2019, Volume: 37, Issue:1

    Topics: Acetaminophen; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Child; Gabapentin; Humans

2019
A Clinical Overview of Off-label Use of Gabapentinoid Drugs.
    JAMA internal medicine, 2019, 05-01, Volume: 179, Issue:5

    Topics: Analgesics; Diabetic Neuropathies; Drug Approval; Fibromyalgia; Gabapentin; Humans; Low Back Pain; M

2019
A review of analgesic compounds used in food animals in the United States.
    The Veterinary clinics of North America. Food animal practice, 2013, Volume: 29, Issue:1

    Topics: Adrenergic alpha-Agonists; Amines; Analgesia; Analgesics; Analgesics, Opioid; Anesthetics, Local; An

2013
Pharmacological treatment for pain in Guillain-Barré syndrome.
    The Cochrane database of systematic reviews, 2013, Oct-20, Issue:10

    Topics: Amines; Analgesics; Carbamazepine; Constipation; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Amin

2013
Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain.
    The Clinical journal of pain, 2014, Volume: 30, Issue:7

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neopla

2014
Treatment of hidradenitis supprurativa associated pain with nonsteroidal anti-inflammatory drugs, acetaminophen, celecoxib, gabapentin, pegabalin, duloxetine, and venlafaxine.
    Dermatology online journal, 2013, Nov-15, Volume: 19, Issue:11

    Topics: Acetaminophen; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclohexaneca

2013
[A case of Guillain-Barré syndrome with severe pain successfully controlled with acetaminophen, gabapentin, and parenterally infused fentanyl].
    No to hattatsu = Brain and development, 2014, Volume: 46, Issue:4

    Topics: Acetaminophen; Amines; Child; Cyclohexanecarboxylic Acids; Drug Combinations; Fentanyl; Gabapentin;

2014
Pharmacological treatment for pain in Guillain-Barré syndrome.
    The Cochrane database of systematic reviews, 2015, Apr-09, Issue:4

    Topics: Amines; Analgesics; Carbamazepine; Constipation; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Amin

2015
Headache and Pain in Guillain-Barré Syndrome.
    Current pain and headache reports, 2015, Volume: 19, Issue:8

    Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Guillain-Barre Sy

2015
Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics.
    Current opinion in supportive and palliative care, 2016, Volume: 10, Issue:2

    Topics: Amines; Analgesics, Opioid; Animals; Antidepressive Agents; Antineoplastic Agents; Cisplatin; Cycloh

2016
Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review.
    Pain practice : the official journal of World Institute of Pain, 2017, Volume: 17, Issue:3

    Topics: Amines; Analgesics; Anticonvulsants; Antidepressive Agents; Chemotherapy, Adjuvant; Cyclohexanecarbo

2017
Analgesia in the surgical intensive care unit.
    Postgraduate medical journal, 2017, Volume: 93, Issue:1095

    Topics: Acetaminophen; Amines; Analgesics; Analgesics, Opioid; Anesthesia, Conduction; Anesthetics, Local; C

2017
Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck.
    Clinical journal of oncology nursing, 2016, 12-01, Volume: 20, Issue:6

    Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric

2016
Practical management strategies for the chronic pain patient.
    The Journal of family practice, 2007, Volume: 56, Issue:8 Suppl Ho

    Topics: Administration, Cutaneous; Amines; Analgesics; Antidepressive Agents, Tricyclic; Carbamazepine; Chro

2007
[Central and peripheral mechanisms in antinociception: current and future perspectives].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2008, Volume: 10, Issue:3

    Topics: Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Bridged Bicyclo Compounds, Heterocycl

2008
Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain.
    BMC neurology, 2009, Feb-10, Volume: 9

    Topics: Amines; Analgesics; Analysis of Variance; Bayes Theorem; Cyclohexanecarboxylic Acids; Diabetic Neuro

2009
Pregabalin in the treatment of chronic pain: an overview.
    Clinical drug investigation, 2009, Volume: 29, Issue:3

    Topics: Amines; Analgesics, Non-Narcotic; Animals; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic

2009
[Pain relief by gabapentin via supraspinal mechanisms in neuropathic conditions].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2009, Volume: 134, Issue:6

    Topics: Amines; Analgesics; Animals; Brain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid

2009
Lumbar spinal stenosis: a brief review of the nonsurgical management.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2010, Volume: 57, Issue:7

    Topics: Administration, Intranasal; Alprostadil; Amines; Analgesics, Non-Narcotic; Anesthetics, Local; Anti-

2010
Central sensitization and Ca(V)α₂δ ligands in chronic pain syndromes: pathologic processes and pharmacologic effect.
    The journal of pain, 2010, Volume: 11, Issue:12

    Topics: Amines; Analgesics; Animals; Calcium Channels; Complex Regional Pain Syndromes; Cyclohexanecarboxyli

2010
Gabapentin for the treatment of cancer-related pain syndromes.
    Reviews on recent clinical trials, 2010, Volume: 5, Issue:3

    Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci

2010
An algorithm for the treatment of chronic testicular pain.
    The Journal of family practice, 2010, Volume: 59, Issue:6

    Topics: Algorithms; Amines; Analgesics; Anesthetics; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive

2010
Oxycodone combinations for pain relief.
    Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46, Issue:6

    Topics: Acetaminophen; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Aspi

2010
Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis.
    Journal of clinical pharmacy and therapeutics, 2010, Volume: 35, Issue:6

    Topics: Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Fem

2010
[Development of animal models of herpetic pain and postherpetic neuralgia and elucidation of the mechanisms of the onset and inhibition of allodynia].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2011, Volume: 131, Issue:2

    Topics: Amines; Analgesics; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Cyclooxygenase Inhibitors

2011
[Molecular mechanisms and clinical pharmacology of chronic pain].
    Masui. The Japanese journal of anesthesiology, 2010, Volume: 59 Suppl

    Topics: Amines; Animals; Anterior Horn Cells; Antidepressive Agents; Brain; Chronic Disease; Cyclohexanecarb

2010
Use of anticonvulsants for treatment of neuropathic pain.
    Neurology, 2002, Sep-10, Volume: 59, Issue:5 Suppl 2

    Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;

2002
Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials.
    Clinical therapeutics, 2003, Volume: 25, Issue:1

    Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anticonvu

2003
Cellular and molecular action of the putative GABA-mimetic, gabapentin.
    Cellular and molecular life sciences : CMLS, 2003, Volume: 60, Issue:4

    Topics: Acetates; Amines; Analgesics; Animals; Anticonvulsants; Anxiety; Brain; Cyclohexanecarboxylic Acids;

2003
The role of gabapentin in treating diseases with cutaneous manifestations and pain.
    International journal of dermatology, 2003, Volume: 42, Issue:6

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp

2003
Gabapentin: a viewpoint by Ian Gilron.
    CNS drugs, 2003, Volume: 17, Issue:13

    Topics: Acetates; Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans;

2003
[Nonorganic pain -- only psychogenic?].
    Praxis, 2003, Nov-26, Volume: 92, Issue:48

    Topics: Acetates; Adult; Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Back Pain; Chronic Dise

2003
Gabapentin in the treatment of neuropathic pain.
    Palliative medicine, 2004, Volume: 18, Issue:1

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma

2004
Post-herpetic neuralgia case study: optimizing pain control.
    European journal of neurology, 2004, Volume: 11 Suppl 1

    Topics: Acetates; Aged; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Cyclohexanecarb

2004
80-year-old man with fever and ear pain.
    Mayo Clinic proceedings, 2004, Volume: 79, Issue:8

    Topics: Acetates; Acyclovir; Age Factors; Aged; Aged, 80 and over; Amines; Analgesics; Antiviral Agents; Cyc

2004
[Evidence-based pharmacotherapy of neuropathic pain syndromes].
    MMW Fortschritte der Medizin, 2004, Dec-09, Volume: 146, Issue:50

    Topics: Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Antioxidants; Cyclohexanec

2004
[Progress on painful diabetic peripheral neuropathy treated by integrative medicine].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2005, Volume: 25, Issue:4

    Topics: Amines; Amitriptyline; Analgesics; Animals; Antidepressive Agents, Tricyclic; Blood Glucose; Cyclohe

2005
Anticonvulsant drugs for acute and chronic pain.
    The Cochrane database of systematic reviews, 2005, Jul-20, Issue:3

    Topics: Acute Disease; Amines; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topic; Cycloh

2005
Gabapentin for acute and chronic pain.
    The Cochrane database of systematic reviews, 2005, Jul-20, Issue:3

    Topics: Acute Disease; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Ga

2005
Combination pharmacotherapy for neuropathic pain: current evidence and future directions.
    Expert review of neurotherapeutics, 2005, Volume: 5, Issue:6

    Topics: Amines; Analgesics; Animals; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drug Synergism;

2005
The mechanism of action of gabapentin in neuropathic pain.
    Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:1

    Topics: Amines; Analgesics, Non-Narcotic; Animals; Binding Sites; Calcium Channels; Cyclohexanecarboxylic Ac

2006
Mechanisms of the antinociceptive action of gabapentin.
    Journal of pharmacological sciences, 2006, Volume: 100, Issue:5

    Topics: Amines; Analgesics; Animals; Anticonvulsants; Calcium Channels, N-Type; Cyclohexanecarboxylic Acids;

2006
Gabapentin for pain: balancing benefit and harm.
    American family physician, 2006, Feb-01, Volume: 73, Issue:3

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Gabapentin; gamma

2006
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
    The American journal of geriatric pharmacotherapy, 2005, Volume: 3, Issue:4

    Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox

2005
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
    The American journal of geriatric pharmacotherapy, 2005, Volume: 3, Issue:4

    Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox

2005
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
    The American journal of geriatric pharmacotherapy, 2005, Volume: 3, Issue:4

    Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox

2005
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
    The American journal of geriatric pharmacotherapy, 2005, Volume: 3, Issue:4

    Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox

2005
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
    The American journal of geriatric pharmacotherapy, 2005, Volume: 3, Issue:4

    Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox

2005
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
    The American journal of geriatric pharmacotherapy, 2005, Volume: 3, Issue:4

    Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox

2005
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
    The American journal of geriatric pharmacotherapy, 2005, Volume: 3, Issue:4

    Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox

2005
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
    The American journal of geriatric pharmacotherapy, 2005, Volume: 3, Issue:4

    Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox

2005
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
    The American journal of geriatric pharmacotherapy, 2005, Volume: 3, Issue:4

    Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox

2005
alpha2delta and the mechanism of action of gabapentin in the treatment of pain.
    Seminars in cell & developmental biology, 2006, Volume: 17, Issue:5

    Topics: Amines; Analgesics; Animals; Brain; Calcium Channels; Cyclohexanecarboxylic Acids; GABA Modulators;

2006
Adjuvant analgesics for the treatment of neuropathic pain: evaluating efficacy and safety profiles.
    The Journal of family practice, 2007, Volume: 56, Issue:2 Suppl Pa

    Topics: Administration, Cutaneous; Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents; Arthritis;

2007
Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain.
    Best practice & research. Clinical rheumatology, 2007, Volume: 21, Issue:3

    Topics: Adrenergic Uptake Inhibitors; Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tr

2007
Gabapentin Extended-Release - Depomed: Gabapentin ER, Gabapentin Gastric Retention, Gabapentin GR.
    Drugs in R&D, 2007, Volume: 8, Issue:5

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Preparations; Diabetic Neuropathies;

2007
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
    Current opinion in anaesthesiology, 2007, Volume: 20, Issue:5

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen

2007
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
    Current opinion in anaesthesiology, 2007, Volume: 20, Issue:5

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen

2007
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
    Current opinion in anaesthesiology, 2007, Volume: 20, Issue:5

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen

2007
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
    Current opinion in anaesthesiology, 2007, Volume: 20, Issue:5

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen

2007
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
    Current opinion in anaesthesiology, 2007, Volume: 20, Issue:5

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen

2007
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
    Current opinion in anaesthesiology, 2007, Volume: 20, Issue:5

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen

2007
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
    Current opinion in anaesthesiology, 2007, Volume: 20, Issue:5

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen

2007
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
    Current opinion in anaesthesiology, 2007, Volume: 20, Issue:5

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen

2007
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
    Current opinion in anaesthesiology, 2007, Volume: 20, Issue:5

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen

2007
[Psychopharmacotherapy in psychiatric comorbidities among patients with chronic pain].
    L'Encephale, 2007, Volume: 33, Issue:Pt 3

    Topics: Amines; Analgesics; Anticonvulsants; Bupropion; Chronic Disease; Cyclohexanecarboxylic Acids; Dopami

2007
Use of gabapentin in pain management.
    The Annals of pharmacotherapy, 1997, Volume: 31, Issue:9

    Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic

1997
A summary of mechanistic hypotheses of gabapentin pharmacology.
    Epilepsy research, 1998, Volume: 29, Issue:3

    Topics: Acetates; Amines; Analgesics; Animals; Anti-Anxiety Agents; Anticonvulsants; Brain; Calcium Channels

1998
Treatment of chronic pain with antiepileptic drugs: a new era.
    Southern medical journal, 1999, Volume: 92, Issue:7

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapen

1999
Postherpetic neuralgia: role of gabapentin and other treatment modalities.
    Epilepsia, 1999, Volume: 40 Suppl 6

    Topics: Acetates; Administration, Topical; Age Factors; Aged; Ambulatory Care; Amines; Analgesics; Anticonvu

1999
Interstitial cystitis and the potential role of gabapentin.
    Southern medical journal, 2000, Volume: 93, Issue:2

    Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Cystitis, Interstitial; Female; Ga

2000
Gabapentin use in neuropathic pain syndromes.
    Acta neurologica Scandinavica, 2000, Volume: 101, Issue:6

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma

2000
Gabapentin in pain management.
    Anesthesia and analgesia, 2000, Volume: 91, Issue:3

    Topics: Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric A

2000
[Gabapentin therapy for pain].
    Der Nervenarzt, 2001, Volume: 72, Issue:2

    Topics: Acetates; Amines; Analgesics; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Diabetic Neurop

2001
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
    Current neurology and neuroscience reports, 2001, Volume: 1, Issue:3

    Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin

2001
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Gabapentin: pharmacology and its use in pain management.
    Anaesthesia, 2002, Volume: 57, Issue:5

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2002
Background and rationale for use of anticonvulsants in psychiatry.
    Cleveland Clinic journal of medicine, 1998, Volume: 65 Suppl 1

    Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cycloh

1998
Gabapentin. Pfizer.
    Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:3

    Topics: Acetates; Amines; Analgesics; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase II

2002

Trials

59 trials available for gabapentin and Ache

ArticleYear
Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma.
    International journal of radiation oncology, biology, physics, 2022, 03-15, Volume: 112, Issue:4

    Topics: Double-Blind Method; Gabapentin; Head and Neck Neoplasms; Humans; Pain; Quality of Life; Squamous Ce

2022
Gabapentin as an adjunct for pain management during dilation and evacuation: A double-blind randomized controlled trial.
    Contraception, 2023, Volume: 118

    Topics: Dilatation; Double-Blind Method; Female; Fentanyl; Gabapentin; Humans; Midazolam; Nausea; Pain; Pain

2023
Efficacy of Prophylactic High-Dose Gabapentin and Venlafaxine on Reducing Oral Mucositis Pain Among Patients Treated With Chemoradiation for Head and Neck Cancer: A Single-Institution, Phase 2, Randomized Clinical Trial.
    International journal of radiation oncology, biology, physics, 2023, Jul-15, Volume: 116, Issue:4

    Topics: Analgesics, Opioid; Gabapentin; Head and Neck Neoplasms; Humans; Mucositis; Pain; Quality of Life; S

2023
A single-institution, randomized, pilot study evaluating the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer.
    Cancer, 2020, 04-01, Volume: 126, Issue:7

    Topics: Adult; Aged; Analgesics; Chemoradiotherapy; Dose-Response Relationship, Drug; Female; Gabapentin; Hu

2020
Efficacy of gabapentin mouthwash in managing oral mucositis pain in patients undergoing chemotherapy: a prospective, randomised, double-blind, controlled clinical trial.
    Scottish medical journal, 2020, Volume: 65, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents; Double-Blind Method; Female; Gaba

2020
Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation.
    Head & neck, 2020, Volume: 42, Issue:12

    Topics: Chemoradiotherapy; Gabapentin; Head and Neck Neoplasms; Humans; Pain; Prospective Studies

2020
Gabapentin for the Treatment of Vulvodynia: A Randomized Controlled Trial.
    Obstetrics and gynecology, 2018, Volume: 131, Issue:6

    Topics: Adult; Analgesics; Cross-Over Studies; Delayed-Action Preparations; Diagnostic Techniques, Obstetric

2018
Pain characterization and response to palliative care in dogs with naturally-occurring appendicular osteosarcoma: An open label clinical trial.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Amitriptyline; Analgesics; Animals; Bone Neoplasms; Central Nervous System Sensitization; Dog Diseas

2018
Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis.
    Clinical rheumatology, 2019, Volume: 38, Issue:10

    Topics: Acetaminophen; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Dulox

2019
Is gabapentin effective in dry eye disease and neuropathic ocular pain?
    Acta neurologica Belgica, 2021, Volume: 121, Issue:2

    Topics: Adult; Analgesics; Dry Eye Syndromes; Eye Pain; Female; Gabapentin; Humans; Male; Middle Aged; Pain;

2021
Analgesic efficacy of prophylactic gabapentin and lornoxicam in preventing postendodontic pain.
    Pain medicine (Malden, Mass.), 2014, Volume: 15, Issue:12

    Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam

2014
The effect of a combination of gabapentin and donepezil in an experimental pain model in healthy volunteers: Results of a randomized controlled trial.
    Pain, 2014, Volume: 155, Issue:12

    Topics: Adolescent; Adult; Amines; Analgesics, Non-Narcotic; Cross-Over Studies; Cyclohexanecarboxylic Acids

2014
Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy.
    Journal of diabetes research, 2016, Volume: 2016

    Topics: Adolescent; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Drug Combinatio

2016
Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer.
    Auris, nasus, larynx, 2016, Volume: 43, Issue:6

    Topics: Acetaminophen; Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Carcinoma

2016
A Validated Fluorometric Method for the Rapid Determination of Pregabalin in Human Plasma Applied to Patients With Pain.
    Therapeutic drug monitoring, 2016, Volume: 38, Issue:5

    Topics: Amines; Analgesics; Chromatography, High Pressure Liquid; Cyclohexanecarboxylic Acids; Data Accuracy

2016
Topical gabapentin in the treatment of localized and generalized vulvodynia.
    Obstetrics and gynecology, 2008, Volume: 112, Issue:3

    Topics: Administration, Topical; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin;

2008
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster.
    Pain, 2009, Volume: 142, Issue:3

    Topics: Acute Disease; Aged; Amines; Analgesics, Opioid; Clinical Trials as Topic; Cyclohexanecarboxylic Aci

2009
Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study.
    Clinical drug investigation, 2009, Volume: 29 Suppl 1

    Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid;

2009
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
    BMC complementary and alternative medicine, 2009, Aug-12, Volume: 9

    Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli

2009
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
    BMC complementary and alternative medicine, 2009, Aug-12, Volume: 9

    Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli

2009
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
    BMC complementary and alternative medicine, 2009, Aug-12, Volume: 9

    Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli

2009
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
    BMC complementary and alternative medicine, 2009, Aug-12, Volume: 9

    Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli

2009
A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain.
    International journal of clinical oncology, 2010, Volume: 15, Issue:1

    Topics: Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Female; Gabapentin

2010
Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine.
    Journal of anesthesia, 2010, Volume: 24, Issue:3

    Topics: Aged; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal;

2010
A fMRI evaluation of lamotrigine for the treatment of trigeminal neuropathic pain: pilot study.
    Pain medicine (Malden, Mass.), 2010, Volume: 11, Issue:6

    Topics: Adult; Amines; Anticonvulsants; Brain; Cold Temperature; Cross-Over Studies; Cyclohexanecarboxylic A

2010
Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy.
    Diabetic medicine : a journal of the British Diabetic Association, 2010, Volume: 27, Issue:9

    Topics: Acetaminophen; Adult; Aged; Amines; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Diabetes Mellit

2010
[Biological age and the pain syndrome at diabetic polyneuropathy].
    Advances in gerontology = Uspekhi gerontologii, 2011, Volume: 24, Issue:2

    Topics: Adult; Aging; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Diabetic Neuropathies;

2011
Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia.
    Singapore medical journal, 2011, Volume: 52, Issue:12

    Topics: Adult; Amines; Anesthesia, Spinal; Anesthesiology; Cyclohexanecarboxylic Acids; Double-Blind Method;

2011
Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2013, Volume: 60, Issue:5

    Topics: Adult; Amines; Analysis of Variance; Anti-Anxiety Agents; Anxiety; Catastrophization; Cyclohexanecar

2013
Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial.
    Pain, 2002, Volume: 99, Issue:3

    Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analysis of Variance; Chi-Square Distribution; Cyc

2002
Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study.
    Neurology, 2002, Nov-26, Volume: 59, Issue:10

    Topics: Acetates; Adult; Aged; Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Method;

2002
Gabapentin for the treatment of pain in guillain-barré syndrome: a double-blinded, placebo-controlled, crossover study.
    Anesthesia and analgesia, 2002, Volume: 95, Issue:6

    Topics: Acetates; Adult; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind M

2002
Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent.
    The Journal of the Association of Physicians of India, 2003, Volume: 51

    Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Anxiety Agents; Clonidine; Cyclohexanecarboxy

2003
Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain.
    Pain medicine (Malden, Mass.), 2003, Volume: 4, Issue:4

    Topics: Acetates; Activities of Daily Living; Aged; Aged, 80 and over; Amines; Analgesics; Anesthetics, Loca

2003
Gabapentin for painful legs and moving toes syndrome.
    European neurology, 2004, Volume: 51, Issue:3

    Topics: Acetates; Aged; Amines; Cyclohexanecarboxylic Acids; Electromyography; Excitatory Amino Acid Antagon

2004
Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-15, Volume: 22, Issue:14

    Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Me

2004
Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-15, Volume: 22, Issue:14

    Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Me

2004
Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-15, Volume: 22, Issue:14

    Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Me

2004
Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-15, Volume: 22, Issue:14

    Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Me

2004
Therapeutic outcome in neuropathic pain: relationship to evidence of nervous system lesion.
    European journal of neurology, 2004, Volume: 11, Issue:8

    Topics: Acetates; Adult; Aged; Amines; Chi-Square Distribution; Cyclohexanecarboxylic Acids; Depression; Dos

2004
Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379].
    BMC neurology, 2004, Sep-29, Volume: 4

    Topics: Adult; Aged; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Metho

2004
Treatment of diabetic neuropathic pain with gabapentin alone or combined with vitamin B complex. preliminary results.
    Proceedings of the Western Pharmacology Society, 2004, Volume: 47

    Topics: Activities of Daily Living; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropat

2004
Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin.
    Acta neurologica Scandinavica, 2005, Volume: 111, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids;

2005
The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit.
    Anesthesia and analgesia, 2005, Volume: 101, Issue:1

    Topics: Adult; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Carbamazepine; Conscious Sedation; Crit

2005
Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans.
    Proceedings of the National Academy of Sciences of the United States of America, 2005, Dec-13, Volume: 102, Issue:50

    Topics: Adult; Amines; Analgesics; Analysis of Variance; Capsaicin; Central Nervous System; Cross-Over Studi

2005
Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study.
    Journal of palliative medicine, 2005, Volume: 8, Issue:6

    Topics: Aged; Amines; Analgesics; Analysis of Variance; Cyclohexanecarboxylic Acids; Dose-Response Relations

2005
CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model.
    The journal of pain, 2006, Volume: 7, Issue:8

    Topics: Adult; Amines; Analgesics; Capsaicin; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind

2006
A randomized study of the effects of gabapentin on postamputation pain.
    Anesthesiology, 2006, Volume: 105, Issue:5

    Topics: Aged; Amines; Amputation Stumps; Amputation, Surgical; Analgesics; Cyclohexanecarboxylic Acids; Fema

2006
Premedication with gabapentin: the effect on tourniquet pain and quality of intravenous regional anesthesia.
    Anesthesia and analgesia, 2007, Volume: 104, Issue:1

    Topics: Adult; Amines; Analgesics; Anesthesia, Conduction; Anesthesia, Intravenous; Cyclohexanecarboxylic Ac

2007
[The tebantin use in the complex therapy of pain syndrome during the mixed forms of alcoholic polyneuropathy].
    Voenno-meditsinskii zhurnal, 2006, Volume: 327, Issue:10

    Topics: Alcoholic Neuropathy; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Fe

2006
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:4

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth

2007
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:4

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth

2007
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:4

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth

2007
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:4

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth

2007
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:4

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth

2007
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:4

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth

2007
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:4

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth

2007
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:4

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth

2007
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:4

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth

2007
Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia.
    Current medical research and opinion, 2007, Volume: 23, Issue:10

    Topics: Amines; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Double-Blind Meth

2007
Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury.
    Archives of physical medicine and rehabilitation, 2007, Volume: 88, Issue:12

    Topics: Adult; Aged; Amines; Amitriptyline; Analgesics; Analysis of Variance; Antidepressive Agents, Tricycl

2007
The effect of gabapentin on neuropathic pain.
    The Clinical journal of pain, 1997, Volume: 13, Issue:3

    Topics: Acetates; Adolescent; Adult; Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Gabapentin; gam

1997
Open label gabapentin treatment for pain in multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 1997, Volume: 3, Issue:4

    Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gab

1997
Gabapentin for treatment of pain and tremor: a large case series.
    Southern medical journal, 1998, Volume: 91, Issue:8

    Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Arachnoiditis; Cerebellar Neoplasms; Cyc

1998
Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.
    JAMA, 1998, Dec-02, Volume: 280, Issue:21

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; D

1998
Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial.
    Journal of neurology, neurosurgery, and psychiatry, 1999, Volume: 66, Issue:2

    Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Cyclohexanecarboxylic Acids; Diabetic Neuropathies

1999
Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain.
    Archives of internal medicine, 1999, Sep-13, Volume: 159, Issue:16

    Topics: Acetates; Adrenergic Uptake Inhibitors; Aged; Amines; Amitriptyline; Analgesics; Cross-Over Studies;

1999
Postherpetic neuralgia: role of gabapentin and other treatment modalities.
    Epilepsia, 1999, Volume: 40 Suppl 6

    Topics: Acetates; Administration, Topical; Age Factors; Aged; Ambulatory Care; Amines; Analgesics; Anticonvu

1999
Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2000, Volume: 6, Issue:3

    Topics: Acetates; Amines; Anticonvulsants; Circadian Rhythm; Cyclohexanecarboxylic Acids; Gabapentin; gamma-

2000
Gabapentin therapy for diabetic neuropathic pain.
    The American journal of medicine, 2000, Jun-01, Volume: 108, Issue:8

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Double-Blind Metho

2000
Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study.
    Journal of pain and symptom management, 2000, Volume: 20, Issue:4

    Topics: Acetates; Aged; Aged, 80 and over; Amines; Amitriptyline; Analgesics; Ataxia; Cyclohexanecarboxylic

2000
Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain.
    Techniques in urology, 2001, Volume: 7, Issue:1

    Topics: Acetates; Administration, Oral; Amines; Analgesics; Cyclohexanecarboxylic Acids; Cystitis, Interstit

2001
Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study.
    Journal of chemotherapy (Florence, Italy), 2002, Volume: 14, Issue:2

    Topics: Acetates; Adolescent; Amines; Analgesics; Antineoplastic Agents; Cyclohexanecarboxylic Acids; Female

2002

Other Studies

291 other studies available for gabapentin and Ache

ArticleYear
Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury.
    Bioorganic & medicinal chemistry letters, 2004, May-17, Volume: 14, Issue:10

    Topics: Amines; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Cyclohexanols; Disease Models, Animal

2004
Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels.
    Bioorganic & medicinal chemistry letters, 2006, Mar-01, Volume: 16, Issue:5

    Topics: Amino Acids; Animals; Benzene; Calcium Channel Blockers; Calcium Channels; Ligands; Molecular Struct

2006
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
    Journal of medicinal chemistry, 2007, May-17, Volume: 50, Issue:10

    Topics: Analgesics; Animals; Anticonvulsants; Disease Models, Animal; gamma-Aminobutyric Acid; Hyperalgesia;

2007
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, May-15, Volume: 104, Issue:20

    Topics: Action Potentials; Analgesics; Aniline Compounds; Animals; Capsaicin; Evoked Potentials; Furans; Gan

2007
Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
    Journal of medicinal chemistry, 2008, Oct-23, Volume: 51, Issue:20

    Topics: Amines; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Histamine Antagonists; Ligands; M

2008
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
    Journal of medicinal chemistry, 2009, May-14, Volume: 52, Issue:9

    Topics: Analgesics; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Fluoxetine; Formaldehyde; gam

2009
Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective
    Journal of medicinal chemistry, 2010, Nov-11, Volume: 53, Issue:21

    Topics: Administration, Oral; Analgesics; Animals; Cell Line; Drug Tolerance; Fluoroquinolones; Humans; In V

2010
Part 3: Design and synthesis of proline-derived α2δ ligands.
    Bioorganic & medicinal chemistry letters, 2011, Jun-15, Volume: 21, Issue:12

    Topics: Animals; Drug Design; Humans; Inhibitory Concentration 50; Ligands; Molecular Structure; Pain; Proli

2011
New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo.
    Journal of medicinal chemistry, 2013, Oct-24, Volume: 56, Issue:20

    Topics: Analgesics; Animals; Binding, Competitive; Cyclic AMP; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP

2013
Gabapentin hybrid peptides and bioconjugates.
    Bioorganic & medicinal chemistry, 2014, Feb-15, Volume: 22, Issue:4

    Topics: Acylation; Amines; Analgesics; Animals; Behavior, Animal; Crystallography, X-Ray; Cyclization; Cyclo

2014
Antinociceptive Grayanoids from the Roots of Rhododendron molle.
    Journal of natural products, 2015, Dec-24, Volume: 78, Issue:12

    Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Diterpenes; Drugs,

2015
Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP
    Bioorganic & medicinal chemistry letters, 2018, 06-01, Volume: 28, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Blood Cells; Dinoprostone; Drug Evaluation, Preclinical; Half-Lif

2018
Circadian rhythmicity on red ear syndrome in a patient with migraine: A case report.
    Headache, 2021, Volume: 61, Issue:10

    Topics: Adult; Circadian Rhythm; Ear; Erythema; Female; Gabapentin; Humans; Migraine Disorders; Pain; Parest

2021
Pharmacokinetics and pharmacodynamics of repeat dosing of gabapentin in adult horses.
    Journal of veterinary internal medicine, 2022, Volume: 36, Issue:2

    Topics: Administration, Oral; Animals; Area Under Curve; Female; Gabapentin; Horses; Pain

2022
The Burning Question: Prophylactic Gabapentin for Mucositis-Related Pain in Patients Undergoing Chemoradiation Therapy for Head and Neck Cancer?
    International journal of radiation oncology, biology, physics, 2022, 03-15, Volume: 112, Issue:4

    Topics: Chemoradiotherapy; Gabapentin; Head and Neck Neoplasms; Humans; Mucositis; Pain

2022
Rate-Dependent Depression: A Predictor of the Therapeutic Efficacy in Treating Painful Diabetic Peripheral Neuropathy.
    Diabetes, 2022, 06-01, Volume: 71, Issue:6

    Topics: Depression; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Gabapentin; Humans; Pain

2022
Effects of Preoperative Gabapentin on Clinical Outcomes After Outpatient Midurethral Sling Placement.
    Female pelvic medicine & reconstructive surgery, 2022, 03-01, Volume: 28, Issue:3

    Topics: Female; Gabapentin; Humans; Male; Outpatients; Pain; Retrospective Studies; Suburethral Slings; Urin

2022
Association of Gabapentin Use With Pain Control and Feeding Tube Placement Among Patients With Head and Neck Cancer Receiving Chemoradiotherapy.
    JAMA network open, 2022, 05-02, Volume: 5, Issue:5

    Topics: Chemoradiotherapy; Gabapentin; Head and Neck Neoplasms; Humans; Intubation, Gastrointestinal; Pain

2022
Functional Impairment and Cognitive Symptoms Among People with HIV Infection on Chronic Opioid Therapy for Pain: The Impact of Gabapentin and Other Sedating Medications.
    AIDS and behavior, 2022, Volume: 26, Issue:12

    Topics: Analgesics, Opioid; Chronic Pain; Cognition; Cross-Sectional Studies; Gabapentin; HIV Infections; Hu

2022
Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy.
    Cardiovascular diabetology, 2022, 09-01, Volume: 21, Issue:1

    Topics: Amines; Analgesics; Cardiovascular Diseases; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Gab

2022
Persistent sensory changes and sex differences in transgenic mice conditionally expressing HIV-1 Tat regulatory protein.
    Experimental neurology, 2022, Volume: 358

    Topics: Animals; Cryopyrin-Associated Periodic Syndromes; Doxycycline; Female; Gabapentin; Gene Products, ta

2022
Antiepileptic prescribing to persons living with dementia residing in nursing homes: A tale of two indications.
    Journal of the American Geriatrics Society, 2023, Volume: 71, Issue:1

    Topics: Aged; Alzheimer Disease; Analgesics, Opioid; Anticonvulsants; Antipsychotic Agents; Gabapentin; Huma

2023
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
    Drug and alcohol dependence, 2023, 01-01, Volume: 242

    Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio

2023
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
    Drug and alcohol dependence, 2023, 01-01, Volume: 242

    Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio

2023
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
    Drug and alcohol dependence, 2023, 01-01, Volume: 242

    Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio

2023
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
    Drug and alcohol dependence, 2023, 01-01, Volume: 242

    Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio

2023
Characterization of Outpatient Gabapentinoid Prescribing for Pain.
    Journal of pain & palliative care pharmacotherapy, 2023, Volume: 37, Issue:2

    Topics: Adult; Amines; Analgesics; Gabapentin; Humans; Outpatients; Pain; Pregabalin; Retrospective Studies

2023
In Response to Regarding: Postoperative Gabapentin's Effect on Opioid Consumption and Pain Control Following Sinonasal Surgery.
    The Laryngoscope, 2023, Volume: 133, Issue:8

    Topics: Amines; Analgesics, Opioid; Gabapentin; Humans; Pain; Pain Management

2023
Postoperative Gabapentin's Effect on Opioid Consumption and Pain Control Following Sinonasal Surgery.
    The Laryngoscope, 2023, Volume: 133, Issue:8

    Topics: Amines; Analgesics, Opioid; Gabapentin; Humans; Pain; Pain Management; Pain, Postoperative

2023
Prescribing Trends of Antiseizure Drugs in Women Veterans With Epilepsy.
    Military medicine, 2023, 11-03, Volume: 188, Issue:11-12

    Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Gabapentin; Humans; Lamotrigine; Levetiracetam

2023
Fighting pain: the structure of gabapentin and its binding site in the Ca
    Nature structural & molecular biology, 2023, Volume: 30, Issue:6

    Topics: Binding Sites; Calcium Channels; Gabapentin; Humans; Pain; Protein Domains

2023
Drug-resistant epicrania fugax: Responding to onabotulinumtoxinA.
    Headache, 2023, Volume: 63, Issue:6

    Topics: Botulinum Toxins, Type A; Gabapentin; Headache; Headache Disorders; Humans; Pain

2023
[Metformin alleviates pathologic pain in mice with radiation dermatitis by inhibiting p38MAPK/NF-κB signaling pathway].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2023, Oct-20, Volume: 43, Issue:10

    Topics: Animals; Gabapentin; Interleukin-6; Male; MAP Kinase Signaling System; Metformin; Mice; Mice, Inbred

2023
Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers.
    Journal of substance abuse treatment, 2019, Volume: 105

    Topics: Analgesics; Florida; Gabapentin; Health Personnel; Humans; Interviews as Topic; Off-Label Use; Pain;

2019
An ethnographic decision model of the initiation of gabapentin misuse among prescription and/or illicit opioid (mis)user.
    Drug and alcohol dependence, 2019, 11-01, Volume: 204

    Topics: Adult; Anthropology, Cultural; Decision Theory; Drug Users; Female; Gabapentin; Humans; Male; Opioid

2019
Gabapentinoids for Pain: Potential Unintended Consequences.
    American family physician, 2019, 12-01, Volume: 100, Issue:11

    Topics: Analgesics; Chronic Pain; Drug Misuse; Gabapentin; Humans; Pain; Practice Guidelines as Topic; Prega

2019
Concomitant Use of Gabapentinoids with Opioids Is Associated with Increased Mortality and Morbidity among Dialysis Patients.
    American journal of nephrology, 2020, Volume: 51, Issue:6

    Topics: Adult; Aged; Analgesics, Opioid; Cause of Death; Drug Prescriptions; Female; Gabapentin; Hospitaliza

2020
Raynaud phenomenon of the nipple successfully treated with nifedipine and gabapentin.
    Cutis, 2020, Volume: 105, Issue:6

    Topics: Adult; Breast Diseases; Breast Feeding; Female; Gabapentin; Humans; Nifedipine; Nipples; Pain; Rayna

2020
A COVID-19 patient with intense burning pain.
    Journal of neurovirology, 2020, Volume: 26, Issue:5

    Topics: Acetaminophen; Analgesics; Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome; Back Pain;

2020
Pain management in patients with end-stage renal disease and calciphylaxis- a survey of clinical practices among physicians.
    BMC nephrology, 2020, 09-18, Volume: 21, Issue:1

    Topics: Acetaminophen; Advance Care Planning; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Analgesic

2020
Association Between Dual Trajectories of Opioid and Gabapentinoid Use and Healthcare Expenditures Among US Medicare Beneficiaries.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2021, Volume: 24, Issue:2

    Topics: Aged; Aged, 80 and over; Analgesics; Analgesics, Opioid; Cross-Sectional Studies; Drug Utilization;

2021
A pilot study of transdermal gabapentin in cats.
    Journal of veterinary internal medicine, 2021, Volume: 35, Issue:4

    Topics: Administration, Cutaneous; Animals; Cats; Gabapentin; Pain; Pilot Projects

2021
Gabapentin in Infants: Critical Evaluation of a Novel Sedative/Analgesic Medication.
    Neonatal network : NN, 2021, Jul-01, Volume: 40, Issue:4

    Topics: Adult; Analgesics; Gabapentin; Humans; Hypnotics and Sedatives; Infant; Infant, Newborn; Intensive C

2021
Gabapentinoid Dosing and Associated Toxicities in Patients With or Without Concomitant Opioids During Hospitalization.
    The American journal of hospice & palliative care, 2022, Volume: 39, Issue:5

    Topics: Adult; Analgesics; Analgesics, Opioid; Gabapentin; Hospitalization; Humans; Pain; Pregabalin

2022
A pilot feasibility study of gabapentin for managing pain in children with dystonic cerebral palsy.
    BMC pediatrics, 2021, 08-28, Volume: 21, Issue:1

    Topics: Adolescent; Australia; Cerebral Palsy; Child; Child, Preschool; Feasibility Studies; Female; Gabapen

2021
Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.
    PLoS medicine, 2017, Volume: 14, Issue:10

    Topics: Adult; Aged; Amines; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studi

2017
A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky.
    Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors, 2018, Volume: 32, Issue:1

    Topics: Adult; Analgesics; Drug Users; Female; Gabapentin; Humans; Kentucky; Longitudinal Studies; Male; Off

2018
Shingles in Pregnancy: An Elusive Case of Left Upper Quadrant Abdominal Pain.
    Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health, 2018, Volume: 77, Issue:8

    Topics: Abdominal Pain; Analgesics; Antiviral Agents; Female; Gabapentin; Gynecological Examination; Hawaii;

2018
Peer-reviewed homeopathy study sparks uproar in Italy.
    Nature, 2018, Volume: 562, Issue:7726

    Topics: Animals; Dissent and Disputes; Gabapentin; Homeopathy; Humans; Inflammation; Italy; Pain; Peer Revie

2018
Prevalence of Opioid, Gabapentinoid, and NSAID Use in Patients with CKD.
    Clinical journal of the American Society of Nephrology : CJASN, 2018, 12-07, Volume: 13, Issue:12

    Topics: Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Drug Utilization; Female; G

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe

2018
Beyond Opioids for Pain Management in Adult Critically Ill Patients.
    Journal of pharmacy practice, 2019, Volume: 32, Issue:3

    Topics: Acetaminophen; Adrenergic alpha-2 Receptor Agonists; Adult; Analgesia; Analgesics; Analgesics, Non-N

2019
Falling Dominoes.
    Anesthesia and analgesia, 2019, Volume: 128, Issue:4

    Topics: Accidental Falls; Adolescent; Child; Gabapentin; Humans; Pain; Pregabalin

2019
Successful treatment of refractory dermal pain with etizolam and clonazepam in a patient with acquired idiopathic generalized anhidrosis.
    The Journal of dermatology, 2019, Volume: 46, Issue:10

    Topics: Adult; Biopsy; Clonazepam; Diazepam; Drug Resistance; Drug Therapy, Combination; Gabapentin; Glucoco

2019
Gabapentin for pain, movement disorders, and irritability in neonates and infants.
    Developmental medicine and child neurology, 2020, Volume: 62, Issue:3

    Topics: Analgesics; Female; Gabapentin; Humans; Infant; Infant, Newborn; Intensive Care Units, Neonatal; Mal

2020
Comment on "Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis".
    Clinical rheumatology, 2019, Volume: 38, Issue:11

    Topics: Analgesics; Duloxetine Hydrochloride; Gabapentin; Humans; Osteoarthritis, Knee; Pain

2019
A study to compare circulating flunixin, meloxicam and gabapentin concentrations with prostaglandin E₂ levels in calves undergoing dehorning.
    Research in veterinary science, 2013, Volume: 95, Issue:1

    Topics: Amines; Analgesics; Animals; Area Under Curve; Cattle; Clonixin; Cyclohexanecarboxylic Acids; Dinopr

2013
Antihyperalgesic activity of a novel synthesized analogue of lidocaine in diabetic rats.
    The Journal of pharmacy and pharmacology, 2013, Volume: 65, Issue:5

    Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Diabetes Complications;

2013
Chronic unilateral eruption of painful, erythematous papules and nodules. Piloleiomyoma.
    JAMA dermatology, 2013, Volume: 149, Issue:7

    Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid;

2013
Semi-mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain.
    Pharmaceutical research, 2014, Volume: 31, Issue:3

    Topics: Amines; Analgesics; Animals; Computer Simulation; Cyclohexanecarboxylic Acids; Dose-Response Relatio

2014
Painful traumatic trigeminal neuropathy: an open study on the pharmacotherapeutic response to stepped treatment.
    Journal of oral & facial pain and headache, 2014,Winter, Volume: 28, Issue:1

    Topics: Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Baclofen; Carbamazepine; Clinical Proto

2014
Effect of gabapentin on swallowing during and after chemoradiation for oropharyngeal squamous cell cancer.
    Dysphagia, 2014, Volume: 29, Issue:3

    Topics: Amines; Analgesics; Carcinoma, Squamous Cell; Chemoradiotherapy; Cyclohexanecarboxylic Acids; Deglut

2014
Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: a potential biomarker of efficacy.
    Pain, 2014, Volume: 155, Issue:8

    Topics: Amines; Analgesics; Animals; Biomarkers; Cyclohexanecarboxylic Acids; Dopamine; Gabapentin; gamma-Am

2014
Effects of NB001 and gabapentin on irritable bowel syndrome-induced behavioral anxiety and spontaneous pain.
    Molecular brain, 2014, Jun-16, Volume: 7

    Topics: Adenosine Triphosphate; Amines; Animals; Anxiety; Behavior, Animal; Cyclohexanecarboxylic Acids; Gab

2014
Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements?
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:3

    Topics: Aged; Amines; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Chemotherapy, Adjuvant; C

2015
Development and pharmacological characterization of a model of sleep disruption-induced hypersensitivity in the rat.
    European journal of pain (London, England), 2015, Volume: 19, Issue:4

    Topics: Amines; Animals; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapenti

2015
Comparison of the effects of gabapentin and pregabalin on wound healing in rats.
    International wound journal, 2016, Volume: 13, Issue:5

    Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Human

2016
Six cases of (severe) hypoglycaemia associated with gabapentin use in both diabetic and non-diabetic patients.
    British journal of clinical pharmacology, 2015, Volume: 79, Issue:5

    Topics: Amines; Analgesics; Blood Glucose; Cyclohexanecarboxylic Acids; Diabetes Mellitus; Gabapentin; gamma

2015
In vivo two-photon imaging of structural dynamics in the spinal dorsal horn in an inflammatory pain model.
    The European journal of neuroscience, 2015, Volume: 41, Issue:7

    Topics: Acute Disease; Amines; Animals; Calcium Channel Blockers; Calcium Channels; Cyclohexanecarboxylic Ac

2015
Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis.
    Journal of palliative medicine, 2015, Volume: 18, Issue:5

    Topics: Adolescent; Adult; Amines; Analgesics; Central Nervous System Diseases; Child; Child, Preschool; Cyc

2015
Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats.
    European journal of pain (London, England), 2015, Volume: 19, Issue:10

    Topics: Adjuvants, Immunologic; Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxy

2015
Chronic progressive polyarthritis in a domestic shorthair cat.
    The Canadian veterinary journal = La revue veterinaire canadienne, 2015, Volume: 56, Issue:6

    Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Buprenorphine; Cat Diseases; Cats;

2015
The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study.
    Pain practice : the official journal of World Institute of Pain, 2016, Volume: 16, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Prep

2016
Evaluation of the Percutaneous Absorption of Ketamine HCl, Gabapentin, Clonidine HCl, and Baclofen, in Compounded Transdermal Pain Formulations, Using the Franz Finite Dose Model.
    Pain medicine (Malden, Mass.), 2016, Volume: 17, Issue:2

    Topics: Administration, Cutaneous; Aged; Amines; Baclofen; Clonidine; Cyclohexanecarboxylic Acids; Drug Comp

2016
Pharmacological characterization of intraplantar Complete Freund's Adjuvant-induced burrowing deficits.
    Behavioural brain research, 2016, Mar-15, Volume: 301

    Topics: Amines; Analgesics; Animals; Antibodies; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; D

2016
Analysis of the behavioral, cellular and molecular characteristics of pain in severe rodent spinal cord injury.
    Experimental neurology, 2016, Volume: 278

    Topics: Amines; Animals; Calcitonin Gene-Related Peptide; Calcium-Binding Proteins; Carbenoxolone; Connexin

2016
Painless legs and moving toes syndrome associated with a sacral Tarlov cyst: a case report.
    Journal of medical case reports, 2016, Mar-09, Volume: 10

    Topics: Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Dyskinesias; Female; Gabapentin; gamma-Am

2016
Transcriptomic and behavioural characterisation of a mouse model of burn pain identify the cholecystokinin 2 receptor as an analgesic target.
    Molecular pain, 2016, Volume: 12

    Topics: Amines; Amitriptyline; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin; Gai

2016
sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain.
    Pharmacological research, 2017, Volume: 117

    Topics: Amides; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin

2017
An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve.
    The journal of pain, 2017, Volume: 18, Issue:8

    Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Functional Lateral

2017
Gabapentin for breakthrough pain due to bone metastases.
    Palliative medicine, 2008, Volume: 22, Issue:4

    Topics: Amines; Analgesics; Bone Neoplasms; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid

2008
Antinociceptive action of GLYX-13: an N-methyl-D-aspartate receptor glycine site partial agonist.
    Neuroreport, 2008, Jul-02, Volume: 19, Issue:10

    Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Disease Models, Animal;

2008
Gabapentin toxicity in renal failure: the importance of dose adjustment.
    Pain medicine (Malden, Mass.), 2009, Volume: 10, Issue:1

    Topics: Acute Kidney Injury; Aged; Amines; Animals; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-A

2009
The interaction of gabapentin and N6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA) on mechanical allodynia in rats with a spinal nerve ligation.
    Journal of Korean medical science, 2008, Volume: 23, Issue:4

    Topics: Adenosine; Amines; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Syne

2008
FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy.
    Neuropharmacology, 2008, Volume: 55, Issue:7

    Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Diabetic

2008
Multiplicative interactions to enhance gabapentin to treat neuropathic pain.
    European journal of pharmacology, 2008, Nov-19, Volume: 598, Issue:1-3

    Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Donepezil; Dose-Response Relationship, Dru

2008
Is there a role for anticonvulsants in the management of rheumatic pain?
    Joint bone spine, 2008, Volume: 75, Issue:6

    Topics: Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Am

2008
Differential analgesic effects of morphine and gabapentin on behavioural measures of pain and disability in a model of osteoarthritis pain in rats.
    European journal of pain (London, England), 2009, Volume: 13, Issue:8

    Topics: Amines; Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Cold Temperature; Cyclohexanecarb

2009
Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats.
    European journal of pain (London, England), 2009, Volume: 13, Issue:8

    Topics: Amines; Analgesics; Animals; Astrocytes; Cell Count; Cyclohexanecarboxylic Acids; Diabetes Mellitus,

2009
Neuropathic pain in children after exposure to mercury.
    Paediatric anaesthesia, 2008, Volume: 18, Issue:12

    Topics: Amines; Analgesics, Non-Narcotic; Burning Mouth Syndrome; Child; Cyclohexanecarboxylic Acids; Gabape

2008
A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling.
    Therapeutic drug monitoring, 2009, Volume: 31, Issue:1

    Topics: Adult; Aged; Algorithms; Amines; Area Under Curve; Bayes Theorem; Biological Availability; Cyclohexa

2009
Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain.
    Neurobiology of disease, 2009, Volume: 33, Issue:3

    Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists;

2009
Intrathecal gabapentin does not act as a hyperpolarization-activated cyclic nucleotide-gated channel activator in the rat formalin test.
    European journal of anaesthesiology, 2009, Volume: 26, Issue:10

    Topics: Amines; Analgesics; Animals; Cardiotonic Agents; Cyclic Nucleotide-Gated Cation Channels; Cyclohexan

2009
Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit.
    Biological & pharmaceutical bulletin, 2009, Volume: 32, Issue:4

    Topics: Administration, Oral; Amines; Analgesics, Non-Narcotic; Animals; Antineoplastic Agents; Antineoplast

2009
A mouse model of sural nerve injury-induced neuropathy: gabapentin inhibits pain-related behaviors and the hyperactivity of wide-dynamic range neurons in the dorsal horn.
    Journal of pharmacological sciences, 2009, Volume: 109, Issue:4

    Topics: Amines; Analgesics, Non-Narcotic; Animals; Behavior, Animal; Cold Temperature; Cyclohexanecarboxylic

2009
Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain.
    Neuropharmacology, 2009, Volume: 57, Issue:2

    Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Cyclopentanes; Diabetes Mellitus, Experime

2009
Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury.
    Pharmacology, biochemistry, and behavior, 2009, Volume: 92, Issue:3

    Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Drug Synergism; Gabapent

2009
Gabapentin therapy for chronic proctalgia following stapled haemorrhoidopexy.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2009, Volume: 11, Issue:7

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hemorrhoids; H

2009
Protein kinase A-dependence of the supraspinally mediated analgesic effects of gabapentin on thermal and mechanical hypersensitivity.
    Journal of pharmacological sciences, 2009, Volume: 110, Issue:2

    Topics: Amines; Analgesics; Animals; Cyclic AMP-Dependent Protein Kinases; Cyclohexanecarboxylic Acids; Dose

2009
How does gabapentin relieve neuropathic pain?
    Pain, 2009, Volume: 145, Issue:1-2

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Pain;

2009
Moving from tube to oral feeding in medically fragile nonverbal toddlers.
    Journal of pediatric gastroenterology and nutrition, 2009, Volume: 49, Issue:2

    Topics: Amines; Analgesics; Antidepressive Agents, Tricyclic; Appetite Regulation; Appetite Stimulants; Chil

2009
Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.
    Clinical and experimental dermatology, 2009, Volume: 34, Issue:8

    Topics: Adolescent; Adult; Amines; Calcium Channel Blockers; Carbamazepine; Cyclohexanecarboxylic Acids; Dru

2009
Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy.
    Head & neck, 2010, Volume: 32, Issue:2

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Deglutition Disorders; Dose-Response Relationship,

2010
Gabapentin therapy for pain and irritability in a neurologically impaired infant.
    Pharmacotherapy, 2009, Volume: 29, Issue:8

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Infant

2009
Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models.
    Brain research, 2009, Oct-27, Volume: 1295

    Topics: Amines; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Axotomy; Carrageenan;

2009
A case of perineal pain related to interstitial cystitis which was supposed to be relieved with gabapentin.
    Journal of anesthesia, 2009, Volume: 23, Issue:3

    Topics: Amines; Analgesics; Anesthetics, Local; Cyclohexanecarboxylic Acids; Cystitis, Interstitial; Cystosc

2009
Suppression of formalin-induced nociception by cilnidipine, a voltage-dependent calcium channel blocker.
    Biological & pharmaceutical bulletin, 2009, Volume: 32, Issue:10

    Topics: Administration, Oral; Amines; Analgesics; Animals; Calcium Channel Blockers; Calcium Channels, N-Typ

2009
Outcome reporting in industry-sponsored trials of gabapentin for off-label use.
    The New England journal of medicine, 2009, Nov-12, Volume: 361, Issue:20

    Topics: Amines; Bipolar Disorder; Clinical Protocols; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobu

2009
Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study.
    International journal of surgery (London, England), 2010, Volume: 8, Issue:3

    Topics: Aged; Amines; Analgesics; Analgesics, Opioid; Chronic Disease; Cyclohexanecarboxylic Acids; Female;

2010
Tri-partite complex for axonal transport drug delivery achieves pharmacological effect.
    BMC neuroscience, 2010, Jan-20, Volume: 11

    Topics: Amines; Analgesics; Animals; Axonal Transport; Cell Line; Cells, Cultured; Cricetinae; Cyclohexaneca

2010
Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy.
    Pain medicine (Malden, Mass.), 2010, Volume: 11, Issue:3

    Topics: Aged; Amines; Analgesics; Cohort Studies; Cyclohexanecarboxylic Acids; Data Interpretation, Statisti

2010
Syringomyelia in the Cavalier King Charles spaniel (CKCS) dog.
    The Canadian veterinary journal = La revue veterinaire canadienne, 2010, Volume: 51, Issue:1

    Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents; Arnold-Chiari Malformation; Breeding; Cyclohe

2010
Analgesic effects of gabapentin on mechanical hypersensitivity in a rat model of chronic pancreatitis.
    Brain research, 2010, Jun-14, Volume: 1337

    Topics: Amines; Analgesics; Animals; Calcium Channels; Calcium Channels, L-Type; Cyclohexanecarboxylic Acids

2010
Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
    Pain medicine (Malden, Mass.), 2010, Volume: 11, Issue:1

    Topics: Amines; Analgesics, Opioid; Animals; Carrageenan; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Ex

2010
Selective potentiation of gabapentin-mediated antinociception in the rat formalin test by the nicotinic acetylcholine receptor agonist ABT-594.
    Neuropharmacology, 2010, Volume: 59, Issue:3

    Topics: Amines; Analgesics; Animals; Azetidines; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-R

2010
Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy.
    Cancer, 2010, Sep-01, Volume: 116, Issue:17

    Topics: Amines; Analgesics; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm

2010
Lack of analgesic efficacy of spinal ondansetron on thermal and mechanical hypersensitivity following spinal nerve ligation in the rat.
    Brain research, 2010, Sep-17, Volume: 1352

    Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gabapen

2010
Characterization of the acute and persistent pain state present in K/BxN serum transfer arthritis.
    Pain, 2010, Volume: 151, Issue:2

    Topics: Activating Transcription Factor 3; Amines; Analgesics; Analysis of Variance; Animals; Arthritis, Rhe

2010
[Disease with generalized pain. Guillain-Barré syndrome].
    Praxis, 2011, Apr-13, Volume: 100, Issue:8

    Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Female; Gabapentin;

2011
Painful traumatic neuroma of the tongue treated with serial alcohol injections.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2011, Volume: 145, Issue:4

    Topics: Aged; Amines; Analgesics; Anesthetics, Local; Central Nervous System Depressants; Cyclohexanecarboxy

2011
Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition.
    The Johns Hopkins medical letter health after 50, 2011, Volume: 23, Issue:4

    Topics: Amines; Bipolar Disorder; Clinical Protocols; Cyclohexanecarboxylic Acids; Drug Approval; Drug Label

2011
Chronic Lyme disease: the controversies and the science.
    Expert review of anti-infective therapy, 2011, Volume: 9, Issue:7

    Topics: Amines; Analgesics; Anti-Bacterial Agents; Arthritis, Rheumatoid; Borrelia burgdorferi; Chronic Dise

2011
Gabapentin as part of multi-modal analgesia in two cats suffering multiple injuries.
    Veterinary anaesthesia and analgesia, 2011, Volume: 38, Issue:5

    Topics: Amines; Analgesia; Analgesics; Animals; Buprenorphine; Cat Diseases; Cats; Cyclohexanecarboxylic Aci

2011
Accounting for perception, placebo and unmasking effects in estimating treatment effects in randomised clinical trials.
    Statistical methods in medical research, 2014, Volume: 23, Issue:3

    Topics: Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Pain

2014
Successful treatment of tabetic lightning pain and visceral crisis with gabapentin.
    Journal of anesthesia, 2011, Volume: 25, Issue:6

    Topics: Amines; Cyclohexanecarboxylic Acids; Extremities; Gabapentin; gamma-Aminobutyric Acid; Humans; Male;

2011
Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy.
    Journal of medical economics, 2012, Volume: 15, Issue:2

    Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Databases, Factual; Diabetic Nephropathies; F

2012
The combined predictive capacity of rat models of algogen-induced and neuropathic hypersensitivity to clinically used analgesics varies with nociceptive endpoint and consideration of locomotor function.
    Pharmacology, biochemistry, and behavior, 2012, Volume: 101, Issue:3

    Topics: Amines; Analgesics; Animals; Capsaicin; Cyclohexanecarboxylic Acids; Disease Models, Animal; Duloxet

2012
Spontaneous burrowing behaviour in the rat is reduced by peripheral nerve injury or inflammation associated pain.
    European journal of pain (London, England), 2012, Volume: 16, Issue:4

    Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Cyclohexanec

2012
Temperature-dependent enhancement of the antinociceptive effects of opioids in combination with gabapentin in mice.
    European journal of pharmacology, 2012, Jul-05, Volume: 686, Issue:1-3

    Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gam

2012
Gabapentin reduces CX3CL1 signaling and blocks spinal microglial activation in monoarthritic rats.
    Molecular brain, 2012, May-30, Volume: 5

    Topics: Amines; Animals; Arthritis; Calcium Channels, L-Type; Chemokine CX3CL1; CX3C Chemokine Receptor 1; C

2012
Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes.
    Proceedings of the National Academy of Sciences of the United States of America, 2012, Jul-10, Volume: 109, Issue:28

    Topics: Amines; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Dia

2012
Non-surgical therapy for bilateral glossopharyngeal neuralgia caused by Eagle's syndrome, diagnosed by three-dimensional computed tomography: a case report.
    Journal of anesthesia, 2012, Volume: 26, Issue:6

    Topics: Aged; Amines; Analgesics; Anesthetics, Local; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobu

2012
Antinociceptive effects of gabapentin & its mechanism of action in experimental animal studies.
    The Indian journal of medical research, 2012, Volume: 135, Issue:5

    Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dinoprostone; Gabapentin; gamma-Aminobutyr

2012
Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment.
    Journal of palliative medicine, 2013, Volume: 16, Issue:4

    Topics: Amines; Analgesics; Apnea; Central Nervous System; Cyclohexanecarboxylic Acids; Female; Gabapentin;

2013
Positive allosteric modulation of GABA-A receptors reduces capsaicin-induced primary and secondary hypersensitivity in rats.
    Neuropharmacology, 2012, Volume: 63, Issue:8

    Topics: Amines; Analgesics, Opioid; Animals; Behavior, Animal; Benzimidazoles; Capsaicin; Cyclohexanecarboxy

2012
Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model.
    Journal of investigative surgery : the official journal of the Academy of Surgical Research, 2013, Volume: 26, Issue:3

    Topics: Amines; Animals; Antioxidants; Calcium Channels; Catalase; Cyclohexanecarboxylic Acids; Drug Combina

2013
Mandatory palliative care education for surgical residents: initial focus on teaching pain management.
    Japanese journal of clinical oncology, 2013, Volume: 43, Issue:2

    Topics: Adult; Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Curriculum;

2013
Changes in expression of voltage-dependent ion channel subunits in dorsal root ganglia of rats with radicular injury and pain.
    Spine, 2002, Jul-15, Volume: 27, Issue:14

    Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Calcium Channels; Cyclohexanecarboxylic Aci

2002
Gabapentin for coeliac plexus pain.
    Palliative medicine, 2002, Volume: 16, Issue:4

    Topics: Acetates; Aged; Amines; Analgesics; Celiac Plexus; Cyclohexanecarboxylic Acids; Female; Gabapentin;

2002
Gabapentin and pregabalin suppress tactile allodynia and potentiate spinal cord stimulation in a model of neuropathy.
    European journal of pain (London, England), 2002, Volume: 6, Issue:4

    Topics: Acetates; Amines; Analgesics; Animals; Anticonvulsants; Calcium Channel Blockers; Cyclohexanecarboxy

2002
SUNCT responsive to gabapentin.
    Headache, 2002, Volume: 42, Issue:6

    Topics: Acetates; Adult; Amines; Analgesics; Conjunctiva; Cyclohexanecarboxylic Acids; Female; Gabapentin; g

2002
Central post-stroke pain syndrome: yet another use for gabapentin?
    American journal of physical medicine & rehabilitation, 2002, Volume: 81, Issue:9

    Topics: Acetates; Activities of Daily Living; Administration, Oral; Amines; Analgesics; Cyclohexanecarboxyli

2002
Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 302, Issue:3

    Topics: Acetates; Acute Disease; Adrenergic alpha-Agonists; Amines; Analgesics, Non-Narcotic; Analgesics, Op

2002
Is gabapentin a "Broad-spectrum" analgesic?
    Anesthesiology, 2002, Volume: 97, Issue:3

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma

2002
Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:2

    Topics: Acetates; Amines; Animals; Benzofurans; Carbamates; Cyclohexanecarboxylic Acids; Diabetes Mellitus,

2002
Anti-allodynic action of the tormentic acid, a triterpene isolated from plant, against neuropathic and inflammatory persistent pain in mice.
    European journal of pharmacology, 2002, Oct-25, Volume: 453, Issue:2-3

    Topics: Acetates; Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Freund'

2002
Cavernous angioma in the brachium pontis presenting with trigeminal neuralgia: a case report.
    European neurology, 2002, Volume: 48, Issue:4

    Topics: Acetates; Amines; Analgesics; Central Nervous System Vascular Malformations; Cyclohexanecarboxylic A

2002
Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia.
    Neuropharmacology, 2002, Volume: 43, Issue:6

    Topics: Acetates; Adrenergic Uptake Inhibitors; Amines; Aminopyridines; Analgesia; Analgesics; Animals; Cell

2002
Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:3

    Topics: Acetates; Amines; Animals; Calcium Channels; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Dis

2002
Lumbar spinal cord stimulation for cervical-originated central pain: a case report.
    Pain, 2002, Volume: 100, Issue:3

    Topics: Acetates; Amines; Antidepressive Agents, Tricyclic; Cervical Vertebrae; Cyclohexanecarboxylic Acids;

2002
Gabapentin markedly reduces acetic acid-induced visceral nociception.
    Anesthesiology, 2003, Volume: 98, Issue:3

    Topics: Acetates; Amines; Analgesics; Animals; Calcium; Cyclohexanecarboxylic Acids; Excitatory Amino Acids;

2003
[Recognizing the "neck-tongue" syndrome].
    Presse medicale (Paris, France : 1983), 2003, Feb-01, Volume: 32, Issue:4

    Topics: Acetates; Amines; Analgesics; Analgesics, Non-Narcotic; Arthritis; Cervical Vertebrae; Cyclohexaneca

2003
Suppression by gabapentin of pain-related mechano-responses in mice given orthotopic tumor inoculation.
    Biological & pharmaceutical bulletin, 2003, Volume: 26, Issue:4

    Topics: Acetates; Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hyperal

2003
[Case report on a patient with SUNCT-syndrome].
    Schmerz (Berlin, Germany), 2003, Volume: 17, Issue:2

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Functional Laterality; Gabapentin

2003
Complete vasomotor collapse: an unusual manifestation of the carotid sinus reflex.
    Anesthesiology, 2003, Volume: 98, Issue:5

    Topics: Acetates; Amines; Animals; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gabapenti

2003
Gabapentin blocks and reverses antinociceptive morphine tolerance in the rat paw-pressure and tail-flick tests.
    Anesthesiology, 2003, Volume: 98, Issue:5

    Topics: Acetates; Amines; Analgesics, Opioid; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal;

2003
An East-West approach to the management of central post-stroke pain.
    Cerebrovascular diseases (Basel, Switzerland), 2003, Volume: 16, Issue:1

    Topics: Acetates; Acupuncture; Aged; Amines; Amitriptyline; Analgesics, Opioid; Antidepressive Agents, Secon

2003
ATP-sensitive potassium channels in rat primary afferent neurons: the effect of neuropathic injury and gabapentin.
    Neuroscience letters, 2003, Jun-12, Volume: 343, Issue:3

    Topics: Acetates; Amines; Animals; ATP-Binding Cassette Transporters; Basal Ganglia; Cyclohexanecarboxylic A

2003
The trend to move palliative care upstream.
    Journal of palliative medicine, 2003, Volume: 6, Issue:2

    Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; H

2003
Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin.
    Pain, 2003, Volume: 104, Issue:1-2

    Topics: Acetates; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Herpes Z

2003
[Effect of anticonvulsant gabapentin on visceral nociception and its relationship with amino acid neurotransmitters released from spinal cord].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2003, Jun-18, Volume: 35, Issue:3

    Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship,

2003
Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain.
    European journal of pharmacology, 2003, Oct-08, Volume: 478, Issue:2-3

    Topics: Acetates; Amines; Analgesics; Animals; Anti-Inflammatory Agents; Cyclohexanecarboxylic Acids; Edema;

2003
[Unclear chronic aches. Often depression plays a part therein].
    MMW Fortschritte der Medizin, 2003, May-26, Volume: 145 Suppl 2

    Topics: Acetates; Amines; Analgesics, Opioid; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Age

2003
[Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2003, Volume: 15, Issue:85

    Topics: Acetates; Aged; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Ty

2003
The pattern of gabapentin use in a tertiary palliative care unit.
    Journal of palliative care, 2003,Fall, Volume: 19, Issue:3

    Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; G

2003
Treatment of neuropathic orbital pain with gabapentin.
    Journal of pain & palliative care pharmacotherapy, 2003, Volume: 17, Issue:2

    Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Eye Diseases; Female; Gabapen

2003
Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited.
    Pain, 2003, Volume: 106, Issue:3

    Topics: Acetates; Amines; Analgesia; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug;

2003
The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain.
    Pharmaceutical research, 2003, Volume: 20, Issue:11

    Topics: Acetates; Amines; Analgesics; Chronic Disease; Clinical Trials, Phase II as Topic; Computer Simulati

2003
A nitric oxide (NO)-releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain-like behavior after spinal cord and peripheral nerve injury.
    British journal of pharmacology, 2004, Volume: 141, Issue:1

    Topics: Acetates; Amines; Animals; Aorta, Thoracic; Behavior, Animal; Cyclic GMP; Cyclohexanecarboxylic Acid

2004
Myoclonic jerks associated with gabapentin.
    Palliative medicine, 2003, Volume: 17, Issue:8

    Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut

2003
Synergistic interaction between spinal gabapentin and oral B vitamins in a neuropathic pain model.
    Proceedings of the Western Pharmacology Society, 2003, Volume: 46

    Topics: Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug

2003
Reduction by gabapentin of K+-evoked release of [3H]-glutamate from the caudal trigeminal nucleus of the streptozotocin-treated rat.
    British journal of pharmacology, 2004, Volume: 141, Issue:4

    Topics: Acetates; Amines; Animals; Blood Glucose; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experiment

2004
Painful neuropathy alters the effect of gabapentin on sensory neuron excitability in rats.
    Acta anaesthesiologica Scandinavica, 2004, Volume: 48, Issue:4

    Topics: Acetates; Action Potentials; Amines; Analgesics; Analysis of Variance; Animals; Calcium Channels; Cy

2004
Effects of the suppression of acute herpetic pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice.
    Life sciences, 2004, Apr-09, Volume: 74, Issue:21

    Topics: Acetates; Amines; Amitriptyline; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, A

2004
Vulvodynia.
    Lancet (London, England), 2004, Mar-27, Volume: 363, Issue:9414

    Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents, Tricyclic; Biofeedback, Psychology; Chroni

2004
Gabapentin (Neurontin) for chronic pain.
    The Medical letter on drugs and therapeutics, 2004, Apr-12, Volume: 46, Issue:1180

    Topics: Acetates; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Costs; Drug Interac

2004
The use of gabapentin in a 12-year-old boy with cancer pain.
    Acta anaesthesiologica Scandinavica, 2004, Volume: 48, Issue:5

    Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Child; Cyclohexanecarboxylic Acids; Dose-Response

2004
Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:5

    Topics: Acetates; Amines; Anticonvulsants; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic Acids; G

2004
Profiles in patient safety: when an error occurs.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2004, Volume: 11, Issue:7

    Topics: Acetates; Aged; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropath

2004
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
    The Journal of pharmacology and experimental therapeutics, 2004, Volume: 311, Issue:2

    Topics: Acute Disease; Amines; Amitriptyline; Animals; Conscious Sedation; Cyclohexanecarboxylic Acids; Cycl

2004
Future Pain Drugs - Europe 2003. 15-16 September 2003, London, UK.
    IDrugs : the investigational drugs journal, 2003, Volume: 6, Issue:11

    Topics: Acetaminophen; Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, A

2003
Differential analgesic sensitivity of two distinct neuropathic pain models.
    Anesthesia and analgesia, 2004, Volume: 99, Issue:2

    Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Animals; Cold Temperature; Cyclohexanecarboxylic A

2004
Treatment of bath PUVA-induced skin pain with gabapentin.
    The British journal of dermatology, 2004, Volume: 151, Issue:2

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Male;

2004
Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model.
    Anesthesiology, 2004, Volume: 101, Issue:3

    Topics: Acetates; Acute Disease; Amines; Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Bradykin

2004
Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents.
    The Journal of pharmacology and experimental therapeutics, 2005, Volume: 312, Issue:2

    Topics: Adrenergic Uptake Inhibitors; Amines; Analgesics; Analgesics, Opioid; Animals; Anti-Inflammatory Age

2005
[Gabapentin (Neurontin) and cancer pain: a pilot study].
    Revue medicale de Bruxelles, 2004, Volume: 25, Issue:5

    Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric

2004
Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain.
    Anesthesiology, 2005, Volume: 102, Issue:1

    Topics: Amines; Analgesics; Animals; Behavior, Animal; Bone Neoplasms; Cell Line, Tumor; Cyclohexanecarboxyl

2005
Analysis of interactions between serotonin and gabapentin or adenosine in the spinal cord of rats.
    Pharmacology, 2005, Volume: 74, Issue:1

    Topics: Adenosine; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Dru

2005
Neutropenia occurring after starting gabapentin for neuropathic pain.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2004, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Amines; Analgesics; Carcinoma, Non-Small-Cell Lung; Cyclohexanecarboxylic Acids; Gab

2004
Gabapentin-induced myoclonus in end-stage renal disease.
    Epilepsia, 2005, Volume: 46, Issue:1

    Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric

2005
Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action.
    The Journal of pharmacology and experimental therapeutics, 2005, Volume: 313, Issue:3

    Topics: Acetates; Acute Disease; Amines; Analgesics; Animals; Benzylamines; Chronic Disease; Cyclohexanecarb

2005
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
    Neuropharmacology, 2005, Volume: 48, Issue:5

    Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anxiety; Ataxia; Behavior, Ani

2005
The effect of antinociceptive drugs tested at different times after nerve injury in rats.
    Anesthesia and analgesia, 2005, Volume: 101, Issue:1

    Topics: Amines; Analgesics; Animals; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Dose-Res

2005
Computed tomography guided lumbar sympathetic block for complex regional pain syndrome in a child: a case report and review.
    European journal of pain (London, England), 2006, Volume: 10, Issue:5

    Topics: Amines; Amitriptyline; Analgesics; Anesthetics, Local; Antidepressive Agents, Tricyclic; Autonomic N

2006
Characterization of pain and pharmacologic responses in an animal model of lumbar adhesive arachnoiditis.
    Spine, 2005, Aug-15, Volume: 30, Issue:16

    Topics: Amines; Analgesics; Analgesics, Opioid; Animals; Arachnoiditis; Behavior, Animal; Cauda Equina; Cycl

2005
CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats.
    European journal of pharmacology, 2005, Sep-20, Volume: 519, Issue:3

    Topics: Administration, Oral; Amines; Analgesics; Animals; Behavior, Animal; Capsaicin; Cyclohexanecarboxyli

2005
Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain.
    Psychopharmacology, 2005, Volume: 182, Issue:4

    Topics: Amines; Analgesics; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Bupropio

2005
Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin.
    Pain, 2005, Volume: 117, Issue:3

    Topics: Action Potentials; Amines; Analgesics; Analysis of Variance; Animals; Behavior, Animal; Cell Count;

2005
Development and expression of neuropathic pain in CB1 knockout mice.
    Neuropharmacology, 2006, Volume: 50, Issue:1

    Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A

2006
Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain.
    Neuropharmacology, 2005, Volume: 49, Issue:8

    Topics: Ambroxol; Amines; Analgesics; Animals; Behavior, Animal; Constriction, Pathologic; Cyclohexanecarbox

2005
The effects of diacerhein on mechanical allodynia in inflammatory and neuropathic models of nociception in mice.
    Anesthesia and analgesia, 2005, Volume: 101, Issue:6

    Topics: Amines; Animals; Anthraquinones; Anti-Inflammatory Agents, Non-Steroidal; Cyclohexanecarboxylic Acid

2005
The nitric oxide-cyclic GMP-protein kinase G-K+ channel pathway participates in the antiallodynic effect of spinal gabapentin.
    European journal of pharmacology, 2006, Feb-15, Volume: 531, Issue:1-3

    Topics: Amines; Analgesics; Animals; Apamin; Carbazoles; Charybdotoxin; Cyclic GMP; Cyclic GMP-Dependent Pro

2006
Motor cortex stimulation for central pain following a traumatic brain injury.
    Pain, 2006, Volume: 123, Issue:1-2

    Topics: Accidental Falls; Adult; Amines; Amitriptyline; Analgesics, Non-Narcotic; Aphasia, Broca; Brain Inju

2006
Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 318, Issue:2

    Topics: Amines; Animals; Antineoplastic Agents, Phytogenic; Behavior, Animal; Blotting, Western; Calcium Cha

2006
Gabapentin may cause reversible visual field constriction.
    BMJ (Clinical research ed.), 2006, May-20, Volume: 332, Issue:7551

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans

2006
Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain.
    Psychopharmacology, 2006, Volume: 187, Issue:3

    Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Cyclohexanols; Dose-Response Relationship,

2006
Does acute pain associated with herpes zoster respond to treatment with gabapentin?
    Nature clinical practice. Neurology, 2006, Volume: 2, Issue:6

    Topics: Acute Disease; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Met

2006
Gabapentin enhances the analgesic response to morphine in acute model of pain in male rats.
    Pharmacology, biochemistry, and behavior, 2006, Volume: 85, Issue:1

    Topics: Amines; Analgesics, Opioid; Animals; Area Under Curve; Cyclohexanecarboxylic Acids; Disease Models,

2006
Effects of gabapentin on morphine consumption and pain in severely burned patients.
    Burns : journal of the International Society for Burn Injuries, 2007, Volume: 33, Issue:1

    Topics: Administration, Oral; Amines; Analgesics; Burns; Case-Control Studies; Cyclohexanecarboxylic Acids;

2007
Bilateral hemifacial spasm and trigeminal neuralgia: a unique form of painful tic convulsif.
    Movement disorders : official journal of the Movement Disorder Society, 2007, Jan-15, Volume: 22, Issue:2

    Topics: Aged; Amines; Amitriptyline; Analgesics; Arachnoid Cysts; Botulinum Toxins, Type A; Cyclohexanecarbo

2007
Neurochemical evidence that supraspinally administered gabapentin activates the descending noradrenergic system after peripheral nerve injury.
    European journal of pharmacology, 2007, Feb-05, Volume: 556, Issue:1-3

    Topics: Amines; Analgesics; Animals; Chromatography, High Pressure Liquid; Cyclohexanecarboxylic Acids; Gaba

2007
Painful pemphigus vulgaris.
    Anesthesia and analgesia, 2007, Volume: 104, Issue:1

    Topics: Administration, Cutaneous; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Fentanyl; Gabapen

2007
A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain.
    Journal of neurochemistry, 2007, Volume: 100, Issue:5

    Topics: Amines; Analgesics; Animals; Anticonvulsants; Cold Temperature; Cyclohexanecarboxylic Acids; Disease

2007
Nociception: Taking the Pain out of Drug Discovery. 28 November 2006, London, UK.
    IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:2

    Topics: Amidohydrolases; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci

2007
Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF.
    Neuropharmacology, 2007, Volume: 52, Issue:5

    Topics: Acetamides; Amines; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Excitatory Amino Acid An

2007
Isobolographic analyses of the gabapentin-metamizol combination after local peripheral, intrathecal and oral administration in the rat.
    Pharmacology, 2007, Volume: 79, Issue:4

    Topics: Administration, Cutaneous; Administration, Oral; Amines; Analgesics; Animals; Cyclohexanecarboxylic

2007
Evaluation of gabapentin in the treatment of generalized vulvodynia, unprovoked.
    The Journal of reproductive medicine, 2007, Volume: 52, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Ad

2007
Pregabalin and duloxetine for the treatment of neuropathic pain disorders.
    Journal of pain & palliative care pharmacotherapy, 2007, Volume: 21, Issue:1

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Duloxetine Hydrochloride; Ga

2007
Oral gabapentin activates spinal cholinergic circuits to reduce hypersensitivity after peripheral nerve injury and interacts synergistically with oral donepezil.
    Anesthesiology, 2007, Volume: 106, Issue:6

    Topics: Administration, Oral; Amines; Analgesics; Animals; Cholinesterase Inhibitors; Cyclohexanecarboxylic

2007
The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy.
    British journal of pharmacology, 2007, Volume: 151, Issue:7

    Topics: Amides; Amines; Animals; Behavior, Animal; Camphanes; Cyclohexanecarboxylic Acids; Dose-Response Rel

2007
Chronic orchialgia: consider gabapentin or nortriptyline before considering surgery.
    International journal of urology : official journal of the Japanese Urological Association, 2007, Volume: 14, Issue:7

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Amines; Calcium Channel Blockers; Chronic Disease; Cycloh

2007
Gabapentin action and interaction on the antinociceptive effect of morphine on visceral pain in mice.
    European journal of anaesthesiology, 2008, Volume: 25, Issue:2

    Topics: Acetic Acid; Amines; Analgesics; Analgesics, Opioid; Analysis of Variance; Animals; Cyclohexanecarbo

2008
Transient allodynia pain models in mice for early assessment of analgesic activity.
    British journal of pharmacology, 2008, Volume: 153, Issue:4

    Topics: Adrenergic alpha-Antagonists; Amines; Amitriptyline; Analgesics; Animals; Clonidine; Cyclohexanecarb

2008
Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005.
    European journal of neurology, 2007, Volume: 14, Issue:12

    Topics: Adolescent; Adult; Age Distribution; Aged; Amines; Anticonvulsants; Carbamazepine; Catchment Area, H

2007
Acupuncture, ketamine and piriformis syndrome--a case report from palliative care.
    Acupuncture in medicine : journal of the British Medical Acupuncture Society, 2007, Volume: 25, Issue:3

    Topics: Acupuncture Therapy; Amines; Analgesics; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Gab

2007
Case reports: zoster pain in haematological malignancies: effective pain relief with oxycodone in patients unresponsive to other analgesic measures.
    Herpes : the journal of the IHMF, 2007, Volume: 14, Issue:2

    Topics: Acute Disease; Aged; Aged, 80 and over; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic

2007
Gestational trophoblastic disease with painful skin metastases.
    Journal of pain and symptom management, 2008, Volume: 35, Issue:3

    Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Fatal Outcome; Female; Gabapentin; gamma-Ami

2008
Gabapentin for painful legs and moving toes syndrome.
    Internal medicine (Tokyo, Japan), 2007, Volume: 46, Issue:23

    Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid;

2007
Gabapentin produces PKA-dependent pre-synaptic inhibition of GABAergic synaptic transmission in LC neurons following partial nerve injury in mice.
    Journal of neurochemistry, 2008, Volume: 105, Issue:3

    Topics: Amines; Animals; Cyclic AMP-Dependent Protein Kinases; Cyclohexanecarboxylic Acids; Efferent Pathway

2008
Regions of interest analysis in pharmacological fMRI: how do the definition criteria influence the inferred result?
    NeuroImage, 2008, Mar-01, Volume: 40, Issue:1

    Topics: Adult; Amines; Analgesics; Brain; Capsaicin; Cyclohexanecarboxylic Acids; Echo-Planar Imaging; Gabap

2008
Gabapentin evoked changes in functional activity in nociceptive regions in the brain of the anaesthetized rat: an fMRI study.
    British journal of pharmacology, 2008, Volume: 153, Issue:7

    Topics: Administration, Oral; Amines; Analgesics; Animals; Blood Pressure; Brain; Brain Mapping; Cyclohexane

2008
Mercury intoxication and neuropathic pain.
    Paediatric anaesthesia, 2008, Volume: 18, Issue:5

    Topics: Adolescent; Amines; Analgesics, Opioid; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Female

2008
Standard error of measurement as a valid alternative to minimally important difference for evaluating the magnitude of changes in patient-reported outcomes measures.
    Journal of clinical epidemiology, 2008, Volume: 61, Issue:4

    Topics: Amines; Analgesics; Cohort Studies; Cyclohexanecarboxylic Acids; Data Interpretation, Statistical; G

2008
Successful use of gabapentin in acute pain management following burn injury: a case series.
    Pain medicine (Malden, Mass.), 2008, Volume: 9, Issue:3

    Topics: Adult; Amines; Analgesics; Burns; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyri

2008
Gabapentin therapy for painful, blind glaucomatous eye: case report.
    Pain medicine (Malden, Mass.), 2008, Volume: 9, Issue:3

    Topics: Aged; Amines; Analgesics; Blindness; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci

2008
The use of gabapentin for recurrent painful attacks with multiple piloleiomyomas.
    Journal of drugs in dermatology : JDD, 2008, Volume: 7, Issue:4

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Leiomy

2008
Pharmacological treatment of neuropathic pain in older persons.
    Clinical interventions in aging, 2008, Volume: 3, Issue:1

    Topics: Aged; Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Chronic Disease

2008
Urinary and rectal incontinence during gabapentin therapy.
    The journal of supportive oncology, 2008, Volume: 6, Issue:4

    Topics: Aged; Amines; Anticonvulsants; Carcinoma, Non-Small-Cell Lung; Cyclohexanecarboxylic Acids; Fecal In

2008
Antinociceptive activity of the S1P-receptor agonist FTY720.
    Journal of cellular and molecular medicine, 2008, Volume: 12, Issue:3

    Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Fingolim

2008
The antinociceptive effects of anticonvulsants in a mouse visceral pain model.
    Anesthesia and analgesia, 2008, Volume: 106, Issue:6

    Topics: Acetic Acid; Amines; Analgesics; Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Cyclohex

2008
Postpoliomyelitis pain treated with gabapentin.
    American family physician, 1996, Volume: 53, Issue:8

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Ac

1996
Erythromelalgia pain managed with gabapentin.
    Anesthesiology, 1997, Volume: 86, Issue:4

    Topics: Acetates; Adult; Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Erythromelalgia; Female; Ga

1997
Spinal gabapentin is antinociceptive in the rat formalin test.
    Neuroscience letters, 1997, Jan-24, Volume: 222, Issue:1

    Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship,

1997
The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain.
    European journal of pharmacology, 1997, Apr-18, Volume: 324, Issue:2-3

    Topics: Acetates; Acute Disease; Amines; Analgesics; Animals; Anticonvulsants; Chronic Disease; Cyclohexanec

1997
Gabapentin for idiopathic trigeminal neuralgia: report of two cases.
    Neurology, 1997, Volume: 48, Issue:5

    Topics: Acetates; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapent

1997
Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin.
    Neurology, 1997, Volume: 49, Issue:1

    Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut

1997
Pain in Guillain-Barré syndrome.
    Neurology, 1997, Volume: 49, Issue:5

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma

1997
Gabapentin reverses the allodynia produced by the administration of anti-GD2 ganglioside, an immunotherapeutic drug.
    Anesthesia and analgesia, 1998, Volume: 86, Issue:1

    Topics: Acetates; Amines; Analgesics; Animals; Antibodies, Monoclonal; Blood Pressure; Cyclohexanecarboxylic

1998
The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat.
    Anesthesia and analgesia, 1998, Volume: 86, Issue:2

    Topics: Acetates; Amines; Animals; Anticonvulsants; Burns; Cyclohexanecarboxylic Acids; Dose-Response Relati

1998
Gabapentin induced polyneuropathy.
    Pain, 1998, Volume: 74, Issue:2-3

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma

1998
Gabapentin for lancinating neuropathic pain.
    The American journal of nursing, 1998, Volume: 98, Issue:4

    Topics: Acetates; Acquired Immunodeficiency Syndrome; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabap

1998
Attenuation of formalin-induced nociceptive behaviors following local peripheral injection of gabapentin.
    Pain, 1998, Volume: 76, Issue:1-2

    Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Dose-Response

1998
A case of spinal cord injury-related pain with baseline rCBF brain SPECT imaging and beneficial response to gabapentin.
    Pain, 1998, Volume: 78, Issue:2

    Topics: Acetates; Adult; Amines; Analgesics; Brain; Cerebrovascular Circulation; Cyclohexanecarboxylic Acids

1998
Symptomatic treatment of painful neuropathy.
    JAMA, 1998, Dec-02, Volume: 280, Issue:21

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; G

1998
Gabapentin for treatment of neuropathic pain in a 12-year-old girl.
    The Clinical journal of pain, 1998, Volume: 14, Issue:4

    Topics: Acetates; Amines; Child; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; H

1998
Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats.
    The Journal of pharmacology and experimental therapeutics, 1999, Volume: 288, Issue:3

    Topics: Acetates; Afferent Pathways; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Disease

1999
Gabapentin for painful diabetic neuropathy.
    The Journal of family practice, 1999, Volume: 48, Issue:3

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Double-Blind Metho

1999
Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat.
    Pain, 1999, Volume: 80, Issue:1-2

    Topics: Acetates; Amines; Amitriptyline; Analgesics; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus

1999
Gabapentin for painful diabetic neuropathy.
    JAMA, 1999, Jul-14, Volume: 282, Issue:2

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Gabapentin; gamma-

1999
Gabapentin for painful diabetic neuropathy.
    JAMA, 1999, Jul-14, Volume: 282, Issue:2

    Topics: Acetates; Amines; Analgesics; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Diabeti

1999
Behavioral effects of RS-45041-190, a selective I2 imidazoline ligand, in rats.
    Annals of the New York Academy of Sciences, 1999, Jun-21, Volume: 881

    Topics: Acetates; Amines; Analgesics; Animals; Carrageenan; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A

1999
The effect of intrathecal gabapentin on pain behavior and hemodynamics on the formalin test in the rat.
    Anesthesia and analgesia, 1999, Volume: 89, Issue:2

    Topics: Acetates; Amines; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Dose-Response Relationship

1999
Use of gabapentin to treat taxane-induced myalgias.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:1

    Topics: Acetates; Amines; Analgesics; Antineoplastic Agents, Phytogenic; Cyclohexanecarboxylic Acids; Doceta

1999
The race to control pain: more participants, more targets.
    Trends in pharmacological sciences, 1999, Volume: 20, Issue:9

    Topics: Acetates; Amines; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gabapentin; gamma-

1999
Gabapentin leads to remission of somatoform pain disorder with major depression.
    Pharmacopsychiatry, 1999, Volume: 32, Issue:6

    Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Depressive Disorder; Female; Gabapen

1999
Repeated administration of systemic gabapentin alleviates allodynia-like behaviors in spinally injured rats.
    Neuroscience letters, 2000, Feb-25, Volume: 280, Issue:3

    Topics: Acetates; Amines; Analgesics; Animals; Cold Temperature; Cyclohexanecarboxylic Acids; Drug Administr

2000
Synergistic effect between intrathecal non-NMDA antagonist and gabapentin on allodynia induced by spinal nerve ligation in rats.
    Anesthesiology, 2000, Volume: 92, Issue:2

    Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxy

2000
Gabapentin for treatment of thalamic pain syndrome.
    Palliative medicine, 2000, Volume: 14, Issue:2

    Topics: Acetates; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric

2000
Gabapentin in acute painful diabetic neuropathy.
    European journal of neurology, 2000, Volume: 7, Issue:3

    Topics: Acetates; Acute Disease; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathie

2000
Pharmacological and immunohistochemical characterization of a mouse model of acute herpetic pain.
    Japanese journal of pharmacology, 2000, Volume: 83, Issue:4

    Topics: Acetates; Amines; Amitriptyline; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants;

2000
Painful gynecomastia: an unusual toxicity of gabapentin?
    Journal of pain and symptom management, 2000, Volume: 20, Issue:1

    Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;

2000
Gabapentin for chronic pain in spinal cord injury: a case report.
    Archives of physical medicine and rehabilitation, 2000, Volume: 81, Issue:10

    Topics: Acetates; Adult; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Gabapenti

2000
Gabapentin, an adjuvant treatment for neuropathic pain in a cancer hospital.
    Journal of pain and symptom management, 2000, Volume: 20, Issue:2

    Topics: Acetates; Amines; Analgesics; Cancer Care Facilities; Cyclohexanecarboxylic Acids; Gabapentin; gamma

2000
Antinociceptive effect of systemic gabapentin in mononeuropathic rats, depends on stimulus characteristics and level of test integration.
    Pain, 2000, Volume: 88, Issue:1

    Topics: Acetates; Amines; Analgesics; Animals; Cold Temperature; Cyclohexanecarboxylic Acids; Gabapentin; ga

2000
Malignant appearing cachexia in an older patient with Bruns-Garland syndrome.
    Journal of the American Geriatrics Society, 2000, Volume: 48, Issue:12

    Topics: Acetates; Aged; Amines; Analgesics; Cachexia; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2

2000
Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection.
    The Journal of pharmacology and experimental therapeutics, 2001, Volume: 296, Issue:2

    Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Drug Tolerance

2001
Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin.
    Journal of neurotrauma, 2000, Volume: 17, Issue:12

    Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Chronic Disease; Contusions; Cyclohexanecar

2000
Three-month follow-up of shoulder-hand syndrome induced by phenobarbital and treated with gabapentin.
    International journal of tissue reactions, 2001, Volume: 23, Issue:1

    Topics: Acetaminophen; Acetates; Amines; Analgesics; Anticonvulsants; Arthralgia; Cyclohexanecarboxylic Acid

2001
Gabapentin for opiod-related myoclonus in cancer patients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2001, Volume: 9, Issue:3

    Topics: Acetates; Amines; Analgesics, Opioid; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamm

2001
Vincristine-induced allodynia in the rat.
    Pain, 2001, Volume: 93, Issue:1

    Topics: Acetates; Amines; Analgesics; Animals; Antineoplastic Agents, Phytogenic; Body Weight; Cyclohexaneca

2001
Treatment of pain with gabapentin in a neonate.
    Pediatrics, 2001, Volume: 108, Issue:2

    Topics: Acetates; Amines; Analgesics; Arthrogryposis; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobu

2001
Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations.
    European journal of neurology, 2001, Volume: 8, Issue:1

    Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami

2001
Gabapentin for pain control in cancer patients' wound dressing care.
    Journal of pain and symptom management, 2001, Volume: 22, Issue:1

    Topics: Acetates; Amines; Analgesics; Bandages; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric

2001
Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury.
    Journal of neurotrauma, 2001, Volume: 18, Issue:10

    Topics: Acetates; Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Exploratory Beh

2001
Treating painful diabetic neuropathy with gabapentin.
    The Nurse practitioner, 2001, Volume: 26, Issue:10

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Dose-Response Rela

2001
[Diabetic neuropathies].
    La Revue du praticien, 2001, Oct-15, Volume: 51, Issue:16

    Topics: Acetates; Amines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbamazepine; Controlled Clinic

2001
Gabapentin treatment of multiple piloleiomyoma-related pain.
    Journal of the American Academy of Dermatology, 2002, Volume: 46, Issue:2 Suppl Ca

    Topics: Acetates; Administration, Oral; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin;

2002
A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy.
    Anesthesiology, 2002, Volume: 96, Issue:3

    Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Animals; Cyclohexanecarboxylic Acids; Electrophysi

2002
The interaction between gabapentin and amitriptyline in the rat formalin test after systemic administration.
    Anesthesia and analgesia, 2002, Volume: 94, Issue:4

    Topics: Acetates; Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Animals; Behavior, Animal; Cy

2002
Effects of analgesics on delayed postherpetic pain in mice.
    Anesthesiology, 2002, Volume: 96, Issue:5

    Topics: Acetates; Acute Disease; Acyclovir; Amines; Analgesics; Analgesics, Opioid; Animals; Antiviral Agent

2002
Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons.
    Neuroscience letters, 2002, May-24, Volume: 324, Issue:3

    Topics: Acetates; Afferent Pathways; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Fluorescent D

2002
Gabapentin for neuropathic pain following spinal cord injury.
    Spinal cord, 2002, Volume: 40, Issue:6

    Topics: Acetates; Acute Disease; Adolescent; Adult; Aged; Amines; Chronic Disease; Cyclohexanecarboxylic Aci

2002
Gabapentin (neuronetin) in the treatment of SUNCT syndrome.
    Cephalalgia : an international journal of headache, 2002, Volume: 22, Issue:3

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Ac

2002
Experimental conditions for the continuous subcutaneous infusion of four central analgesics in rats.
    Pharmacology, biochemistry, and behavior, 2002, Volume: 72, Issue:4

    Topics: Acetates; Amines; Analgesics; Anesthetics, Dissociative; Animals; Anticonvulsants; Antidepressive Ag

2002